_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502939255,7/14/2014 17:29:50,,1322979550,7/14/2014 17:29:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,100,155,,,111,163,ISLET CELLS,DIABETES,secretory responses of ISLET CELLS to D glucose,77-97-100-106-112-115-117-87,133-146-152-155,experimental model of DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 17:59:16,,1323000938,7/14/2014 17:58:56,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:10:18,,1323007297,7/14/2014 18:09:53,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:17:25,,1323010626,7/14/2014 18:16:37,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,100,155,,,111,163,ISLET CELLS,DIABETES,preferential impairment of the oxidative secretory responses of ISLET CELLS to D glucose diabetes mitochondria glycerol phosphate shuttle.,32-45-56-59-63-77-87-97-100-106-112-115-117-155-256-288-297-307,32-45-56-59-63-77-87-97-100-106-112-115-117-155-256-288-297-307,preferential impairment of the oxidative secretory responses of islet cells to D glucose DIABETES mitochondria glycerol phosphate shuttle.,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:19:59,,1323011665,7/14/2014 18:19:47,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,100,155,,,111,163,ISLET CELLS,DIABETES,secretory responses of ISLET CELLS to D glucose,77-87-97-100-106-112-115-117,133-146-152-155,experimental model of DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:35:32,,1323018225,7/14/2014 18:35:13,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:39:19,,1323019908,7/14/2014 18:38:55,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:39:38,,1323020042,7/14/2014 18:39:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:39:53,,1323020154,7/14/2014 18:39:29,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939255,7/14/2014 18:39:58,,1323020170,7/14/2014 18:39:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,100,155,,,111,163,ISLET CELLS,DIABETES,ISLET CELLS,100-106,155,DIABETES,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle.",100 106,155,100,155,111,163,1,RO-disease_has_primary_anatomic_site,902036,"We propose, therefore, that the preferential impairment of the oxidative and secretory responses of islet cells to D-glucose in this experimental model of diabetes may be at least partly attributable to an altered transfer of reducing equivalents into the mitochondria as mediated by the glycerol phosphate shuttle",islet cells,diabetes
502939256,7/14/2014 17:34:12,,1322983457,7/14/2014 17:33:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,middle and lower ESOPHAGUS,70-77-81-87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 17:37:46,,1322986926,7/14/2014 17:37:29,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,middle and lower ESOPHAGUS,70-77-81-87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 17:45:08,,1322994435,7/14/2014 17:44:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,ESOPHAGUS,87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 17:48:07,,1322995815,7/14/2014 17:47:01,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,middle and lower ESOPHAGUS composed microscopically of submucosal multiple nests accompanied with a small focus of squamous cell carcinoma,70-77-81-87-105-114-130-133-144-153-199-211-216-218-224-230-233-242-247,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:13:05,,1323008578,7/14/2014 18:12:33,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,ESOPHAGUS,87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:19:34,,1323011499,7/14/2014 18:18:05,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,ESOPHAGUS,87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:24:08,,1323013337,7/14/2014 18:22:51,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,esophageal tumor showed a fungating growth at the junction of the middle and lower ESOPHAGUS and was composed microscopically of submucosal multiple nests with solid and cribriform like patterns with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,4-15-21-28-30-40-47-50-54-63-66-70-77-81-87-97-101-105-114-130-133-144-153-159-164-170-174-185-190-211-216-218-224-230-233-242-247-257-266-269-273-283-294,0-4-15-21-28-30-40-47-50-54-63-66-70-77-81-87-97-105-114-130-133-144-153-159-164-170-174-185-190-211-216-218-224-230-242-247-257-266-269-273-283-294-233,The ESOPHAGEAL TUMOR showed a fungating growth at the junction of the middle and lower esophagus and composed microscopically of submucosal multiple nests with solid and cribriform like patterns with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:31:51,,1323016725,7/14/2014 18:31:27,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,ESOPHAGUS,87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:38:28,,1323019477,7/14/2014 18:38:11,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,middle and lower ESOPHAGUS,70-77-81-87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939256,7/14/2014 18:39:09,,1323019818,7/14/2014 18:38:56,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,87,4,,,96,20,ESOPHAGUS,ESOPHAGEAL TUMOR,middle and lower ESOPHAGUS,70-77-81-87,4-15,ESOPHAGEAL TUMOR,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium.,87,4 15,87,4,96,20,1,RO-has_finding_site,905417,The esophageal tumor showed a fungating growth at the junction of the middle and lower esophagus and was composed microscopically of submucosal multiple nests with solid and cribriform-like patterns accompanied with a small focus of squamous cell carcinoma adjacent to the overlying esophageal epithelium,esophagus,esophageal tumor
502939257,7/14/2014 17:30:40,,1322980285,7/14/2014 17:30:35,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,virus reaches the BRAIN and causes progressive,15-21-29-33-39-43-50,39-43-50-62-73-94-96-110,"and causes progressive MULTIFOCAL LEUKOENCEPHALOPATHY, a demyelinating disease","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:33:43,,1322983029,7/14/2014 17:33:28,instagc,1.0,18960682,GBR,"","",86.29.147.112,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,50-62-73,"progressive MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:35:25,,1322984671,7/14/2014 17:33:49,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,"Neurotropic JC virus BRAIN progressive multifocal leukoencephalopathy, demyelinating disease central nervous system",0-12-15-33-50-62-73-96-110-125-133-141,0-12-15-50-62-73-96-110,"Neurotropic JC virus progressive MULTIFOCAL LEUKOENCEPHALOPATHY, demyelinating disease","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:42:35,,1322991576,7/14/2014 17:42:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:47:20,,1322995487,7/14/2014 17:47:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:47:58,,1322995759,7/14/2014 17:47:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:51:55,,1322997599,7/14/2014 17:51:20,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,Neurotropic JC virus reaches the BRAIN,0-12-15-21-29-33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 17:58:40,,1323000676,7/14/2014 17:58:20,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 18:19:41,,1323011550,7/14/2014 18:19:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,62-73,"MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939257,7/14/2014 18:21:02,,1323012102,7/14/2014 18:20:15,vivatic,1.0,25451531,GBR,"","",83.67.28.193,33,62,,,38,92,BRAIN,MULTIFOCAL LEUKOENCEPHALOPATHY,BRAIN,33,50-62-73,"progressive MULTIFOCAL LEUKOENCEPHALOPATHY,","Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate.",33,62 73,33,62,38,92,1,RO-disease_has_primary_anatomic_site,902284,"Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate",brain,multifocal leukoencephalopathy
502939258,7/14/2014 17:29:19,,1322979072,7/14/2014 17:28:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS,52,63-73-89,(CERVICAL INTRAEPITHELIAL NEOPLASIAS,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 17:48:51,,1322996185,7/14/2014 17:48:33,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS,52,73-89,INTRAEPITHELIAL NEOPLASIAS,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 17:52:06,,1322997682,7/14/2014 17:51:28,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,"DYSPLASIAS (cervical intraepithelial neoplasias or CIN I, II, or III)",52-73-89-100-103-107-110-114-117-63,63-73-89-100-103-107-110-114-117,"(CERVICAL INTRAEPITHELIAL NEOPLASIAS or CIN I, II, or III)","In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 17:52:13,,1322997790,7/14/2014 17:51:37,elite,1.0,27888773,GBR,"","",128.199.166.81,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,in detection of DYSPLASIAS intraepithelial neoplasias,36-39-49-52-73-89,49-52-63-73-89-100-103-107-110-114-117,"of dysplasias (CERVICAL INTRAEPITHELIAL NEOPLASIAS or CIN I, II, or III)","In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 17:56:57,,1322999977,7/14/2014 17:56:28,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS,52,73-89,INTRAEPITHELIAL NEOPLASIAS,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 18:13:15,,1323008683,7/14/2014 18:12:52,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS,52,73-89,INTRAEPITHELIAL NEOPLASIAS,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 18:16:11,,1323010072,7/14/2014 18:15:47,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS,52,63-73-89-100-103-107-110-117-114,"(CERVICAL INTRAEPITHELIAL NEOPLASIAS or CIN I, II, or III)","In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 18:27:59,,1323014975,7/14/2014 18:27:16,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,"DYSPLASIAS (cervical intraepithelial neoplasias or CIN I, II, or III) cancer of the cervix, epidemiologic, biochemical, cytologic",52-63-73-89-100-103-107-110-114-117-126-133-136-140-157-172-185,49-52-63-73-89-100-103-107-114-117-126-133-136-140-148-157-172-185-110,"of dysplasias (CERVICAL INTRAEPITHELIAL NEOPLASIAS or CIN I, II, or III) cancer of the cervix, numerous epidemiologic, biochemical, cytologic","In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 18:34:19,,1323017663,7/14/2014 18:33:58,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,DYSPLASIAS (cervical intraepithelial neoplasias,52-73-89-63,52-63-73-89,dysplasias (CERVICAL INTRAEPITHELIAL NEOPLASIAS,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939258,7/14/2014 18:34:30,,1323017790,7/14/2014 18:33:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,52,64,,,62,99,DYSPLASIAS,CERVICAL INTRAEPITHELIAL NEOPLASIAS,"DYSPLASIAS (cervical intraepithelial neoplasias or CIN I, II, or III)",52-63-73-89-100-103-107-110-114-117,52-63-73-89-100-103-107-110-114-117,"dysplasias (CERVICAL INTRAEPITHELIAL NEOPLASIAS or CIN I, II, or III)","In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved.",52,73 89,52,64,62,99,-1,RO-disease_has_finding,901757,"In spite of the apparent simplicity in detection of dysplasias (cervical intraepithelial neoplasias or CIN I, II, or III) and cancer of the cervix, numerous epidemiologic, biochemical, cytologic and socioeconomic problems are involved",dysplasias,cervical intraepithelial neoplasias
502939259,7/14/2014 17:29:04,,1322978850,7/14/2014 17:28:58,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,185,103,,,197,109,RABIES VIRUS,RABIES,G protein of RABIES VIRUS has been developed,172-174-182-185-192-198-202-207,79-89-95-103-111-113-125,"vaccinate foxes against RABIES, a recombinant vaccinia","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 17:32:47,,1322982118,7/14/2014 17:32:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103-134,"RABIES, virus,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 17:45:28,,1322994614,7/14/2014 17:45:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 17:46:03,,1322994894,7/14/2014 17:45:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 17:48:44,,1322996105,7/14/2014 17:48:16,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 17:50:44,,1322997007,7/14/2014 17:50:30,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,185,103,,,197,109,RABIES VIRUS,RABIES,immunizing G protein of RABIES VIRUS,161-172-174-182-185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 18:08:03,,1323006187,7/14/2014 18:07:43,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 18:29:14,,1323015526,7/14/2014 18:29:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 18:30:49,,1323016189,7/14/2014 18:30:35,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939259,7/14/2014 18:30:50,,1323016190,7/14/2014 18:30:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,185,103,,,197,109,RABIES VIRUS,RABIES,RABIES VIRUS,185-192,103,"RABIES,","To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus.",185 192,103,185,103,197,109,-1,RO-has_causative_agent,903925,"To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus",rabies virus,rabies
502939260,7/14/2014 17:31:06,,1322980659,7/14/2014 17:30:44,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,22-25,IV DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 17:48:43,,1322996101,7/14/2014 17:48:08,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,25,DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 17:53:15,,1322998263,7/14/2014 17:52:50,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,25,DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 17:58:20,,1323000553,7/14/2014 17:58:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA is suspected,67-80-83,18-22-25-34-37-47,for IV DEXTROSE in emergency situations,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:17:33,,1323010662,7/14/2014 18:17:10,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,25,DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:26:44,,1323014374,7/14/2014 18:26:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,22-25,IV DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:28:10,,1323015086,7/14/2014 18:27:59,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,22-25,IV DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:35:19,,1323018145,7/14/2014 18:34:55,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,25-67,DEXTROSE hypoglycemia,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:38:44,,1323019627,7/14/2014 18:38:29,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA,67,25,DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939260,7/14/2014 18:40:25,,1323020420,7/14/2014 18:39:46,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,67,25,,,79,33,HYPOGLYCEMIA,DEXTROSE,HYPOGLYCEMIA but,67-93,25,DEXTROSE,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established.,67,25,67,25,79,33,1,RO-may_treat,907545,Do not substitute for IV dextrose in emergency situations in which hypoglycemia is suspected but not established,hypoglycemia,dextrose
502939261,7/14/2014 17:46:34,,1322995132,7/14/2014 17:45:56,clixsense,1.0,21875134,GBR,"","",91.125.61.83,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 17:47:45,,1322995709,7/14/2014 17:47:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 17:54:18,,1322998697,7/14/2014 17:54:03,elite,1.0,27888773,GBR,"","",128.199.166.81,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,administered inadvertently during PREGNANCY or if the,39-52-66-73-83-86-89,0-12-24-27-31,Discontinue LEFLUNOMIDE if the drug,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:06:32,,1323005483,7/14/2014 18:06:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,0-12,Discontinue LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:07:52,,1323006119,7/14/2014 18:07:50,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,administered inadvertently during PREGNANCY or if the,39-52-66-73-83-86-89,0-12-24-27-31,Discontinue LEFLUNOMIDE if the drug,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:12:53,,1323008484,7/14/2014 18:12:34,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:16:40,,1323010267,7/14/2014 18:16:24,vivatic,1.0,25451531,GBR,"","",83.67.28.193,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:21:18,,1323012207,7/14/2014 18:21:06,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:41:08,,1323020751,7/14/2014 18:40:55,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939261,7/14/2014 18:41:17,,1323020862,7/14/2014 18:41:06,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,73,12,,,82,23,PREGNANCY,LEFLUNOMIDE,PREGNANCY,73,12,LEFLUNOMIDE,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug.,73,12,73,12,82,23,1,RO-contraindicated_drug,901397,Discontinue leflunomide if the drug is administered inadvertently during pregnancy or if the patient becomes pregnant while receiving the drug,pregnancy,leflunomide
502939262,7/14/2014 17:30:43,,1322980308,7/14/2014 17:30:21,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,23-42-34,controlled release MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 17:38:08,,1322987300,7/14/2014 17:37:42,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,42,MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 17:40:31,,1322989506,7/14/2014 17:40:13,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,remission in ULCERATIVE COLITIS.,72-82-85-96,23-34-42-85-96,controlled release MESALAMINE ulcerative colitis.,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 17:43:58,,1322992844,7/14/2014 17:43:06,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,42,MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 17:47:11,,1322995404,7/14/2014 17:46:53,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,42,MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 18:04:56,,1323003614,7/14/2014 18:04:35,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,of remission in ULCERATIVE COLITIS.,69-72-82-85-96,20-23-34-42-53-57-69,of controlled release MESALAMINE for maintenance of,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 18:09:46,,1323007045,7/14/2014 18:09:21,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,42,MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 18:15:37,,1323009837,7/14/2014 18:15:16,vivatic,1.0,25451531,GBR,"","",83.67.28.193,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,23-34-42,controlled release MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 18:16:42,,1323010270,7/14/2014 18:16:25,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,ULCERATIVE COLITIS.,85-96,42,MESALAMINE,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939262,7/14/2014 18:27:15,,1323014583,7/14/2014 18:26:53,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,85,42,,,103,52,ULCERATIVE COLITIS,MESALAMINE,controlled release mesalamine for maintenance of remission in ULCERATIVE COLITIS.,23-34-42-53-69-72-82-85-96-57,20-23-34-42-53-57-69-72-82-85-96,of controlled release MESALAMINE for maintenance of remission in ulcerative colitis.,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis.,85 96,42,85,42,103,52,1,RO-may_treat,907599,Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis,ulcerative colitis,mesalamine
502939263,7/14/2014 17:36:41,,1322985966,7/14/2014 17:36:27,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE disorders,92-100,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 17:47:34,,1322995634,7/14/2014 17:47:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE,92,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 17:54:28,,1322998796,7/14/2014 17:54:08,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,cerebral calcifications encephalofacial angiomatosis SEIZURE disorders Sturge Weber syndrome.,21-30-59-75-92-100-127-134-140,21-30-59-75-92-100-127-134-140,cerebral calcifications encephalofacial angiomatosis seizure disorders STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:01:31,,1323001940,7/14/2014 18:01:12,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE disorders the,92-100-123,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:06:55,,1323005688,7/14/2014 18:06:53,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,encephalofacial angiomatosis and SEIZURE disorders characterize the,59-75-88-92-100-110-123,100-110-123-127-134-140,disorders characterize the STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:08:14,,1323006309,7/14/2014 18:07:46,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,encephalofacial angiomatosis and SEIZURE disorders,59-75-92-100-88,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:34:55,,1323017952,7/14/2014 18:34:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE disorders,92-100,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:38:31,,1323019501,7/14/2014 18:38:19,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,encephalofacial angiomatosis SEIZURE disorders,59-75-92-100,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:40:21,,1323020402,7/14/2014 18:40:12,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE disorders,92-100,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939263,7/14/2014 18:40:24,,1323020415,7/14/2014 18:40:06,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,92,127,,,99,148,SEIZURE,STURGE-WEBER SYNDROME,SEIZURE,92,127-134-140,STURGE WEBER SYNDROME.,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome.,92,127 134 140,92,127,99,148,1,RO-has_manifestation,906322,Different degrees of cerebral calcifications together with encephalofacial angiomatosis and seizure disorders characterize the Sturge-Weber syndrome,seizure,Sturge-Weber syndrome
502939264,7/14/2014 17:28:33,,1322978446,7/14/2014 17:28:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,270,305,,,277,313,ASCITES,HEPATOMA,rat ASCITES hepatoma,270-278-266,291-297-305,mouse ascites HEPATOMA,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 17:34:07,,1322983425,7/14/2014 17:33:42,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,270,305,,,277,313,ASCITES,HEPATOMA,"ASCITES hepatoma and mouse ascites hepatoma 22a,",270-278-287-291-297-305-314,297-305-314,"ascites HEPATOMA 22a,","Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 17:35:03,,1322984331,7/14/2014 17:34:20,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,270,305,,,277,313,ASCITES,HEPATOMA,ASCITES,270,305-314,"HEPATOMA 22a,","Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 17:41:25,,1322990328,7/14/2014 17:41:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,270,305,,,277,313,ASCITES,HEPATOMA,ASCITES hepatoma,270-278,305,HEPATOMA,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 17:52:47,,1322998036,7/14/2014 17:51:21,clixsense,1.0,21875134,GBR,"","",91.125.61.83,270,305,,,277,313,ASCITES,HEPATOMA,ASCITES hepatoma,270-278,297-305,ascites HEPATOMA,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 17:53:31,,1322998398,7/14/2014 17:52:46,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,270,305,,,277,313,ASCITES,HEPATOMA,ASCITES hepatoma,270-278,297-305,ascites HEPATOMA,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 18:06:57,,1323005714,7/14/2014 18:06:24,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,270,305,,,277,313,ASCITES,HEPATOMA,rat ASCITES hepatoma,266-270-278,291-297-305,mouse ascites HEPATOMA,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 18:09:39,,1323006989,7/14/2014 18:07:59,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,270,305,,,277,313,ASCITES,HEPATOMA,"Rabbit antiserum alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 residual proteins immunodiffusion agarose gel, immunoprecipitation nuclei immunofluorescence with Zajdela's rat ASCITES hepatoma and mouse ascites hepatoma 22a, non liver tumors rat Jensen, Yoshida M 1 sarcomas Ehrlich ascites carcinoma",0-7-25-32-42-50-59-67-70-85-89-98-114-123-139-158-166-180-212-232-251-256-266-270-278-287-291-297-305-314-343-347-353-361-365-373-385-387-389-408-416-424,0-7-25-32-42-50-59-67-70-85-89-98-114-123-139-158-166-180-212-232-251-256-266-270-278-287-291-297-305-314-319-325-343-347-353-361-365-373-385-387-389-408-416-424,"Rabbit antiserum alkali insoluble nuclear residual protein of transplantable rat hepatoma 27 residual proteins immunodiffusion agarose gel, immunoprecipitation nuclei immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites HEPATOMA 22a, while the non liver tumors rat Jensen, Yoshida M 1 sarcomas Ehrlich ascites carcinoma","Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 18:18:45,,1323011225,7/14/2014 18:18:36,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,270,305,,,277,313,ASCITES,HEPATOMA,Zajdela's rat ASCITES hepatoma and mouse,256-266-270-278-287-291,297-305-314-319-325,"ascites HEPATOMA 22a, while the","Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939264,7/14/2014 18:21:34,,1323012326,7/14/2014 18:19:42,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,270,305,,,277,313,ASCITES,HEPATOMA,Zajdela's rat ASCITES hepatoma,256-266-270-278,291-297-305-314,"mouse ascites HEPATOMA 22a,","Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative.",270,305,270,305,277,313,-1,RO-disease_may_have_finding,902597,"Rabbit antiserum against alkali-insoluble nuclear residual protein of transplantable rat hepatoma 27 reacted with residual proteins during immunodiffusion in agarose gel, provided immunoprecipitation of isolated nuclei and indirect immunofluorescence with Zajdela's rat ascites hepatoma and mouse ascites hepatoma 22a, while the reaction with non-liver tumors--rat Jensen, Yoshida and M 1 sarcomas and mouse Ehrlich ascites carcinoma was negative",ascites,hepatoma
502939265,7/14/2014 18:12:50,,1323008472,7/14/2014 18:12:22,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:17:10,,1323010486,7/14/2014 18:16:55,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:19:02,,1323011311,7/14/2014 18:18:50,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,counselors' providing NICOTINE counseling.,160-172-182-191,73-82-87-96-105-115-125-128,programs that provided NICOTINE ADDICTION education or treatment,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:30:11,,1323015955,7/14/2014 18:29:55,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:31:57,,1323016758,7/14/2014 18:31:48,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,of NICOTINE,157-182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:34:44,,1323017875,7/14/2014 18:34:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE counseling.,182-191,96-105-115-125-128,NICOTINE ADDICTION education or treatment,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:37:14,,1323018929,7/14/2014 18:35:30,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:37:27,,1323019003,7/14/2014 18:37:13,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE counseling.,182-191,96-105-115-125-128,NICOTINE ADDICTION education or treatment,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:40:05,,1323020292,7/14/2014 18:39:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939265,7/14/2014 18:41:07,,1323020739,7/14/2014 18:40:42,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,182,96,,,190,114,NICOTINE,NICOTINE ADDICTION,NICOTINE,182,96-105,NICOTINE ADDICTION,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling.,182,96 105,182,96,190,114,-1,RO-has_causative_agent,903591,Greater knowledge of the effects of nicotine addiction and employment in programs that provided nicotine addiction education or treatment increased the odds of counselors' providing nicotine counseling,nicotine,nicotine addiction
502939266,7/14/2014 17:37:01,,1322986250,7/14/2014 17:36:35,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY Waldenstrom's macroglobulinemia venous stasis vascular pathology.,13-31-45-95-102-136-145,13-31-45-95-102-136-145,hyperviscosity WALDENSTROM'S MACROGLOBULINEMIA venous stasis vascular pathology.,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 17:37:26,,1322986570,7/14/2014 17:37:08,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY in Waldenstrom's macroglobulinemia,13-28-31-45,13-28-31-45,hyperviscosity in WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 17:55:30,,1322999331,7/14/2014 17:55:12,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:06:07,,1323004868,7/14/2014 18:05:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:28:37,,1323015311,7/14/2014 18:28:26,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:33:53,,1323017435,7/14/2014 18:33:39,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:37:41,,1323019095,7/14/2014 18:36:45,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:39:24,,1323019955,7/14/2014 18:39:10,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:40:10,,1323020324,7/14/2014 18:39:48,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY,13,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939266,7/14/2014 18:40:54,,1323020601,7/14/2014 18:40:25,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,13,31,,,27,62,HYPERVISCOSITY,WALDENSTROM'S MACROGLOBULINEMIA,HYPERVISCOSITY Waldenstrom's macroglobulinemia,13-31-45,31-45,WALDENSTROM'S MACROGLOBULINEMIA,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology.",13,31 45,13,31,27,62,1,RO-disease_may_have_finding,902947,"However, the hyperviscosity in Waldenstrom's macroglobulinemia is an ideal representative of a venous stasis that is without associated vascular pathology",hyperviscosity,Waldenstrom's macroglobulinemia
502939267,7/14/2014 17:33:24,,1322982740,7/14/2014 17:32:40,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"atypICAL PERiodic headache,",128-137-146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:35:34,,1322984858,7/14/2014 17:35:13,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"atypICAL PERiodic headache,",128-137-146,190-193-204-216,AS MIGRAIN PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:47:00,,1322995329,7/14/2014 17:46:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"headache,",146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:48:47,,1322996113,7/14/2014 17:48:30,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"PERiodic headache,",137-146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:51:20,,1322997303,7/14/2014 17:50:53,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"atypICAL PERiodic headache,",128-137-146,190-193,AS MIGRAIN,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:52:43,,1322998009,7/14/2014 17:52:20,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"headache,",146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 17:57:59,,1323000403,7/14/2014 17:57:33,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"atypICAL PERiodic headache,",128-137-146,168-178-181-190-193-201-204-216,difficult to consider AS MIGRAIN OR PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 18:08:39,,1323006506,7/14/2014 18:08:04,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"headache,",146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 18:20:56,,1323012077,7/14/2014 18:20:18,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"headache,",146,190-204-216,AS PSYCHOgenic headache,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939267,7/14/2014 18:27:22,,1323014663,7/14/2014 18:26:59,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,132,190,,,140,210,HEADACHE,PSYCHOGENIC HEADACHE,"atypICAL PERiodic headache,",128-137-146,128-137-146-190,"atypical periodic headache, AS","The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone.",,190,132,190,140,210,-1,RO-has_definitional_manifestation,904825,"The piribedil test appears to possess good specificity vis-����渇�膩�����鐃緒申鐃順�s migraine, enabling a differential diagnosis from atypical periodic headache, a condition difficult to consider as migrain or psychogenic headache on clinical grounds alone",headache,psychogenic headache
502939268,7/14/2014 17:31:11,,1322980680,7/14/2014 17:31:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 17:31:24,,1322980894,7/14/2014 17:31:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 17:38:36,,1322987698,7/14/2014 17:38:21,instagc,1.0,13763729,USA,"","",75.182.89.225,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 17:58:32,,1323000613,7/14/2014 17:58:15,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:00:59,,1323001714,7/14/2014 18:00:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN, weight loss, abdominal masses, obstruction, and perforation.",51-61-67-74-80-90-98-111-115,10-19-28-36,"lymphoma patients without IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:01:15,,1323001832,7/14/2014 18:00:53,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:12:01,,1323008112,7/14/2014 18:11:12,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"IPSID, ABDOMINAL PAIN,",36-51-61,10-36,"lymphoma IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:16:23,,1323010160,7/14/2014 18:15:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,36,"IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:18:36,,1323011163,7/14/2014 18:18:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"ABDOMINAL PAIN,",51-61,10-19-28-36,"lymphoma patients without IPSID,","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939268,7/14/2014 18:20:27,,1323011877,7/14/2014 18:19:59,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,51,36,,,65,41,ABDOMINAL PAIN,IPSID,"lymphoma IPSID, ABDOMINAL PAIN, weight loss, abdominal masses, obstruction, perforation.",10-36-51-61-67-74-80-98-115-90,10-36-51-61-67-74-80-90-98-115,"lymphoma IPSID, abdominal pain, weight loss, abdominal masses, obstruction, perforation.","Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation.",51 61,36,51,36,65,41,1,RO-disease_may_have_finding,902542,"Among the lymphoma patients without IPSID, 65% had abdominal pain, weight loss, abdominal masses, obstruction, and perforation",abdominal pain,IPSID
502939269,7/14/2014 17:30:59,,1322980483,7/14/2014 17:30:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:36:08,,1322985421,7/14/2014 17:35:43,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:37:53,,1322987053,7/14/2014 17:37:38,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,152-169-176,in SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:39:16,,1322988332,7/14/2014 17:38:59,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,238,169,,,245,183,OBESITY,SEVERE OBESITY,"OBESITY through adolescence,",238-246-254,152-169-176,in SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:42:10,,1322991102,7/14/2014 17:41:53,instagc,1.0,13763729,USA,"","",75.182.89.225,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:45:32,,1322994647,7/14/2014 17:45:10,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 17:48:40,,1322996077,7/14/2014 17:47:53,clixsense,1.0,21875134,GBR,"","",91.125.61.83,238,169,,,245,183,OBESITY,SEVERE OBESITY,"persistence of OBESITY through adolescence,",223-235-238-246-254,169-176-184-190-196,SEVERE OBESITY among young men,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 18:05:03,,1323003760,7/14/2014 18:05:01,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,238,169,,,245,183,OBESITY,SEVERE OBESITY,"increased persistence of OBESITY through adolescence, which",213-223-235-238-246-254-267,152-155-166-169-176-184-190-196,in prevalence of SEVERE OBESITY among young men,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 18:08:58,,1323006672,7/14/2014 18:08:40,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939269,7/14/2014 18:26:41,,1323014330,7/14/2014 18:26:18,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,238,169,,,245,183,OBESITY,SEVERE OBESITY,OBESITY,238,169-176,SEVERE OBESITY,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country.",238,169 176,238,169,245,183,-1,RO-has_definitional_manifestation,904974,"Investigation of the developmental course through the school ages and distributional changes over time among school children suggests that the increase in prevalence of severe obesity among young men is due to an increased persistence of obesity through adolescence, which parallels the development of welfare conditions in this country",obesity,severe obesity
502939270,7/14/2014 17:32:12,,1322981643,7/14/2014 17:31:55,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA,112-119,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 17:36:34,,1322985828,7/14/2014 17:35:26,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"atypical benign reactive atypia, mild moderate dysplasia, SEVERE DYSPLASIA squamous carcinoma situ malignancies,",40-49-59-68-80-88-97-112-119-132-141-154-171,40-49-59-68-80-88-97-112-119-132-141-151-154-171,"atypical benign reactive atypia, mild moderate dysplasia, severe dysplasia SQUAMOUS CARCINOMA IN SITU malignancies,","The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 17:40:52,,1322989836,7/14/2014 17:40:36,instagc,1.0,13763729,USA,"","",75.182.89.225,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA,112-119,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 17:43:42,,1322992602,7/14/2014 17:43:12,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA,112-119,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 17:44:56,,1322994316,7/14/2014 17:44:42,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,"moderate dysplasia, (3) SEVERE DYSPLASIA or squamous carcinoma",88-97-108-112-119-129-132-141,112-119-129-132-141-151-154,severe dysplasia or SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 18:01:19,,1323001843,7/14/2014 18:01:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA or squamous carcinoma in situ,112-119-129-132-141-151-154,112-119-129-132-141-151-154,severe dysplasia or SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 18:16:36,,1323010213,7/14/2014 18:16:16,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA,112-119,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 18:20:14,,1323011765,7/14/2014 18:19:48,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA,112-119,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 18:21:41,,1323012386,7/14/2014 18:21:19,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA or squamous carcinoma in situ,112-119-129-132-141-151-154,112-119-129-132-141-151-154,severe dysplasia or SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939270,7/14/2014 18:22:53,,1323012905,7/14/2014 18:21:35,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,112,132,,,128,158,SEVERE DYSPLASIA,SQUAMOUS CARCINOMA IN SITU,SEVERE DYSPLASIA in situ,112-119-151-154,132-141-151-154,SQUAMOUS CARCINOMA IN SITU,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative.",112 119,132 141 151 154,112,132,128,158,-1,RO-disease_has_finding,901780,"The use of four categories, (1) normal, atypical benign or reactive atypia, (2) mild or moderate dysplasia, (3) severe dysplasia or squamous carcinoma in situ and (4) all malignancies, was almost equally informative",severe dysplasia,squamous carcinoma in situ
502939271,7/14/2014 17:33:49,,1322983146,7/14/2014 17:33:37,instagc,1.0,13763729,USA,"","",75.182.89.225,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,18-27,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 17:42:55,,1322991848,7/14/2014 17:42:44,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,18-27,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 17:44:29,,1322993815,7/14/2014 17:44:16,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,27,111,,,36,119,HEADACHES,MIGRAINE,HEADACHES,27,111,MIGRAINE,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 17:46:27,,1322995073,7/14/2014 17:46:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,27,111,,,36,119,HEADACHES,MIGRAINE,HEADACHES,27,111,MIGRAINE,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 17:59:15,,1323000925,7/14/2014 17:58:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,27,111,,,36,119,HEADACHES,MIGRAINE,prevalence of migraine HEADACHES,4-15-18-27,93-97-108-111-120,the prevalence of MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 18:06:45,,1323005632,7/14/2014 18:06:24,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,18-27,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 18:11:48,,1323008042,7/14/2014 18:11:26,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,18-27,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 18:13:16,,1323008686,7/14/2014 18:12:54,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,27,111,,,36,119,HEADACHES,MIGRAINE,HEADACHES,27,111,MIGRAINE,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 18:15:56,,1323009986,7/14/2014 18:15:39,vivatic,1.0,25451531,GBR,"","",83.67.28.193,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,18-27,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939271,7/14/2014 18:17:53,,1323010810,7/14/2014 18:17:22,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,27,111,,,36,119,HEADACHES,MIGRAINE,migraine HEADACHES,27-18,111-120,MIGRAINE headaches,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years.",27,111,27,111,36,119,-1,RO-has_definitional_manifestation,904693,"The prevalence of migraine headaches in males was constant through the ages studied, whereas the prevalence of migraine headaches in females reached a peak at age 12 and plateaued over the following two years",headaches,migraine
502939272,7/14/2014 17:28:23,,1322978326,7/14/2014 17:28:17,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,190,118,,,201,125,RENAL STONE,CITRATE,the management of RENAL STONE disease.,172-176-187-190-196-202,95-100-115-118-126-130-135,oral administration of CITRATE has been suggested,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 17:32:05,,1322981561,7/14/2014 17:31:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE disease.,190-196-202,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 17:43:29,,1322992378,7/14/2014 17:43:16,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE disease.,190-196-202,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 17:50:47,,1322997031,7/14/2014 17:50:01,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE,190-196,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:05:46,,1323004022,7/14/2014 18:05:34,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,190,118,,,201,125,RENAL STONE,CITRATE,the management of RENAL STONE disease.,172-176-187-190-196-202,95-100-115-118-126-130-135,oral administration of CITRATE has been suggested,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:12:32,,1323008346,7/14/2014 18:12:13,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE,190-196,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:16:39,,1323010259,7/14/2014 18:16:15,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE disease.,190-196-202,118-190-196-202,CITRATE renal stone disease.,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:24:08,,1323013338,7/14/2014 18:23:53,vivatic,1.0,25451531,GBR,"","",83.67.28.193,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE disease.,190-196-202,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:35:22,,1323018161,7/14/2014 18:35:08,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE disease.,190-196-202,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939272,7/14/2014 18:40:07,,1323020293,7/14/2014 18:39:54,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,190,118,,,201,125,RENAL STONE,CITRATE,RENAL STONE,190-196,118,CITRATE,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease.",190 196,118,190,118,201,125,1,RO-may_prevent,907076,"Urinary citrate is an important determinant for crystallization of calcium salts, and recently oral administration of citrate has been suggested to be clinically useful in the management of renal stone disease",renal stone,citrate
502939273,7/14/2014 17:28:45,,1322978625,7/14/2014 17:28:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0-11-14-21-27,DEFICIENCY of sulfur amino acids,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 17:30:54,,1322980418,7/14/2014 17:30:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,such as protein CALORIE MALNUTRITION.,77-82-85-93-101,0-11-14-21,DEFICIENCY of sulfur amino,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 17:32:13,,1322981655,7/14/2014 17:32:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0-11-14-21-27,DEFICIENCY of sulfur amino acids,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 17:57:17,,1323000099,7/14/2014 17:57:11,elite,1.0,27888773,GBR,"","",128.199.166.81,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,such as protein CALORIE MALNUTRITION.,77-82-85-93-101,0-11-14-21,DEFICIENCY of sulfur amino,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:11:26,,1323007889,7/14/2014 18:11:06,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0-11-14-21,DEFICIENCY of sulfur amino,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:31:38,,1323016572,7/14/2014 18:31:27,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0,DEFICIENCY,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:34:31,,1323017799,7/14/2014 18:34:18,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0-11-14-21-27,DEFICIENCY of sulfur amino acids,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:36:34,,1323018655,7/14/2014 18:36:06,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0-11-14-21-27,DEFICIENCY of sulfur amino acids,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:37:38,,1323019076,7/14/2014 18:37:15,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,protein CALORIE MALNUTRITION.,85-93-101,0,DEFICIENCY,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939273,7/14/2014 18:38:33,,1323019515,7/14/2014 18:38:20,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,93,0,,,113,10,CALORIE MALNUTRITION,DEFICIENCY,CALORIE MALNUTRITION.,93-101,0,DEFICIENCY,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition.,93 101,0,93,0,113,10,-1,RO-cause_of,900213,Deficiency of sulfur amino acids occurs in certain pathophysiological states such as protein-calorie malnutrition,calorie malnutrition,Deficiency
502939274,7/14/2014 17:30:21,,1322980005,7/14/2014 17:30:08,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:33:01,,1322982324,7/14/2014 17:32:47,instagc,1.0,18960682,GBR,"","",86.29.147.112,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:33:44,,1322983074,7/14/2014 17:33:25,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:49:29,,1322996436,7/14/2014 17:49:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106-123,TRAUMA significant,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:50:37,,1322996957,7/14/2014 17:50:21,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:56:43,,1322999877,7/14/2014 17:56:38,elite,1.0,27888773,GBR,"","",128.199.166.81,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,decreases survival after TRAUMATIC SHOCK and that alcohol,44-54-63-69-79-85-89-94,89-94-102-106-113-121-123,that alcohol and TRAUMA induced a significant,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 17:59:30,,1323000999,7/14/2014 17:59:16,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 18:07:00,,1323005765,7/14/2014 18:06:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,TRAUMATIC SHOCK,69-79,106,TRAUMA,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 18:07:06,,1323005822,7/14/2014 18:06:34,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,alcohol intoxication decreases after TRAUMATIC SHOCK,23-31-44-63-69-79,94-102-106-113-121-123-135,alcohol and TRAUMA induced a significant increase,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939274,7/14/2014 18:14:22,,1323009240,7/14/2014 18:13:39,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,69,106,,,84,112,TRAUMATIC SHOCK,TRAUMA,alcohol intoxication TRAUMATIC SHOCK alcohol trauma circulating microaggregates.,23-31-69-79-94-106-159-147,23-31-69-79-94-106-147-159,alcohol intoxication traumatic shock alcohol TRAUMA circulating microaggregates.,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates.,69 79,106,69,106,84,112,-1,RO-cause_of,900439,The data indicate that alcohol intoxication decreases survival after traumatic shock and that alcohol and trauma induced a significant increase in circulating microaggregates,traumatic shock,trauma
502939275,7/14/2014 17:38:44,,1322987788,7/14/2014 17:38:16,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,160,99,,,164,112,PAIN,ENDOMETRIOSIS,differential,89,89,differentiAL,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 17:41:51,,1322990755,7/14/2014 17:40:53,instagc,1.0,13763729,USA,"","",75.182.89.225,160,99,,,164,112,PAIN,ENDOMETRIOSIS,QRS,120,102,DIAGNOSIS,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 17:43:22,,1322992283,7/14/2014 17:42:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,160,99,,,164,112,PAIN,ENDOMETRIOSIS,tachycardias,132,47-59,ventricular tachycardias,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:03:13,,1323002662,7/14/2014 18:02:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,160,99,,,164,112,PAIN,ENDOMETRIOSIS,complex tachycardias and ventricular tachycardia.,124-132-145-188-200,89-102-112-115-120-124-132,differentiAL DIAGNOSIS of wide QRS complex tachycardias,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:05:16,,1323003874,7/14/2014 18:04:47,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,160,99,,,164,112,PAIN,ENDOMETRIOSIS,QRS complex tachycardias,120-124-132,89-102,differentiAL DIAGNOSIS,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:08:35,,1323006480,7/14/2014 18:07:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,160,99,,,164,112,PAIN,ENDOMETRIOSIS,recognition OF the site of origin of a ventricular tachycardia.,149-161-164-168-173-176-183-186-188-200,89-102-112-115-120-124-132,differentiAL DIAGNOSIS of wide QRS complex tachycardias,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:15:46,,1323009936,7/14/2014 18:15:05,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,160,99,,,164,112,PAIN,ENDOMETRIOSIS,QRS,120,120,QRS,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:25:44,,1323013918,7/14/2014 18:24:05,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,160,99,,,164,112,PAIN,ENDOMETRIOSIS,site of origin of a ventricular tachycardia.,168-173-176-183-186-188-200,89-102-112-115-120-124-132,differentiAL DIAGNOSIS of wide QRS complex tachycardias,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:28:58,,1323015414,7/14/2014 18:28:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,160,99,,,164,112,PAIN,ENDOMETRIOSIS,wide QRS complex tachycardias,120-124-132-115,89-102,differentiAL DIAGNOSIS,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939275,7/14/2014 18:30:54,,1323016246,7/14/2014 18:30:09,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,160,99,,,164,112,PAIN,ENDOMETRIOSIS,wide QRS complex tachycardias and recognition OF the site of origin of a ventricular tachycardia.,120-124-132-145-149-161-164-168-173-176-183-186-188-200-115,102-112-115-120-124-132,DIAGNOSIS of wide QRS complex tachycardias,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia.,,,160,99,164,112,-1,RO-has_definitional_manifestation,904502,This article concerns the electrocardiogram in ventricular tachycardias with two themes: differential diagnosis of wide QRS complex tachycardias and recognition of the site of origin of a ventricular tachycardia,pain,endometriosis
502939276,7/14/2014 17:28:48,,1322978685,7/14/2014 17:28:23,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS,105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 17:34:00,,1322983284,7/14/2014 17:33:46,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS oxygen radicals,105-113-120,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 17:35:45,,1322984988,7/14/2014 17:35:32,instagc,1.0,13763729,USA,"","",75.182.89.225,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS,105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 17:36:19,,1322985613,7/14/2014 17:36:06,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS,105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 17:58:51,,1323000737,7/14/2014 17:58:29,clixsense,1.0,21875134,GBR,"","",91.125.61.83,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,diseases of the KIDNEYS,89-98-101-105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 18:01:31,,1323001958,7/14/2014 18:01:16,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS,105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 18:03:39,,1323002869,7/14/2014 18:03:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,diseases of the KIDNEYS,89-98-101-105,43-49-55-64-79-83-89-98-101-105,"acute renal failure, PYELONEPHRITIS and other diseases of the kidneys","In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 18:12:09,,1323008205,7/14/2014 18:11:49,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,KIDNEYS,105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 18:18:34,,1323011149,7/14/2014 18:18:04,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,"pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis diseases of the KIDNEYS oxygen radicals",7-20-23-43-49-55-64-89-98-101-105-113-120,7-20-23-43-49-55-64-89-98-101-105-113-120,"pathogenesis of glomerulonephritis, acute renal failure, PYELONEPHRITIS diseases of the kidneys oxygen radicals","In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939276,7/14/2014 18:22:03,,1323012555,7/14/2014 18:21:43,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,105,64,,,112,78,KIDNEYS,PYELONEPHRITIS,diseases of the KIDNEYS,89-98-101-105,64,PYELONEPHRITIS,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved.",105,64,105,64,112,78,1,RO-has_finding_site,905268,"In the pathogenesis of glomerulonephritis, acute renal failure, pyelonephritis and other diseases of the kidneys oxygen radicals are involved",kidneys,pyelonephritis
502939277,7/14/2014 17:39:35,,1322988590,7/14/2014 17:39:17,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,disorders THROMBOCYTOSIS.,174-200,122-130-146-149-155-174,PRIMARY THROMBOCYTHEMIA or other myeloproliferative disorders,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 17:57:36,,1323000240,7/14/2014 17:57:14,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,THROMBOCYTOSIS.,200,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:02:37,,1323002396,7/14/2014 18:02:22,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,THROMBOCYTOSIS.,200,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:11:05,,1323007740,7/14/2014 18:10:46,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,THROMBOCYTOSIS.,200,122-130-146-149-155,PRIMARY THROMBOCYTHEMIA or other myeloproliferative,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:11:41,,1323007994,7/14/2014 18:11:08,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,21q marker chromosome primary thrombocythemia myeloproliferative disorders associated with THROMBOCYTOSIS.,30-35-42-130-155-174-184-195-200-122,30-35-42-122-130-155-174-184-195-200,21q marker chromosome PRIMARY THROMBOCYTHEMIA myeloproliferative disorders associated with thrombocytosis.,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:12:34,,1323008356,7/14/2014 18:10:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,other myeloproliferative disorders associated with THROMBOCYTOSIS.,149-174-184-195-200-155,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:19:58,,1323011664,7/14/2014 18:19:01,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,chromosome thrombocythemia myeloproliferative THROMBOCYTOSIS.,42-130-155-200,42-122-130-155-200,chromosome PRIMARY THROMBOCYTHEMIA myeloproliferative thrombocytosis.,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:22:35,,1323012784,7/14/2014 18:22:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,THROMBOCYTOSIS.,200,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:25:47,,1323013938,7/14/2014 18:25:11,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,THROMBOCYTOSIS.,200,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939277,7/14/2014 18:29:31,,1323015617,7/14/2014 18:29:08,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,200,122,,,214,145,THROMBOCYTOSIS,PRIMARY THROMBOCYTHEMIA,myeloproliferative disorders associated with THROMBOCYTOSIS.,174-184-195-200-155,122-130,PRIMARY THROMBOCYTHEMIA,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis.,200,122 130,200,122,214,145,-1,RO-has_manifestation,906481,The results indicate that the 21q- marker chromosome may be due to a true deletion and that the marker is no specific for primary thrombocythemia or other myeloproliferative disorders associated with thrombocytosis,thrombocytosis,primary thrombocythemia
502939278,7/14/2014 17:32:19,,1322981762,7/14/2014 17:32:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,34-45-50,INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 17:33:14,,1322982546,7/14/2014 17:33:02,instagc,1.0,18960682,GBR,"","",86.29.147.112,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,4-22-31-34-45-50,clinicopathologic features of INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 17:46:47,,1322995244,7/14/2014 17:46:32,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,34-45-50,INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:05:26,,1323003917,7/14/2014 18:05:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,4-22-31-34-45-50,clinicopathologic features of INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:10:35,,1323007458,7/14/2014 18:10:17,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,34-45-50,INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:22:50,,1323012887,7/14/2014 18:22:11,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,"clinicopathologic intestinal type adenocarcinoma stomach, and INTESTINAL METAPLASIA and intestinal type adenocarcinoma gallbladder.",4-34-45-50-98-107-111-122-133-137-148-153-198,4-34-45-50-98-107-111-122-133-137-148-153-198,"clinicopathologic INTESTINAL TYPE ADENOCARCINOMA stomach, and intestinal metaplasia and intestinal type adenocarcinoma gallbladder.","The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:24:40,,1323013507,7/14/2014 18:24:18,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,adenocarcinoma INTESTINAL METAPLASIA adenocarcinoma,50-111-122-153,34-45-50-153,INTESTINAL TYPE ADENOCARCINOMA adenocarcinoma,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:25:32,,1323013840,7/14/2014 18:25:20,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,34-45-50,INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:27:48,,1323014892,7/14/2014 18:27:31,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,4-22-31-34-45-50-65-70-75-80-91-94-98,"clinicopathologic features of INTESTINAL TYPE ADENOCARCINOMA have been well documented in the stomach,","The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939278,7/14/2014 18:35:07,,1323018066,7/14/2014 18:34:53,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,111,34,,,132,64,INTESTINAL METAPLASIA,INTESTINAL TYPE ADENOCARCINOMA,INTESTINAL METAPLASIA,111-122,34-45-50,INTESTINAL TYPE ADENOCARCINOMA,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder.",111 122,34 45 50,111,34,132,64,-1,RO-disease_has_finding,901591,"The clinicopathologic features of intestinal type adenocarcinoma have been well documented in the stomach, and intestinal metaplasia and intestinal type adenocarcinoma has also been reported in the gallbladder",intestinal metaplasia,intestinal type adenocarcinoma
502939279,7/14/2014 17:34:28,,1322983688,7/14/2014 17:34:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease, it",104-108-114-120-137,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:35:32,,1322984831,7/14/2014 17:35:17,instagc,1.0,13763729,USA,"","",75.182.89.225,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:37:15,,1322986445,7/14/2014 17:37:05,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:38:02,,1322987222,7/14/2014 17:37:48,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,163-174-182-194,"CIRRHOSIS, chronic cholestatic diseases,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:49:03,,1322996270,7/14/2014 17:48:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,114,163,,,119,172,LIVER,CIRRHOSIS,LIVER,114,163,"CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:55:35,,1322999376,7/14/2014 17:55:26,elite,1.0,27888773,GBR,"","",128.199.166.81,114,163,,,119,172,LIVER,CIRRHOSIS,"with end stage LIVER disease, whether it",99-104-108-114-120-129-137,143-150-153-163-174-182-194,"caused by alcoholic CIRRHOSIS, chronic cholestatic diseases,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 17:58:39,,1323000667,7/14/2014 17:58:21,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 18:00:20,,1323001370,7/14/2014 18:00:10,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 18:13:01,,1323008549,7/14/2014 18:12:35,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-108-114-120,153-163,"alcoholic CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939279,7/14/2014 18:18:03,,1323010897,7/14/2014 18:17:34,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,114,163,,,119,172,LIVER,CIRRHOSIS,"end stage LIVER disease,",104-114-120-108,163,"CIRRHOSIS,","SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction.",114,163,114,163,119,172,1,RO-disease_has_primary_anatomic_site,902320,"SEE:   liver    liver transplantation    The surgical implantation of a donor liver into a patient with end-stage liver disease, whether it is caused by alcoholic cirrhosis, chronic cholestatic diseases, chronic or fulminant hepatitis, or toxic liver destruction",liver,cirrhosis
502939280,7/14/2014 17:25:45,,1322976376,7/14/2014 17:25:36,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 17:46:12,,1322994965,7/14/2014 17:45:55,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA mean,16-34,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 17:47:40,,1322995668,7/14/2014 17:47:24,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 17:47:50,,1322995721,7/14/2014 17:47:37,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 17:54:01,,1322998593,7/14/2014 17:53:54,elite,1.0,27888773,GBR,"","",128.199.166.81,16,60,,,24,69,DIARRHEA,DYSENTERY,Each episode of DIARRHEA lasted a mean,0-5-13-16-25-32-34,47-51-57-60-70-74-79,"and those of DYSENTERY and ARI, 5","Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 18:04:21,,1323003165,7/14/2014 18:04:06,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,16,60,,,24,69,DIARRHEA,DYSENTERY,episode of DIARRHEA,5-13-16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 18:15:45,,1323009927,7/14/2014 18:15:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 18:16:57,,1323010400,7/14/2014 18:16:41,vivatic,1.0,25451531,GBR,"","",83.67.28.193,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 18:30:27,,1323016074,7/14/2014 18:30:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939280,7/14/2014 18:33:45,,1323017411,7/14/2014 18:33:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,16,60,,,24,69,DIARRHEA,DYSENTERY,DIARRHEA,16,60,DYSENTERY,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d.",16,60,16,60,24,69,-1,RO-has_definitional_manifestation,904873,"Each episode of diarrhea lasted a mean of 3 d, and those of dysentery and ARI, 5 d",diarrhea,dysentery
502939281,7/14/2014 17:27:40,,1322977786,7/14/2014 17:27:26,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,Rasburicase (Elitek ����渇�膩����申FOR HYPERuricemia.,0-12-20-36,0-36,RASBURICASE hyperuricemia.,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:30:55,,1322980435,7/14/2014 17:30:08,clixsense,1.0,21875134,GBR,"","",91.125.61.83,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:32:30,,1322981930,7/14/2014 17:32:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:32:39,,1322981994,7/14/2014 17:32:14,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:39:30,,1322988530,7/14/2014 17:39:14,instagc,1.0,13763729,USA,"","",75.182.89.225,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:42:02,,1322990968,7/14/2014 17:41:54,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,Rasburicase (Elitek HYPERuricemia.,0-12-36,0-36,RASBURICASE hyperuricemia.,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:46:34,,1322995125,7/14/2014 17:45:52,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 17:56:23,,1322999735,7/14/2014 17:56:07,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,HYPERuricemia.,36,0,RASBURICASE,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 18:07:45,,1323006087,7/14/2014 18:07:28,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,Rasburicase (Elitek ����渇�膩����申FOR HYPERuricemia.,0-12-20-36,0-36,RASBURICASE hyperuricemia.,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939281,7/14/2014 18:08:55,,1323006641,7/14/2014 18:08:27,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,28,0,,,41,11,HYPERURICEMIA,RASBURICASE,Rasburicase HYPERuricemia.,0-36,0-36,RASBURICASE hyperuricemia.,Rasburicase (Elitek ����渇�膩����申for hyperuricemia.,,0,28,0,41,11,1,RO-may_treat,907511,Rasburicase (Elitek ����渇�膩����申for hyperuricemia,hyperuricemia,Rasburicase
502939282,7/14/2014 17:38:15,,1322987418,7/14/2014 17:38:04,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"MENINGIOMA,",88,182-190,CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 17:52:39,,1322997968,7/14/2014 17:52:10,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"meningiomas aggressive characteristics, invasive MENINGIOMA, malignant meningioma, hemangiopericytic meningioma, meningiomas central neurofibromatosis.",26-43-54-79-88-100-110-122-140-165-182-190,26-43-54-88-100-110-122-140-165-182-190,"meningiomas aggressive characteristics, meningioma, malignant meningioma, hemangiopericytic meningioma, meningiomas CENTRAL NEUROFIBROMATOSIS.","There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 17:53:53,,1322998539,7/14/2014 17:53:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"MENINGIOMA,",88,182-190,CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 17:55:04,,1322999053,7/14/2014 17:54:23,clixsense,1.0,21875134,GBR,"","",91.125.61.83,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"invasive MENINGIOMA,",79-88,182-190,CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:06:36,,1323005516,7/14/2014 18:06:34,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"such as invasive MENINGIOMA, malignant meningioma, hemangiopericytic",71-76-79-88-100-110-122,156-165-177-182-190,multiple meningiomas with CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:15:24,,1323009676,7/14/2014 18:14:42,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"MENINGIOMA, malignant meningioma, hemangiopericytic meningioma, multiple meningiomas central neurofibromatosis.",88-100-110-122-140-156-165-182-190,88-100-110-122-156-165-182-190-140,"meningioma, malignant meningioma, hemangiopericytic meningioma, multiple meningiomas CENTRAL NEUROFIBROMATOSIS.","There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:20:27,,1323011881,7/14/2014 18:20:22,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"such as invasive MENINGIOMA, malignant meningioma, hemangiopericytic",71-76-79-88-100-110-122,156-165-177-182-190,multiple meningiomas with CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:31:10,,1323016382,7/14/2014 18:30:54,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"invasive MENINGIOMA,",79-88,156-165-177-182-190,multiple meningiomas with CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:34:04,,1323017506,7/14/2014 18:33:54,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"invasive MENINGIOMA,",79-88,182-190,CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939282,7/14/2014 18:34:17,,1323017633,7/14/2014 18:33:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,88,182,,,98,207,MENINGIOMA,CENTRAL NEUROFIBROMATOSIS,"invasive MENINGIOMA,",79-88,182-190,CENTRAL NEUROFIBROMATOSIS.,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis.",88,182 190,88,182,98,207,-1,RO-has_manifestation,906180,"There were eight cases of meningiomas with aggressive characteristics, such as invasive meningioma, malignant meningioma, hemangiopericytic meningioma, and multiple meningiomas with central neurofibromatosis",meningioma,central neurofibromatosis
502939283,7/14/2014 17:39:47,,1322988771,7/14/2014 17:39:30,instagc,1.0,13763729,USA,"","",75.182.89.225,92,69,,,97,78,JOINT,ARTHRITIS,basal JOINT,86-92,69,ARTHRITIS,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 17:42:12,,1322991177,7/14/2014 17:41:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,92,69,,,97,78,JOINT,ARTHRITIS,basal JOINT of the thumb,86-92-98-101-105,69,ARTHRITIS,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 17:45:33,,1322994648,7/14/2014 17:45:19,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,92,69,,,97,78,JOINT,ARTHRITIS,basal JOINT,86-92,69,ARTHRITIS,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 17:54:50,,1322998924,7/14/2014 17:54:44,elite,1.0,27888773,GBR,"","",128.199.166.81,92,69,,,97,78,JOINT,ARTHRITIS,of the basal JOINT of the thumb,79-82-86-92-98-101-105,44-52-65-69-79-82-86,implant arthroplasty for ARTHRITIS of the basal,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 17:57:03,,1323000025,7/14/2014 17:56:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,92,69,,,97,78,JOINT,ARTHRITIS,the basal JOINT of the thumb,82-86-92-98-101-105,52-65-69-79-82-86-92-98-101-105,arthroplasty for ARTHRITIS of the basal joint of the thumb,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 18:05:25,,1323003914,7/14/2014 18:05:23,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,92,69,,,97,78,JOINT,ARTHRITIS,of the basal JOINT of the thumb,79-82-86-92-98-101-105,44-52-65-69-79-82-86,implant arthroplasty for ARTHRITIS of the basal,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 18:09:59,,1323007127,7/14/2014 18:09:40,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,92,69,,,97,78,JOINT,ARTHRITIS,Swanson implant arthroplasty arthritis of the basal JOINT of the thumb,36-44-52-79-82-86-92-98-101-105-69,36-44-52-65-69-79-82-86-92-98-101-105,Swanson implant arthroplasty for ARTHRITIS of the basal joint of the thumb,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 18:12:10,,1323008212,7/14/2014 18:11:49,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,92,69,,,97,78,JOINT,ARTHRITIS,arthritis of the basal JOINT of the thumb,69-79-82-86-92-98-101-105,44-52-65-69-79-82-86,implant arthroplasty for ARTHRITIS of the basal,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 18:25:46,,1323013935,7/14/2014 18:25:32,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,92,69,,,97,78,JOINT,ARTHRITIS,JOINT,92,69,ARTHRITIS,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939283,7/14/2014 18:29:07,,1323015468,7/14/2014 18:28:49,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,92,69,,,97,78,JOINT,ARTHRITIS,the basal JOINT of the thumb,82-86-92-98-101-105,44-52-65-69,implant arthroplasty for ARTHRITIS,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years.,92,69,92,69,97,78,1,RO-disease_has_primary_anatomic_site,902328,The senior author has performed the Swanson implant arthroplasty for arthritis of the basal joint of the thumb for the past 12 years,joint,arthritis
502939284,7/14/2014 17:43:39,,1322992550,7/14/2014 17:43:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,90-95,oral DANAZOL,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:44:29,,1322993869,7/14/2014 17:44:16,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,oral danazol for ENDOMETRIOSIS:,90-95-103-107,90-95-103-107,oral DANAZOL for endometriosis:,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:45:52,,1322994795,7/14/2014 17:44:50,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,95-103-107,DANAZOL for endometriosis:,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:50:12,,1322996730,7/14/2014 17:49:59,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,95,DANAZOL,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:54:27,,1322998795,7/14/2014 17:53:57,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,95-122,DANAZOL a,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:54:46,,1322998905,7/14/2014 17:54:06,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,95,DANAZOL,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 17:56:11,,1322999665,7/14/2014 17:55:39,clixsense,1.0,21875134,GBR,"","",91.125.61.83,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,90-95,oral DANAZOL,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 18:00:09,,1323001256,7/14/2014 17:59:51,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,90-95,oral DANAZOL,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 18:16:24,,1323010152,7/14/2014 18:16:05,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,ENDOMETRIOSIS:,107,95-103-107,DANAZOL for endometriosis:,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939284,7/14/2014 18:19:00,,1323011304,7/14/2014 18:17:51,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,107,95,,,120,102,ENDOMETRIOSIS,DANAZOL,"Henzl MR, Corson SL, Moghissi K nasal nafarelin oral danazol ENDOMETRIOSIS: clinical trial.",0-6-10-17-21-30-57-63-90-95-107-161-170,0-6-10-17-21-30-57-63-90-95-107-122-170-161,"Henzl MR, Corson SL, Moghissi K nasal nafarelin oral DANAZOL endometriosis: a clinical trial.","Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial.",107,95,107,95,120,102,1,RO-may_treat,907879,"Henzl MR, Corson SL, Moghissi K et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial",endometriosis,danazol
502939285,7/14/2014 17:26:17,,1322976754,7/14/2014 17:25:21,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES,",180-188-198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:32:42,,1322982032,7/14/2014 17:32:15,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES,",180-188-198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:44:05,,1322992976,7/14/2014 17:43:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"ASCITES,",198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:44:14,,1322993252,7/14/2014 17:44:01,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES,",180-188-198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:49:53,,1322996598,7/14/2014 17:49:38,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"ASCITES,",198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:52:45,,1322998030,7/14/2014 17:52:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"ASCITES,",198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 17:56:32,,1322999784,7/14/2014 17:56:10,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"ASCITES,",198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 18:06:27,,1323005453,7/14/2014 18:06:15,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES,",180-188-198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 18:17:55,,1323010822,7/14/2014 18:17:40,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES, 46 patients",180-188-198-207-210,259-263-272-277-292,"123 patients with HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939285,7/14/2014 18:23:19,,1323013062,7/14/2014 18:22:54,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,198,277,,,205,301,ASCITES,HEPATOCELLULAR CARCINOMA,"sterile cirrhotic ASCITES,",180-188-198,277-292,"HEPATOCELLULAR CARCINOMA,","To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied.",198,277 292,198,277,205,301,-1,RO-disease_may_have_finding,902776,"To define patients with an ascitic fluid polymorphonuclear cell count &gt; or = 250 cells/mm3 or &gt; or = 500 cells/mm3 but without spontaneous bacterial peritonitis, 166 patients with sterile cirrhotic ascites, 46 patients with spontaneous bacterial peritonitis, 123 patients with hepatocellular carcinoma, 67 patients with peritoneal carcinomatosis or massive liver metastasis and 12 patients with other miscellaneous diseases were studied",ascites,hepatocellular carcinoma
502939286,7/14/2014 17:29:46,,1322979486,7/14/2014 17:29:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,56,30,,,60,41,LICE,PEDICULOSIS,Pediculosis Capitis (Head LICE Infestation),30-42-50-56-61,30-42-56-61-50,PEDICULOSIS Capitis (Head Lice Infestation),1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:31:36,,1322981077,7/14/2014 17:31:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,56,30,,,60,41,LICE,PEDICULOSIS,(Head LICE Infestation),50-56-61,30-42,PEDICULOSIS Capitis,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:44:59,,1322994359,7/14/2014 17:44:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,56,30,,,60,41,LICE,PEDICULOSIS,(Head LICE Infestation),50-56-61,30-42,PEDICULOSIS Capitis,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:49:59,,1322996645,7/14/2014 17:49:00,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,56,30,,,60,41,LICE,PEDICULOSIS,(Head LICE,56-50,30-42,PEDICULOSIS Capitis,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:52:21,,1322997859,7/14/2014 17:51:57,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,56,30,,,60,41,LICE,PEDICULOSIS,LICE,56,30,PEDICULOSIS,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:53:08,,1322998210,7/14/2014 17:52:44,elite,1.0,27888773,GBR,"","",128.199.166.81,56,30,,,60,41,LICE,PEDICULOSIS,Pediculosis Capitis (Head LICE Infestation) Topical: Apply,30-42-50-56-61-75-85,3-11-24-30-42-56,Adults Pediculosis &gt; PEDICULOSIS Capitis Lice,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:57:36,,1323000242,7/14/2014 17:57:12,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,56,30,,,60,41,LICE,PEDICULOSIS,Pediculosis Capitis (Head LICE Infestation),30-42-50-56-61,3-11-24-30-42-50-56-61,Adults Pediculosis &gt; PEDICULOSIS Capitis (Head Lice Infestation),1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:58:18,,1323000539,7/14/2014 17:57:59,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,56,30,,,60,41,LICE,PEDICULOSIS,LICE,56,30,PEDICULOSIS,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 17:59:15,,1323000927,7/14/2014 17:58:47,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,56,30,,,60,41,LICE,PEDICULOSIS,(Head LICE Infestation),50-56-61,30-42,PEDICULOSIS Capitis,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939286,7/14/2014 18:14:06,,1323009115,7/14/2014 18:13:43,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,56,30,,,60,41,LICE,PEDICULOSIS,Pediculosis Capitis (Head LICE Infestation),30-42-50-56-61,30,PEDICULOSIS,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck.,56,30,56,30,60,41,-1,RO-has_causative_agent,903972,1  Adults  Pediculosis  &gt;     Pediculosis Capitis (Head Lice Infestation)  Topical:  Apply to  dry  scalp hair in an amount sufficient to thoroughly wet the hair and scalp (including areas on the back of the head and nape of the neck,Lice,Pediculosis
502939287,7/14/2014 17:27:11,,1322977454,7/14/2014 17:26:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA,",38-46,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 17:30:56,,1322980442,7/14/2014 17:30:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA, sentinel lymph node biopsy",38-46-56-65-71-76,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 17:41:55,,1322990857,7/14/2014 17:41:15,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"of the primary MELANOMA, sentinel lymph node",31-34-38-46-56-65-71,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:04:30,,1323003207,7/14/2014 18:04:26,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"of the primary MELANOMA, sentinel lymph node",31-34-38-46-56-65-71,121-125-133-136-146-156-160-163,"the staging of CUTANEOUS MELANOMA, and is one","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:10:09,,1323007177,7/14/2014 18:09:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA,",38-46,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:18:19,,1323011020,7/14/2014 18:18:06,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"MELANOMA, sentinel lymph node",46-56-65-71,121-125-133-136-146,"the staging of CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:23:17,,1323013052,7/14/2014 18:22:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA,",46-38,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:27:43,,1323014840,7/14/2014 18:27:27,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA,",46-38,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:37:48,,1323019179,7/14/2014 18:37:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"primary MELANOMA,",38-46,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939287,7/14/2014 18:38:52,,1323019686,7/14/2014 18:38:32,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,46,136,,,54,154,MELANOMA,CUTANEOUS MELANOMA,"MELANOMA,",46,136-146,"CUTANEOUS MELANOMA,","Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors.",46,136 146,46,136,54,154,-1,RO-has_manifestation,906492,"Depending on the Breslow depth of the primary melanoma, sentinel lymph node biopsy is considered as standard of care for the staging of cutaneous melanoma, and is one of the most important prognostic factors",melanoma,cutaneous melanoma
502939288,7/14/2014 17:34:18,,1322983540,7/14/2014 17:34:04,instagc,1.0,13763729,USA,"","",75.182.89.225,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 17:39:35,,1322988569,7/14/2014 17:39:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 17:42:13,,1322991180,7/14/2014 17:41:56,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 17:47:19,,1322995480,7/14/2014 17:47:01,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320-338,SEVERE CONGENITAL NEUTROPENIA GI,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 17:52:54,,1322998110,7/14/2014 17:52:22,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 18:00:14,,1323001315,7/14/2014 17:59:43,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 18:26:47,,1323014393,7/14/2014 18:26:32,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 18:27:54,,1323014936,7/14/2014 18:26:27,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,severe NEUTROPENIA neutropenia,290-320-283,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 18:31:36,,1323016584,7/14/2014 18:31:24,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939288,7/14/2014 18:32:08,,1323016820,7/14/2014 18:30:31,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,290,302,,,301,331,NEUTROPENIA,SEVERE CONGENITAL NEUTROPENIA,NEUTROPENIA,290,302-309-320,SEVERE CONGENITAL NEUTROPENIA,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous.",290,302 309 320,290,302,301,331,-1,RO-has_manifestation,906040,"pneumonia, osteomyelitis Chronic granulomatous disease Recurrent staphylococcal abscesses of the skin, lungs, joints, and viscera, pneumatoceles, coarse facial features, pruritic dermatitis Hyper-IgE syndrome       Chronic gingivitis, recurrent apht hous ulcers and skin infections, severe neutropenia Severe congenital neutropenia       GI bleeding (eg, bloody diarrhea), eczema Wiskott-Aldrich syndrome 6 mo to 5 yr Paralysis after oral polio immunization X-linked agammaglobulinemia       Severe progressive infectious mononucleosis X-linked lymphoproliferative syndrome Persistent oral candidiasis, nail dystrophy, endocrine disorders (hypoparathyroidism, Addison's disease) Chronic mucocutaneous",neutropenia,Severe congenital neutropenia
502939289,7/14/2014 17:40:03,,1322989023,7/14/2014 17:39:48,instagc,1.0,13763729,USA,"","",75.182.89.225,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS,149-152,225-236,MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:06:13,,1323005341,7/14/2014 18:05:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,several JC VIRUS,141-149-152,205-213-225-236-256-260-268-277-280-291,without progressive MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls by nucleotide sequencing.,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:15:49,,1323009935,7/14/2014 18:15:00,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,"JC virus genotypes etiology progressive multifocal leukoencephalopathy, JC VIRUS isolates AIDS patients progressive multifocal leukoencephalopathy nucleotide sequencing.",47-50-56-73-85-97-108-149-152-158-182-187-213-225-236-280-291,47-50-56-73-85-97-108-149-152-158-182-187-213-225-236-280-291,"JC virus genotypes etiology progressive multifocal leukoencephalopathy, JC virus isolates AIDS patients progressive MULTIFOCAL LEUKOENCEPHALOPATHY nucleotide sequencing.","To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:16:55,,1323010402,7/14/2014 18:16:42,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,we analysed several JC VIRUS isolates amplified,129-132-141-149-152-158-167,225-236-256-260-268,MULTIFOCAL LEUKOENCEPHALOPATHY and healthy controls,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:24:48,,1323013549,7/14/2014 18:24:29,vivatic,1.0,25451531,GBR,"","",83.67.28.193,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS isolates,149-152-158,213-225-236,progressive MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:25:05,,1323013659,7/14/2014 18:24:50,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS isolates,149-152-158,225-236,MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:25:15,,1323013766,7/14/2014 18:24:42,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,"multifocal leukoencephalopathy, JC VIRUS AIDS multifocal leukoencephalopathy",108-149-152-182-225-236-97,97-108-182-225-236,"multifocal leukoencephalopathy, AIDS MULTIFOCAL LEUKOENCEPHALOPATHY","To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:28:20,,1323015184,7/14/2014 18:28:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS isolates,149-152-158,213-225-236,progressive MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:33:51,,1323017427,7/14/2014 18:33:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS,149-152,225-236,MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939289,7/14/2014 18:38:34,,1323019522,7/14/2014 18:38:03,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,149,225,,,157,255,JC VIRUS,MULTIFOCAL LEUKOENCEPHALOPATHY,JC VIRUS isolates,149-152-158,213-225-236,progressive MULTIFOCAL LEUKOENCEPHALOPATHY,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing.",149 152,225 236,149,225,157,255,1,RO-has_causative_agent,903673,"To verify the possibility of different role of JC virus genotypes in the etiology of progressive multifocal leukoencephalopathy, we analysed several JC virus isolates amplified from AIDS patients with and without progressive multifocal leukoencephalopathy and healthy controls by nucleotide sequencing",JC virus,multifocal leukoencephalopathy
502939290,7/14/2014 17:27:24,,1322977604,7/14/2014 17:27:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 17:38:03,,1322987232,7/14/2014 17:37:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 17:51:02,,1322997125,7/14/2014 17:50:39,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:21:34,,1323012336,7/14/2014 18:21:00,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,144-156-172-175,echographic characteristics of RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:31:07,,1323016340,7/14/2014 18:30:43,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:34:34,,1323017807,7/14/2014 18:34:20,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:37:06,,1323018882,7/14/2014 18:36:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:38:55,,1323019702,7/14/2014 18:38:35,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:41:04,,1323020719,7/14/2014 18:40:54,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939290,7/14/2014 18:41:28,,1323020971,7/14/2014 18:40:27,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,123,175,,,136,189,CALCIFICATION,RETINOBLASTOMA,CALCIFICATION,123,175,RETINOBLASTOMA.,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma.",123,175,123,175,136,189,1,RO-disease_may_have_finding,902875,"Disagreement still exists regarding the influence of rosette formation, pseudorosettes, necrotic changes, vascularity, and calcification on the echographic characteristics of retinoblastoma",calcification,retinoblastoma
502939291,7/14/2014 17:26:39,,1322977005,7/14/2014 17:26:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:30:21,,1322980007,7/14/2014 17:30:15,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,156,166,,,161,172,BRAIN,STROKE,infarction) or the BRAIN stroke.,137-149-152-156-166,152-156-162-166,the brain (in STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:33:37,,1322982980,7/14/2014 17:33:21,instagc,1.0,13763729,USA,"","",75.182.89.225,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:50:03,,1322996684,7/14/2014 17:49:51,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:55:49,,1322999485,7/14/2014 17:55:32,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:56:33,,1322999794,7/14/2014 17:55:50,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,156,166,,,161,172,BRAIN,STROKE,myocardial infarction) BRAIN stroke.,126-137-156-166,156-166,brain STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 17:57:24,,1323000143,7/14/2014 17:57:19,elite,1.0,27888773,GBR,"","",128.199.166.81,156,166,,,161,172,BRAIN,STROKE,infarction) or the BRAIN stroke.,137-149-152-156-166,152-156-162-166,the brain (in STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 18:16:16,,1323010085,7/14/2014 18:16:02,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 18:19:27,,1323011459,7/14/2014 18:18:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,156,166,,,161,172,BRAIN,STROKE,the BRAIN (in stroke.,156-162-166-152,152-156-162-166,the brain (in STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939291,7/14/2014 18:23:12,,1323013012,7/14/2014 18:21:35,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.93,156,166,,,161,172,BRAIN,STROKE,BRAIN,156,166,STROKE.,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke.",156,166,156,166,161,172,1,RO-disease_has_primary_anatomic_site,902102,"The restoration of blood flow to a part of the body previously deprived of adequate circulation, such as the heart muscle (in myocardial infarction) or the brain (in stroke",brain,stroke
502939292,7/14/2014 17:33:21,,1322982680,7/14/2014 17:33:07,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,183,103,,,187,112,SKIN,PSORIASIS,SKIN mucosa,183-192,66-77-86-103-114-125,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, etc.)","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 17:56:25,,1322999743,7/14/2014 17:56:19,elite,1.0,27888773,GBR,"","",128.199.166.81,183,103,,,187,112,SKIN,PSORIASIS,involvement of the SKIN and mucosa in,164-176-179-183-188-192-199,66-77-86-103-114-125-131,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, etc.) have","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:02:21,,1323002271,7/14/2014 18:02:00,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,183,103,,,187,112,SKIN,PSORIASIS,SKIN and mucosa,183-188-192,66-77-86-103-114-125,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, etc.)","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:12:06,,1323008196,7/14/2014 18:11:38,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,183,103,,,187,112,SKIN,PSORIASIS,"chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, SKIN mucosa",58-66-77-86-103-114-183-192,58-66-77-86-103-114-183-192,"chronic dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, skin mucosa","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:13:08,,1323008597,7/14/2014 18:12:34,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,183,103,,,187,112,SKIN,PSORIASIS,chronic dermatoses SKIN,58-66-183,66-77-86-103-114,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus,","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:17:18,,1323010541,7/14/2014 18:16:15,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,183,103,,,187,112,SKIN,PSORIASIS,SKIN mucosa,183-192,103,"PSORIASIS,","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:21:48,,1323012459,7/14/2014 18:21:39,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,183,103,,,187,112,SKIN,PSORIASIS,involvement of the SKIN and mucosa,164-176-179-183-188-192,66-77-86-103-114-125-131,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, etc.) have","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:26:16,,1323014141,7/14/2014 18:25:53,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,183,103,,,187,112,SKIN,PSORIASIS,secondary candidal involvement of the SKIN and mucosa,145-155-164-176-179-183-188-192,66-77-86-103-114-125,"dermatoses (eczema, neurodermatitis, PSORIASIS, pemphigus, etc.)","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:32:19,,1323016889,7/14/2014 18:31:54,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,183,103,,,187,112,SKIN,PSORIASIS,SKIN and mucosa,183-188-192,103,"PSORIASIS,","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939292,7/14/2014 18:36:48,,1323018772,7/14/2014 18:36:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,183,103,,,187,112,SKIN,PSORIASIS,candidal involvement of the SKIN,155-164-176-183-179,103,"PSORIASIS,","Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%.",183,103,183,103,187,112,1,RO-disease_has_primary_anatomic_site,902277,"Clinical and laboratory examinations of 250 patients with chronic dermatoses (eczema, neurodermatitis, psoriasis, pemphigus, etc.) have revealed secondary candidal involvement of the skin and mucosa in 121 (46.6%",skin,psoriasis
502939293,7/14/2014 17:28:44,,1322978600,7/14/2014 17:28:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,"gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance,",66-79-84-87-98-109-112-125,139-148-157-161-179-182,"multiple myeloma, and MACROGLOBULINEMIA of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis","Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 17:35:45,,1322984982,7/14/2014 17:35:29,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 17:36:45,,1322986004,7/14/2014 17:36:21,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,monoclonal gammopathies MONOCLONAL GAMMOPATHY,55-66-87-98,139-148-157-161,"multiple myeloma, and MACROGLOBULINEMIA","Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 17:44:45,,1322994152,7/14/2014 17:44:29,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 17:52:45,,1322998021,7/14/2014 17:52:24,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 18:04:25,,1323003175,7/14/2014 18:01:44,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,"gammopathies such as MONOCLONAL GAMMOPATHY of undetermined significance,",66-79-84-87-98-109-112-125,139-148-157-161-179-182,"multiple myeloma, and MACROGLOBULINEMIA of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis","Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 18:11:03,,1323007718,7/14/2014 18:10:37,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 18:13:39,,1323008868,7/14/2014 18:13:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 18:30:07,,1323015895,7/14/2014 18:28:57,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,MONOCLONAL GAMMOPATHY,87-98,161,MACROGLOBULINEMIA,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939293,7/14/2014 18:30:08,,1323015899,7/14/2014 18:29:32,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,87,161,,,108,178,MONOCLONAL GAMMOPATHY,MACROGLOBULINEMIA,monoclonal gammopathies such as MONOCLONAL GAMMOPATHY,55-66-79-84-87-98,161-179-182,MACROGLOBULINEMIA of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition.",87 98,161,87,161,108,178,-1,RO-disease_has_finding,901695,"Because of the occasional familial occurrence of other monoclonal gammopathies such as monoclonal gammopathy of undetermined significance, multiple myeloma, and macroglobulinemia of Waldenstr����渇�膩�����鐃緒申鐃順�amyloidosis (AL) should be added to the list of immunopathies with a familial predisposition",monoclonal gammopathy,macroglobulinemia
502939294,7/14/2014 17:36:11,,1322985505,7/14/2014 17:36:01,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE,61,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:36:55,,1322986138,7/14/2014 17:36:44,instagc,1.0,13763729,USA,"","",75.182.89.225,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE concentration,61-74,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:40:40,,1322989663,7/14/2014 17:40:15,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE,61,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:41:12,,1322990212,7/14/2014 17:40:53,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE,61,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:42:35,,1322991564,7/14/2014 17:42:13,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE,61,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:48:41,,1322996082,7/14/2014 17:48:28,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE concentration,61-74,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:52:35,,1322997950,7/14/2014 17:52:17,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE concentration,61-74,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 17:53:40,,1322998469,7/14/2014 17:53:31,elite,1.0,27888773,GBR,"","",128.199.166.81,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,because once the FORMALDEHYDE concentration was extremely,44-52-57-61-74-88-92,0-13-22-26-33,FORMALDEHYDE TOXICITY was partly reversible,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 18:01:45,,1323002023,7/14/2014 18:01:34,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,FORMALDEHYDE concentration,61-74,0-13,FORMALDEHYDE TOXICITY,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939294,7/14/2014 18:13:13,,1323008661,7/14/2014 18:12:48,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,61,0,,,73,21,FORMALDEHYDE,FORMALDEHYDE TOXICITY,Formaldehyde toxicity FORMALDEHYDE concentration methane production rate,0-13-61-74-148-156-167,0-13-61-74-148-156-167,FORMALDEHYDE TOXICITY formaldehyde concentration methane production rate,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered.",61,0 13,61,0,73,21,1,RO-has_causative_agent,903610,"Formaldehyde toxicity was partly reversible because once the formaldehyde concentration was extremely low or virtually removed from the system, the methane production rate was partially recovered",formaldehyde,Formaldehyde toxicity
502939295,7/14/2014 17:30:00,,1322979679,7/14/2014 17:29:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:39:54,,1322988914,7/14/2014 17:39:39,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:51:49,,1322997556,7/14/2014 17:51:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:54:04,,1322998608,7/14/2014 17:53:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:54:07,,1322998617,7/14/2014 17:53:42,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER cirrhosis,106-144,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:54:41,,1322998860,7/14/2014 17:54:30,elite,1.0,27888773,GBR,"","",128.199.166.81,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,to the native LIVER and leads more,92-95-99-106-112-116-122,122-127-135-138-144-154-158-164,more rapidly to LIVER CIRRHOSIS and graft failure.,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:58:57,,1323000782,7/14/2014 17:58:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,the native LIVER,99-106-95,138-144-154-158-164,LIVER CIRRHOSIS and graft failure.,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 17:59:50,,1323001105,7/14/2014 17:59:30,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,native LIVER,99-106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 18:20:47,,1323012038,7/14/2014 18:20:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939295,7/14/2014 18:34:03,,1323017502,7/14/2014 18:31:03,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,106,138,,,111,153,LIVER,LIVER CIRRHOSIS,LIVER,106,138-144,LIVER CIRRHOSIS,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure.",106,138 144,106,138,111,153,1,RO-disease_has_primary_anatomic_site,902010,"Generally, chronic HCV infection develops more aggressively in the liver allograft compared to the native liver and leads more rapidly to liver cirrhosis and graft failure",liver,liver cirrhosis
502939296,7/14/2014 17:37:52,,1322987036,7/14/2014 17:37:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,19-35-42-59-67,intraepithelial lesion (LSIL) changes consistent,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 17:44:13,,1322993131,7/14/2014 17:43:48,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,,,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 17:46:38,,1322995174,7/14/2014 17:46:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,93,43,,,102,47,DYSPLASIA,LSIL,"mild DYSPLASIA, CIN 1)",88-93-104-108,19-35-42,intraepithelial lesion (LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 17:47:32,,1322995620,7/14/2014 17:47:11,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,42,(LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 17:53:36,,1322998413,7/14/2014 17:53:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,19-35-42,intraepithelial lesion (LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 17:57:32,,1323000211,7/14/2014 17:57:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA, CIN 1)",93-104-108,19-35-42-49-59-67-78-83-88-93-104-108,"intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1)","Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 18:07:33,,1323005987,7/14/2014 18:07:01,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,0-4-10-19-35-42-3,Low - grade squamous intraepithelial lesion (LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 18:12:29,,1323008314,7/14/2014 18:12:10,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,93,43,,,102,47,DYSPLASIA,LSIL,"mild DYSPLASIA,",88-93,19-35-42,intraepithelial lesion (LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 18:18:04,,1323010889,7/14/2014 18:16:07,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,93,43,,,102,47,DYSPLASIA,LSIL,"DYSPLASIA,",93,42,(LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939296,7/14/2014 18:35:12,,1323018105,7/14/2014 18:34:31,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,93,43,,,102,47,DYSPLASIA,LSIL,"mild DYSPLASIA,",88-93,19-35-42,intraepithelial lesion (LSIL),"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive.",93,,93,43,102,47,-1,RO-disease_has_finding,901899,"Low-grade squamous intraepithelial lesion (LSIL) (cellular changes consistent with HPV, mild dysplasia, CIN 1) High-grade squamous intraepithelial lesion (HSIL) (moderate to severe dysplasia, CIN 2, CIN 3, CIS) (indicate if there are features suspicious of invasion) Squamous cell carcinoma Glandular cell Atypical glandular cells (specify endocervical, endometrial, or not otherwise specified) Atypical glandular cells, favor neoplastic (specify endocervi calor or not otherwise specified) Endocervical adenocarcinoma in situ (AIS) Adenocarcinoma Other (list not comprehensive",dysplasia,LSIL
502939297,7/14/2014 17:35:15,,1322984506,7/14/2014 17:35:03,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS into,15-26-43,91-106-114,streptozotocin induced DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 17:39:37,,1322988604,7/14/2014 17:39:23,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS,15-26,91-106-114,streptozotocin induced DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 17:42:52,,1322991858,7/14/2014 17:42:36,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS,15-26,114,DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 17:45:06,,1322994426,7/14/2014 17:44:21,clixsense,1.0,21875134,GBR,"","",91.125.61.83,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS,15-26,91-106-114,streptozotocin induced DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:07:20,,1323005887,7/14/2014 18:07:18,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,The ability of PANCREATIC ISLETS implanted into abdominal,0-4-12-15-26-33-43-48,86-91-106-114-123-127-136,from streptozotocin induced DIABETES was compared with,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:11:06,,1323007748,7/14/2014 18:10:39,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS implanted into abdominal muscle streptozotocin induced diabetes i.p implants.,15-26-33-43-48-58-91-106-114-149-153,15-26-33-48-58-91-106-114-149-153,pancreatic islets implanted abdominal muscle streptozotocin induced DIABETES i.p implants.,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:12:11,,1323008211,7/14/2014 18:11:52,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS,15-26,114,DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:20:34,,1323011930,7/14/2014 18:20:27,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,The ability of PANCREATIC ISLETS implanted into abdominal muscle,0-4-12-15-26-33-43-48-58,86-91-106-114-123-127-136,from streptozotocin induced DIABETES was compared with,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:21:05,,1323012125,7/14/2014 18:20:48,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS implanted into abdominal muscle,15-26-33-43-48-58,91-106-114,streptozotocin induced DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939297,7/14/2014 18:34:44,,1323017879,7/14/2014 18:34:32,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,15,114,,,32,122,PANCREATIC ISLETS,DIABETES,PANCREATIC ISLETS,15-26,91-106-114,streptozotocin induced DIABETES,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants.,15 26,114,15,114,32,122,1,RO-disease_has_primary_anatomic_site,902403,The ability of pancreatic islets implanted into abdominal muscle to effect a recovery from streptozotocin-induced diabetes was compared with that of i.p implants,pancreatic islets,diabetes
502939298,7/14/2014 17:31:21,,1322980930,7/14/2014 17:31:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,59,17,,,63,23,SKIN,ECZEMA,SKIN symptoms,59-64,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:31:53,,1322981360,7/14/2014 17:31:37,instagc,1.0,18960682,GBR,"","",86.29.147.112,59,17,,,63,23,SKIN,ECZEMA,SKIN symptoms,59-64,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:44:19,,1322993532,7/14/2014 17:44:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,59,17,,,63,23,SKIN,ECZEMA,SKIN,59,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:48:03,,1322995783,7/14/2014 17:47:51,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,59,17,,,63,23,SKIN,ECZEMA,SKIN,59,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:48:11,,1322995828,7/14/2014 17:47:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,59,17,,,63,23,SKIN,ECZEMA,SKIN,59,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:52:58,,1322998150,7/14/2014 17:52:44,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,59,17,,,63,23,SKIN,ECZEMA,SKIN,59,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:55:27,,1322999289,7/14/2014 17:55:04,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,59,17,,,63,23,SKIN,ECZEMA,"SKIN symptoms on airborne areas,",59-64-73-76-85,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:55:55,,1322999526,7/14/2014 17:55:47,elite,1.0,27888773,GBR,"","",128.199.166.81,59,17,,,63,23,SKIN,ECZEMA,"addition, 4 had SKIN symptoms on airborne",43-53-55-59-64-73-76,0-4-13-17-24-27-33,All patients had ECZEMA on their hands;,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 17:59:30,,1323001000,7/14/2014 17:59:14,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,59,17,,,63,23,SKIN,ECZEMA,SKIN,59,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939298,7/14/2014 18:11:10,,1323007778,7/14/2014 18:10:18,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,59,17,,,63,23,SKIN,ECZEMA,eczema SKIN symptoms,17-59-64,17,ECZEMA,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face.",59,17,59,17,63,23,1,RO-disease_has_primary_anatomic_site,902001,"All patients had eczema on their hands; in addition, 4 had skin symptoms on airborne areas, i.e., wrists, neck and face",skin,eczema
502939299,7/14/2014 17:28:29,,1322978374,7/14/2014 17:28:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,disorders affecting the NERVOUS SYSTEM.,85-95-105-109-117,0-19-32-41,"NEUROFIBROMATOSIS, Huntington's disease, and","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:36:22,,1322985660,7/14/2014 17:35:41,clixsense,1.0,21875134,GBR,"","",91.125.61.83,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,hereditary disorders affecting the NERVOUS SYSTEM.,85-95-105-109-117-74,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:40:34,,1322989538,7/14/2014 17:40:23,instagc,1.0,13763729,USA,"","",75.182.89.225,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,NERVOUS SYSTEM.,109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:44:15,,1322993282,7/14/2014 17:44:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,NERVOUS SYSTEM.,109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:52:34,,1322997930,7/14/2014 17:52:07,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,NERVOUS SYSTEM.,109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:55:24,,1322999254,7/14/2014 17:55:16,elite,1.0,27888773,GBR,"","",128.199.166.81,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,disorders affecting the NERVOUS SYSTEM.,85-95-105-109-117,0-19-32-41,"NEUROFIBROMATOSIS, Huntington's disease, and","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:55:31,,1322999334,7/14/2014 17:55:13,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,NERVOUS SYSTEM.,109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:56:45,,1322999891,7/14/2014 17:55:19,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,"Neurofibromatosis, Huntington's disease, myotonic dystrophy hereditary disorders NERVOUS SYSTEM.",0-19-32-45-54-74-85-109-117,0-19-32-45-54-74-85-109-117,"NEUROFIBROMATOSIS, Huntington's disease, myotonic dystrophy hereditary disorders nervous system.","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 17:56:49,,1322999918,7/14/2014 17:56:34,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,NERVOUS SYSTEM.,109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939299,7/14/2014 18:05:58,,1323004352,7/14/2014 18:05:49,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,109,0,,,123,17,NERVOUS SYSTEM,NEUROFIBROMATOSIS,disorders affecting the NERVOUS SYSTEM.,85-95-105-109-117,0,"NEUROFIBROMATOSIS,","Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system.",109 117,0,109,0,123,17,1,RO-has_finding_site,905210,"Neurofibromatosis, Huntington's disease, and myotonic dystrophy are three hereditary disorders affecting the nervous system",nervous system,Neurofibromatosis
502939300,7/14/2014 17:43:33,,1322992438,7/14/2014 17:43:19,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,73,152,,,80,163,OBESITY,PHENTERMINE,OBESITY,73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 17:53:36,,1322998436,7/14/2014 17:53:18,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,73,152,,,80,163,OBESITY,PHENTERMINE,OBESITY,73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 17:53:40,,1322998451,7/14/2014 17:53:16,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,73,152,,,80,163,OBESITY,PHENTERMINE,OBESITY,73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 17:58:13,,1323000523,7/14/2014 17:57:41,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,73,152,,,80,163,OBESITY,PHENTERMINE,exogenous OBESITY,63-73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:16:04,,1323010052,7/14/2014 18:15:41,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,73,152,,,80,163,OBESITY,PHENTERMINE,OBESITY,73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:19:01,,1323011310,7/14/2014 18:18:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,73,152,,,80,163,OBESITY,PHENTERMINE,exogenous OBESITY,63-73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:24:32,,1323013447,7/14/2014 18:24:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,73,152,,,80,163,OBESITY,PHENTERMINE,exogenous OBESITY,63-73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:27:58,,1323014976,7/14/2014 18:27:39,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,73,152,,,80,163,OBESITY,PHENTERMINE,exogenous OBESITY,63-73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:27:59,,1323014979,7/14/2014 18:27:44,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,73,152,,,80,163,OBESITY,PHENTERMINE,exogenous OBESITY,63-73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939300,7/14/2014 18:33:55,,1323017446,7/14/2014 18:33:41,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,73,152,,,80,163,OBESITY,PHENTERMINE,OBESITY,73,152,"PHENTERMINE),","3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders.",73,152,73,152,80,163,1,RO-may_treat,907893,"3 ,   39 ,   40  Obesity  Not  indicated for the management of exogenous obesity   +    (either alone or in combination with weight loss agents such as phentermine), although weight loss reported in some patients receiving the drug for other disorders",obesity,phentermine
502939301,7/14/2014 17:28:03,,1322978003,7/14/2014 17:27:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,submucosal layer of the STOMACH.,99-116-119-123-110,52-58-66-73,EARLY GASTRIC CANCER patients,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 17:39:48,,1322988782,7/14/2014 17:39:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,STOMACH.,123,52-58-66,EARLY GASTRIC CANCER,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 17:46:19,,1322995035,7/14/2014 17:46:07,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,STOMACH.,123,52-58-66,EARLY GASTRIC CANCER,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 17:47:22,,1322995529,7/14/2014 17:47:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,STOMACH.,123,52-58-66,EARLY GASTRIC CANCER,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 17:56:41,,1322999846,7/14/2014 17:56:24,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,STOMACH.,123,52-58-66,EARLY GASTRIC CANCER,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 18:12:32,,1323008339,7/14/2014 18:12:02,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,gastric cancer STOMACH.,58-123-66,52-58-66-87,EARLY GASTRIC CANCER DSCs,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 18:19:26,,1323011453,7/14/2014 18:19:21,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,layer of the STOMACH.,110-116-119-123,35-44-47-52-58-66-73-82-87,features of four EARLY GASTRIC CANCER patients with DSCs,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 18:24:17,,1323013374,7/14/2014 18:24:03,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,early gastric cancer STOMACH.,52-58-66-123,52-58-66,EARLY GASTRIC CANCER,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 18:32:38,,1323017018,7/14/2014 18:32:15,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,submucosal layer of the STOMACH.,99-110-119-123-116,52-58-66-73,EARLY GASTRIC CANCER patients,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939301,7/14/2014 18:34:20,,1323017682,7/14/2014 18:33:42,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,123,52,,,130,72,STOMACH,EARLY GASTRIC CANCER,gastric cancer STOMACH.,58-123-66,52-58-66-87,EARLY GASTRIC CANCER DSCs,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach.,123,52 58 66,123,52,130,72,1,RO-has_finding_site,905016,We studied the clinicopathological features of four early gastric cancer patients with DSCs in the submucosal layer of the stomach,stomach,early gastric cancer
502939302,7/14/2014 17:36:21,,1322985635,7/14/2014 17:35:57,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS,118-128-131-141,52-57-68-75,"oral antifungal (e.g., KETOCONAZOLE)","424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:37:27,,1322986593,7/14/2014 17:36:42,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,pulmonary BLASTOMYCOSIS,131-141,75,KETOCONAZOLE),"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:40:22,,1322989306,7/14/2014 17:40:03,instagc,1.0,13763729,USA,"","",75.182.89.225,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,pulmonary BLASTOMYCOSIS,131-141,75,KETOCONAZOLE),"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:45:47,,1322994750,7/14/2014 17:45:29,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,BLASTOMYCOSIS,141,75,KETOCONAZOLE),"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:55:37,,1322999410,7/14/2014 17:55:06,clixsense,1.0,21875134,GBR,"","",91.125.61.83,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS,118-128-131-141,75,KETOCONAZOLE),"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:56:35,,1322999808,7/14/2014 17:56:27,elite,1.0,27888773,GBR,"","",128.199.166.81,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS in patients who,118-128-131-141-155-158-167,52-57-68-75-89-93-98,"oral antifungal (e.g., KETOCONAZOLE) was used in","424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 17:59:24,,1323000976,7/14/2014 17:58:51,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS,118-128-131-141,52-57-68-75,"oral antifungal (e.g., KETOCONAZOLE)","424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 18:07:17,,1323005855,7/14/2014 18:06:57,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS in patients who,118-128-131-141-155-158-167,52-57-68-75-89-93-98,"oral antifungal (e.g., KETOCONAZOLE) was used in","424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 18:09:37,,1323006976,7/14/2014 18:09:09,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,cutaneous or pulmonary BLASTOMYCOSIS,118-128-131-141,52-57-68-75,"oral antifungal (e.g., KETOCONAZOLE)","424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939302,7/14/2014 18:13:19,,1323008741,7/14/2014 18:12:06,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,141,75,,,154,87,BLASTOMYCOSIS,KETOCONAZOLE,oral antifungal ketoconazole) cutaneous pulmonary BLASTOMYCOSIS patients asymptomatic subclinical CNS initial diagnosis.,52-57-75-118-131-141-158-175-191-203-238-246,52-57-75-118-131-141-175-191-203-238-246,oral antifungal KETOCONAZOLE) cutaneous pulmonary blastomycosis asymptomatic subclinical CNS initial diagnosis.,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis.",141,75,141,75,154,87,1,RO-may_treat,907862,"424   Treatment failures have been reported when an oral antifungal (e.g., ketoconazole) was used in the treatment of cutaneous or pulmonary blastomycosis in patients who had asymptomatic or subclinical CNS involvement at the time of the initial diagnosis",blastomycosis,ketoconazole
502939303,7/14/2014 18:04:06,,1323003054,7/14/2014 18:03:37,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,severe acute respiratory syndrome associated coronavirus (SARS COV),43-50-56-77-88-100-106-68,43-50-56-68-77-88-100-106,SEVERE ACUTE RESPIRATORY SYNDROME associated coronavirus (SARS CoV),The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:11:50,,1323008053,7/14/2014 18:11:29,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,COV),106,43-50-56-68,SEVERE ACUTE RESPIRATORY SYNDROME,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:15:12,,1323009601,7/14/2014 18:14:24,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,envelope spike (S) glycoprotein severe acute respiratory syndrome coronavirus (SARS COV) virus target cells.,4-13-19-23-50-56-68-88-100-106-137-148-155-43,4-13-19-23-43-50-56-68-88-100-106-148-155-137,envelope spike (S) glycoprotein SEVERE ACUTE RESPIRATORY SYNDROME coronavirus (SARS CoV) virus target cells.,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:17:49,,1323010783,7/14/2014 18:15:49,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,envelope spike (S) glycoprotein severe acute respiratory syndrome coronavirus (SARS COV) virus target cells.,13-19-23-43-50-56-68-88-100-106-137-148-155-4,0-4-13-19-23-43-50-56-68-88-100-106-137-148-155,The envelope spike (S) glycoprotein SEVERE ACUTE RESPIRATORY SYNDROME coronavirus (SARS CoV) virus target cells.,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:20:04,,1323011681,7/14/2014 18:19:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,coronavirus COV),88-106,43-50-56-68-100,SEVERE ACUTE RESPIRATORY SYNDROME (SARS,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:21:33,,1323012308,7/14/2014 18:20:34,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,COV),106,43-50-56-68,SEVERE ACUTE RESPIRATORY SYNDROME,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:21:55,,1323012502,7/14/2014 18:21:48,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,associated coronavirus (SARS COV) mediates the entry,77-88-100-106-111-120-124,23-36-39-43-50-56-68-77-88,glycoprotein of the SEVERE ACUTE RESPIRATORY SYNDROME associated coronavirus,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:33:02,,1323017146,7/14/2014 18:32:43,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,coronavirus (SARS COV),88-100-106,43-50-56-68-77-88,SEVERE ACUTE RESPIRATORY SYNDROME associated coronavirus,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:34:40,,1323017845,7/14/2014 18:34:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,associated coronavirus (SARS COV),77-88-100-106,43-50-56-68,SEVERE ACUTE RESPIRATORY SYNDROME,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939303,7/14/2014 18:40:41,,1323020522,7/14/2014 18:40:12,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,101,43,,,109,76,SARS-COV,SEVERE ACUTE RESPIRATORY SYNDROME,coronavirus (SARS COV),88-100-106,43-50-56-68-77-88,SEVERE ACUTE RESPIRATORY SYNDROME associated coronavirus,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells.,106,43 50 56 68,101,43,109,76,1,RO-has_causative_agent,903653,The envelope spike (S) glycoprotein of the severe acute respiratory syndrome associated coronavirus (SARS-CoV) mediates the entry of the virus into target cells,SARS-CoV,severe acute respiratory syndrome
502939304,7/14/2014 17:29:11,,1322978939,7/14/2014 17:29:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,a number of NEUROENDOCRINE DIFFERENTIATION features and antigenic,40-42-49-52-67-83-92-96,11-16-23-30-40-42,lung cancer (SCLC) manifests a number,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:36:26,,1322985727,7/14/2014 17:36:12,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,0-6-11-16-23,Small cell lung cancer (SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:42:09,,1322991085,7/14/2014 17:41:36,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,23,(SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:42:32,,1322991533,7/14/2014 17:42:10,instagc,1.0,13763729,USA,"","",75.182.89.225,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,23,(SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:44:41,,1322994094,7/14/2014 17:44:30,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,11-16,lung cancer,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:46:34,,1322995144,7/14/2014 17:46:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,23,(SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:49:34,,1322996484,7/14/2014 17:49:22,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,a number of NEUROENDOCRINE DIFFERENTIATION,40-42-49-52-67,11-16-23,lung cancer (SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 17:54:27,,1322998788,7/14/2014 17:54:08,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION,52-67,11-16-23,lung cancer (SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 18:00:03,,1323001221,7/14/2014 17:58:52,clixsense,1.0,21875134,GBR,"","",91.125.61.83,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION features,52-67-83,0-6-11-16-23,Small cell lung cancer (SCLC),Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939304,7/14/2014 18:04:15,,1323003124,7/14/2014 18:03:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,52,24,,,82,28,NEUROENDOCRINE DIFFERENTIATION,SCLC,NEUROENDOCRINE DIFFERENTIATION features,52-67-83,0-6-11-16-23-155-159-165-170-175-182,Small cell lung cancer (SCLC) non small cell lung cancer (NSCLC.,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC.,52 67,,52,24,82,28,1,RO-disease_has_finding,901737,Small cell lung cancer (SCLC) manifests a number of neuroendocrine differentiation features and antigenic characteristics that distinguish the tumour from non-small cell lung cancer (NSCLC,neuroendocrine differentiation,SCLC
502939305,7/14/2014 17:27:10,,1322977443,7/14/2014 17:26:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,Severe HYPERTENSION,13-20,64-80-83,hyperthyroidism or PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 17:46:52,,1322995277,7/14/2014 17:46:29,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 17:47:05,,1322995363,7/14/2014 17:46:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 17:48:59,,1322996223,7/14/2014 17:48:42,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,Severe HYPERTENSION,13-20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 17:51:19,,1322997300,7/14/2014 17:48:42,clixsense,1.0,21875134,GBR,"","",91.125.61.83,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,Severe HYPERTENSION,13-20,64-80-83,hyperthyroidism or PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 17:55:08,,1322999083,7/14/2014 17:54:48,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 18:27:38,,1323014797,7/14/2014 18:27:29,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 18:34:14,,1323017605,7/14/2014 18:34:03,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,Severe HYPERTENSION,13-20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 18:35:29,,1323018208,7/14/2014 18:35:09,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,Severe HYPERTENSION,13-20,64-83,hyperthyroidism PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939305,7/14/2014 18:38:51,,1323019684,7/14/2014 18:38:34,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,20,83,,,32,99,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,20,83,PHEOCHROMOCYTOMA.,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma.",20,83,20,83,32,99,1,RO-disease_may_have_finding,902850,"127 ,   a ?  Severe hypertension including that associated with hyperthyroidism or pheochromocytoma",hypertension,pheochromocytoma
502939306,7/14/2014 17:29:06,,1322978861,7/14/2014 17:28:49,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 17:31:50,,1322981329,7/14/2014 17:31:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,91,147,,,96,159,COLON,COLON CANCER,microbial growth in the COLON,67-77-84-87-91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 17:34:13,,1322983451,7/14/2014 17:34:01,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 17:48:07,,1322995820,7/14/2014 17:47:51,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 17:58:20,,1323000543,7/14/2014 17:58:02,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,91,147,,,96,159,COLON,COLON CANCER,growth in the COLON,77-84-87-91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 18:01:44,,1323001991,7/14/2014 18:01:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 18:14:59,,1323009474,7/14/2014 18:14:35,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,91,147,,,96,159,COLON,COLON CANCER,substrates microbial COLON colon cancer.,52-67-91-147-153,52-67-91-147-153,substrates microbial colon COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 18:20:01,,1323011672,7/14/2014 18:19:35,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 18:30:42,,1323016170,7/14/2014 18:30:29,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,91,147,,,96,159,COLON,COLON CANCER,microbial growth in the COLON,67-77-84-91-87,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939306,7/14/2014 18:31:47,,1323016708,7/14/2014 18:31:37,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,91,147,,,96,159,COLON,COLON CANCER,COLON,91,147-153,COLON CANCER.,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer.,91,147 153,91,147,96,159,1,RO-disease_has_primary_anatomic_site,902475,Nutrients not absorbed in the small bowel will form substrates for microbial growth in the colon which may have implication for the development of colon cancer,colon,colon cancer
502939307,7/14/2014 17:26:08,,1322976616,7/14/2014 17:25:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,"a OPIOID agonist antagonist,",15-23-30-38,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:37:10,,1322986375,7/14/2014 17:36:55,instagc,1.0,13763729,USA,"","",75.182.89.225,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,OPIOID,23,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:37:29,,1322986625,7/14/2014 17:37:11,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,"Buprenorphine, OPIOID agonist antagonist,",0-23-30-38,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:41:35,,1322990575,7/14/2014 17:41:06,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,OPIOID,23,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:44:41,,1322994095,7/14/2014 17:44:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,OPIOID,23,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:50:20,,1322996803,7/14/2014 17:49:53,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,"Buprenorphine, a mixed OPIOID agonist antagonist,",0-15-17-23-30-38,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:52:28,,1322997895,7/14/2014 17:52:16,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,OPIOID,23,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 17:58:35,,1323000633,7/14/2014 17:58:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,"Buprenorphine, a mixed OPIOID agonist antagonist,",0-15-17-23-30-38,75-77-87-91-98,a treatment for OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 18:00:51,,1323001675,7/14/2014 18:00:16,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,OPIOID,23,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939307,7/14/2014 18:01:15,,1323001812,7/14/2014 18:00:46,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,23,91,,,29,108,OPIOID,OPIOID DEPENDENCE,"mixed OPIOID agonist antagonist,",17-23-30-38,91-98,OPIOID DEPENDENCE.,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence.",23,91 98,23,91,29,108,-1,RO-has_causative_agent,903537,"Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence",opioid,opioid dependence
502939308,7/14/2014 17:29:32,,1322979255,7/14/2014 17:29:07,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"GALLSTONE dissolution,",123-133,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 17:47:01,,1322995332,7/14/2014 17:46:47,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,GALLSTONE,123,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 17:53:17,,1322998279,7/14/2014 17:52:59,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,GALLSTONE,123,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:26:52,,1323014407,7/14/2014 18:25:55,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for GALLSTONE dissolution, it dissolves stones more rapidly, with a lower incidence of stone calcifications,",31-43-46-63-68-72-88-93-97-101-111-119-123-133-154-157-167-174-179-188-193-195-201-211-214-220,31-43-46-63-68-72-88-93-97-101-111-119-123-133-154-157-167-174-179-188-193-195-201-211-214-220,"combination of chenodeoxycholic acid and URSODEOXYCHOLIC ACID was the preferred therapy for gallstone dissolution, it dissolves stones more rapidly, with a lower incidence of stone calcifications,","The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:26:58,,1323014454,7/14/2014 18:26:42,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"GALLSTONE dissolution,",123-133,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:27:15,,1323014556,7/14/2014 18:27:01,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,GALLSTONE,123,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:37:58,,1323019267,7/14/2014 18:36:53,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,GALLSTONE,123,46-63-68-72-88,chenodeoxycholic acid and URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:39:28,,1323019971,7/14/2014 18:39:11,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"GALLSTONE dissolution,",123-133,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:39:56,,1323020167,7/14/2014 18:39:43,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"GALLSTONE dissolution,",123-133,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939308,7/14/2014 18:40:09,,1323020307,7/14/2014 18:38:29,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,123,72,,,132,92,GALLSTONE,URSODEOXYCHOLIC ACID,"GALLSTONE dissolution,",123-133,72-88,URSODEOXYCHOLIC ACID,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment.",123,72 88,123,72,132,92,1,RO-may_treat,908173,"The authors concluded that the combination of chenodeoxycholic acid and ursodeoxycholic acid was the preferred therapy for gallstone dissolution, because it dissolves stones more rapidly, with a lower incidence of stone calcifications, and thus might reduce the long-term cost of treatment",gallstone,ursodeoxycholic acid
502939309,7/14/2014 17:29:24,,1322979185,7/14/2014 17:29:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,51,17,,,66,21,HEMOCHROMATOSIS,IRON,for patients with HEMOCHROMATOSIS and for others,33-37-46-51-67-71-75,2-7-14-17-22-25-33,high intake of IRON is harmful for,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 17:42:53,,1322991851,7/14/2014 17:42:33,instagc,1.0,13763729,USA,"","",75.182.89.225,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 17:46:28,,1322995090,7/14/2014 17:45:35,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 17:52:14,,1322997806,7/14/2014 17:51:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 17:57:11,,1323000058,7/14/2014 17:56:31,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 18:30:28,,1323016085,7/14/2014 18:30:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,2-7-14-17,high intake of IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 18:32:42,,1323017053,7/14/2014 18:32:29,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 18:39:53,,1323020157,7/14/2014 18:39:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 18:40:37,,1323020502,7/14/2014 18:40:22,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939309,7/14/2014 18:41:47,,1323021150,7/14/2014 18:41:10,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,51,17,,,66,21,HEMOCHROMATOSIS,IRON,HEMOCHROMATOSIS,51,17,IRON,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload.,51,17,51,17,66,21,1,RO-contraindicated_drug,901227,A high intake of iron is harmful for patients with hemochromatosis and for others at risk for iron overload,hemochromatosis,iron
502939310,7/14/2014 17:27:47,,1322977860,7/14/2014 17:27:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,Tuberculous involvement of PITUITARY is extremely rare,0-12-24-27-37-40-50,84-90-98-103-113-123-128-131,"while dealing with PITUITARY ADENOMAS, even in patients","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 17:28:23,,1322978306,7/14/2014 17:28:04,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,PITUITARY,27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 17:34:03,,1322983360,7/14/2014 17:33:50,instagc,1.0,13763729,USA,"","",75.182.89.225,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,PITUITARY,27,103-113-123,"PITUITARY ADENOMAS, even","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 17:55:01,,1322999002,7/14/2014 17:54:53,elite,1.0,27888773,GBR,"","",128.199.166.81,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,Tuberculous involvement of PITUITARY is extremely rare,0-12-24-27-37-40-50,84-90-98-103-113-123-128-131,"while dealing with PITUITARY ADENOMAS, even in patients","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:01:17,,1323001839,7/14/2014 18:00:05,clixsense,1.0,21875134,GBR,"","",91.125.61.83,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,Tuberculous involvement of PITUITARY,0-12-24-27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:22:13,,1323012596,7/14/2014 18:21:39,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,Tuberculous involvement of PITUITARY,0-12-27-24,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:22:18,,1323012641,7/14/2014 18:22:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,PITUITARY,27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:34:01,,1323017482,7/14/2014 18:33:47,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,Tuberculous involvement of PITUITARY,0-12-24-27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:34:17,,1323017628,7/14/2014 18:34:05,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,PITUITARY,27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939310,7/14/2014 18:38:57,,1323019729,7/14/2014 18:38:22,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,27,103,,,36,121,PITUITARY,PITUITARY ADENOMAS,PITUITARY,27,103-113,"PITUITARY ADENOMAS,","Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis.",27,103 113,27,103,36,121,1,RO-has_finding_site,905046,"Tuberculous involvement of pituitary is extremely rare and is usually not suspected while dealing with pituitary adenomas, even in patients with history of systemic tuberculosis",pituitary,pituitary adenomas
502939311,7/14/2014 17:35:28,,1322984773,7/14/2014 17:35:05,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,109,46,,,113,55,DRUG,TOLERANCE,DRUG naive animals.,109-114-120,40-46,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 17:44:13,,1322993129,7/14/2014 17:43:56,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,109,46,,,113,55,DRUG,TOLERANCE,DRUG naive animals.,109-114-120,46-40,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 17:51:07,,1322997161,7/14/2014 17:50:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,109,46,,,113,55,DRUG,TOLERANCE,DRUG,109,46,TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 17:53:09,,1322998212,7/14/2014 17:52:40,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,109,46,,,113,55,DRUG,TOLERANCE,acute tolerance DRUG naive animals.,40-46-109-114-120,40-46-109-114-120,acute TOLERANCE drug naive animals.,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:07:42,,1323006061,7/14/2014 18:07:20,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,109,46,,,113,55,DRUG,TOLERANCE,DRUG,109,40-46,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:11:06,,1323007747,7/14/2014 18:10:45,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,109,46,,,113,55,DRUG,TOLERANCE,DRUG,109,46,TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:17:15,,1323010531,7/14/2014 18:16:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,109,46,,,113,55,DRUG,TOLERANCE,DRUG naive,109-114,40-46,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:23:29,,1323013108,7/14/2014 18:22:52,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,109,46,,,113,55,DRUG,TOLERANCE,DRUG - naive,109-114-113,40-46,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:25:51,,1323013969,7/14/2014 18:25:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,109,46,,,113,55,DRUG,TOLERANCE,DRUG naive animals.,109-114-120,40-46,acute TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939311,7/14/2014 18:32:28,,1323016964,7/14/2014 18:32:12,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,109,46,,,113,55,DRUG,TOLERANCE,DRUG,109,46,TOLERANCE,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals.",109,46,109,46,113,55,-1,RO-has_causative_agent,903964,"In the OF experiment, the occurrence of acute tolerance was examined for different spontaneous behaviours in drug-naive animals",drug,tolerance
502939312,7/14/2014 17:29:30,,1322979242,7/14/2014 17:29:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,"cruris is extensive, DERMATOPHYTE folliculitis is present,",103-110-113-124-137-150-153,61-64-74-79-85-94-97-103,be necessary when TINEA CORPORIS or tinea cruris,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 17:47:00,,1322995334,7/14/2014 17:46:34,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE folliculitis,124-137,79-85-94-97-103,TINEA CORPORIS or tinea cruris,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 17:51:57,,1322997623,7/14/2014 17:51:37,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE,124,79-85,TINEA CORPORIS,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 17:54:27,,1322998793,7/14/2014 17:54:21,elite,1.0,27888773,GBR,"","",128.199.166.81,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,"cruris is extensive, DERMATOPHYTE folliculitis is present,",103-110-113-124-137-150-153,61-64-74-79-85-94-97-103,be necessary when TINEA CORPORIS or tinea cruris,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 17:55:19,,1322999199,7/14/2014 17:54:32,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,"antifungal tinea corporis tinea cruris DERMATOPHYTE folliculitis infection chronic topical therapy, immunocompromised coexisting disease concomitant therapy.",46-79-85-97-103-124-137-162-175-206-214-237-266-277-288-300,79-85-97-103-124-137-162-175-206-214-237-266-277-288-300,"TINEA CORPORIS tinea cruris dermatophyte folliculitis infection chronic topical therapy, immunocompromised coexisting disease concomitant therapy.","100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 18:07:14,,1323005849,7/14/2014 18:06:58,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE folliculitis,124-137,79-85,TINEA CORPORIS,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 18:10:15,,1323007279,7/14/2014 18:09:40,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE folliculitis,124-137,79-85,TINEA CORPORIS,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 18:18:21,,1323011053,7/14/2014 18:17:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE folliculitis,124-137,79-85,TINEA CORPORIS,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 18:18:35,,1323011156,7/14/2014 18:18:26,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,"cruris is extensive, DERMATOPHYTE folliculitis is present,",103-110-113-124-137-150-153,79-85-94-97-103,TINEA CORPORIS or tinea cruris,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939312,7/14/2014 18:24:49,,1323013556,7/14/2014 18:24:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,124,79,,,136,93,DERMATOPHYTE,TINEA CORPORIS,DERMATOPHYTE folliculitis,124-137,79-85-94-97-103,TINEA CORPORIS or tinea cruris,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.",124,79 85,124,79,136,93,-1,RO-has_causative_agent,903527,"100 ,   101 ,   104 ,   105 ,   106   An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy",dermatophyte,tinea corporis
502939313,7/14/2014 17:50:31,,1322996910,7/14/2014 17:50:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,8,DEFICIT,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 17:52:24,,1322997881,7/14/2014 17:51:40,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,0-8,Protein DEFICIT,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 17:52:41,,1322997996,7/14/2014 17:52:16,elite,1.0,27888773,GBR,"","",128.199.166.81,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,deficit (PD) and PROTEIN CALORIE MALNUTRITION were estimated,8-16-21-25-33-41-60-65,0-8-21-25,Protein DEFICIT and protein,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 17:58:51,,1323000735,7/14/2014 17:58:13,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION (PCM),25-33-41-54,0-8-16,Protein DEFICIT (PD),"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:04:35,,1323003231,7/14/2014 18:04:15,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,Protein deficit (PD) and PROTEIN CALORIE MALNUTRITION (PCM),0-8-16-21-25-33-41-54,0-8-16-21-25-33-41-54,Protein DEFICIT (PD) and protein calorie malnutrition (PCM),"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:09:38,,1323006980,7/14/2014 18:08:56,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,0-8-16,Protein DEFICIT (PD),"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:17:06,,1323010453,7/14/2014 18:16:55,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,0-8-21-25,Protein DEFICIT and protein,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:18:55,,1323011293,7/14/2014 18:18:39,vivatic,1.0,25451531,GBR,"","",83.67.28.193,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION (PCM),25-33-41-54,0-8-16,Protein DEFICIT (PD),"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:27:28,,1323014722,7/14/2014 18:27:16,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,0-8,Protein DEFICIT,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939313,7/14/2014 18:37:39,,1323019090,7/14/2014 18:34:45,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,25,8,,,53,15,PROTEIN CALORIE MALNUTRITION,DEFICIT,PROTEIN CALORIE MALNUTRITION,25-33-41,0-8,Protein DEFICIT,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively.",25 33 41,8,25,8,53,15,-1,RO-cause_of,900289,"Protein deficit (PD) and protein calorie malnutrition (PCM) were estimated from comparisons between control and 10% protein, and control and 2% protein-fed animals, respectively",protein calorie malnutrition,deficit
502939314,7/14/2014 17:35:29,,1322984784,7/14/2014 17:35:17,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 17:37:11,,1322986382,7/14/2014 17:36:46,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS is a herpesvirus disease.,0-8-13-19-22-24-109,48-59-74-89-109,"INFECTIOUS MONONUCLEOSIS, carcinomas immunoproliferative disease.","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 17:48:09,,1322995826,7/14/2014 17:48:00,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 17:48:21,,1322995924,7/14/2014 17:48:09,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 17:48:34,,1322996040,7/14/2014 17:48:13,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 18:06:40,,1323005534,7/14/2014 18:06:38,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS is a herpesvirus,0-8-13-19-22-24,24-36-41-48-59-74-85-89,"herpesvirus that causes INFECTIOUS MONONUCLEOSIS, carcinomas and immunoproliferative","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 18:27:30,,1323014745,7/14/2014 18:27:05,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59-74,"INFECTIOUS MONONUCLEOSIS, carcinomas","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 18:29:31,,1323015612,7/14/2014 18:28:47,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 18:34:28,,1323017746,7/14/2014 18:34:16,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939314,7/14/2014 18:37:06,,1323018880,7/14/2014 18:36:29,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,0,48,,,18,72,EPSTEIN-BARR VIRUS,INFECTIOUS MONONUCLEOSIS,EPSTEIN BARR VIRUS,0-8-13,48-59,"INFECTIOUS MONONUCLEOSIS,","Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease.",0 8 13,48 59,0,48,18,72,1,RO-has_causative_agent,903553,"Epstein-Barr virus is a herpesvirus that causes infectious mononucleosis, carcinomas and immunoproliferative disease",Epstein-Barr virus,infectious mononucleosis
502939315,7/14/2014 18:01:54,,1323002084,7/14/2014 18:01:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE,106,73,MIGRAINE,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:05:04,,1323003772,7/14/2014 18:04:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,106,73,,,114,81,HEADACHE,MIGRAINE,"migraine diagnosis, comorbidity, HEADACHE treatments",73-82-93-106-115,73-82-93-106-115,"MIGRAINE diagnosis, comorbidity, headache treatments","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:06:14,,1323005332,7/14/2014 18:05:59,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE treatments,106-115,73-82,"MIGRAINE diagnosis,","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:07:27,,1323005943,7/14/2014 18:07:25,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,106,73,,,114,81,HEADACHE,MIGRAINE,"migraine diagnosis, comorbidity, HEADACHE treatments and their",73-82-93-106-115-126-130,48-58-64-73-82-93-106,"interview about previous MIGRAINE diagnosis, comorbidity, headache","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:15:24,,1323009691,7/14/2014 18:15:09,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,106,73,,,114,81,HEADACHE,MIGRAINE,"migraine diagnosis, comorbidity, HEADACHE",73-82-93-106,73-82-93-106,"MIGRAINE diagnosis, comorbidity, headache","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:29:30,,1323015601,7/14/2014 18:29:07,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE,106,73,MIGRAINE,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:38:11,,1323019355,7/14/2014 18:37:49,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE treatments,106-115,73-82,"MIGRAINE diagnosis,","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:38:21,,1323019414,7/14/2014 18:37:42,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE,106,73,MIGRAINE,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:40:11,,1323020325,7/14/2014 18:39:57,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE treatments,106-115,73-82,"MIGRAINE diagnosis,","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939315,7/14/2014 18:41:09,,1323020767,7/14/2014 18:40:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,106,73,,,114,81,HEADACHE,MIGRAINE,HEADACHE treatments,106-115,73-82,"MIGRAINE diagnosis,","Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine.",106,73,106,73,114,81,-1,RO-has_definitional_manifestation,904719,"Migraine patients underwent a structured direct interview about previous migraine diagnosis, comorbidity, headache treatments and their side-effects and healthcare utilization for migraine",headache,migraine
502939316,7/14/2014 17:27:46,,1322977836,7/14/2014 17:27:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,176,149,,,182,157,CARIES,FLUORIDE,CARIES prophylactic purpose.,176-183-196,135-149,supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 17:37:05,,1322986287,7/14/2014 17:36:42,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,176,149,,,182,157,CARIES,FLUORIDE,CARIES,176,149,FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 17:56:12,,1322999663,7/14/2014 17:55:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,176,149,,,182,157,CARIES,FLUORIDE,CARIES,176,135-149-158-161-172-176,supplementary FLUORIDE is prescribed for caries,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 17:58:01,,1323000407,7/14/2014 17:57:37,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,176,149,,,182,157,CARIES,FLUORIDE,CARIES prophylactic purpose.,176-183-196,135-149,supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:10:38,,1323007499,7/14/2014 18:10:00,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,176,149,,,182,157,CARIES,FLUORIDE,high F groundwater supplementary fluoride CARIES prophylactic,22-27-29-135-149-176-183,22-27-29-135-149-176-183,high F groundwater supplementary FLUORIDE caries prophylactic,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:14:41,,1323009353,7/14/2014 18:14:22,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,176,149,,,182,157,CARIES,FLUORIDE,CARIES,176,149-135,supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:19:40,,1323011537,7/14/2014 18:18:11,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,176,149,,,182,157,CARIES,FLUORIDE,CARIES prophylactic,176-183,135-149,supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:20:14,,1323011760,7/14/2014 18:20:05,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,176,149,,,182,157,CARIES,FLUORIDE,is prescribed for CARIES prophylactic purpose.,158-161-172-176-183-196,118-128-135-149,available before supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:24:44,,1323013515,7/14/2014 18:23:14,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,176,149,,,182,157,CARIES,FLUORIDE,CARIES,176,149,FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939316,7/14/2014 18:25:28,,1323013819,7/14/2014 18:24:48,vivatic,1.0,25451531,GBR,"","",83.67.28.193,176,149,,,182,157,CARIES,FLUORIDE,CARIES prophylactic purpose.,176-183-196,149-135,supplementary FLUORIDE,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose.,176,149,176,149,182,157,1,RO-may_prevent,907269,The results show that high-F groundwater is prevalent and emphasize that information on domestic water supply must be available before supplementary fluoride is prescribed for caries prophylactic purpose,caries,fluoride
502939317,7/14/2014 17:34:04,,1322983370,7/14/2014 17:33:29,clixsense,1.0,21875134,GBR,"","",91.125.61.83,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS,77-81-89-99-108,30-38-48-57,INSULIN dependent diabetes mellitus,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:35:02,,1322984281,7/14/2014 17:34:47,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS,77-81-89-99-108,30-38-48-57-66,INSULIN dependent diabetes mellitus (IDDM),Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:38:19,,1322987487,7/14/2014 17:38:03,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,mellitus (IDDM) and NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM),57-66-73-77-81-89-99-108-117,30-38-48-57-66,INSULIN dependent diabetes mellitus (IDDM),Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:41:54,,1322990832,7/14/2014 17:41:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM),77-81-89-99-108-117,30,INSULIN,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:43:05,,1322992006,7/14/2014 17:42:53,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS,77-81-89-99-108,30,INSULIN,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:45:22,,1322994575,7/14/2014 17:45:09,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS,77-81-89-99-108,30,INSULIN,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:46:47,,1322995248,7/14/2014 17:46:28,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS,77-81-89-99-108,30,INSULIN,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:48:13,,1322995837,7/14/2014 17:47:46,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM),77-81-89-99-108-117,30-38-48-57-66,INSULIN dependent diabetes mellitus (IDDM),Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 17:49:16,,1322996361,7/14/2014 17:48:44,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,mellitus (IDDM) and NON INSULIN DEPENDENT DIABETES MELLITUS (NIDDM),57-66-73-77-81-89-99-108-117,30-38-48-57-66-73-77-81-89-99-108-117,INSULIN dependent diabetes mellitus (IDDM) and non insulin dependent diabetes mellitus (NIDDM),Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939317,7/14/2014 18:09:19,,1323006865,7/14/2014 18:08:56,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,77,30,,,116,37,NON-INSULIN-DEPENDENT DIABETES MELLITUS,INSULIN,mellitus (IDDM) and NON INSULIN DEPENDENT DIABETES MELLITUS,57-66-73-77-81-89-99-108,30-38-48-57,INSULIN dependent diabetes mellitus,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed.,77 81 89 99 108,30,77,30,116,37,1,RO-may_treat,908355,Analysis of the prevalence of insulin-dependent diabetes mellitus (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM) in various climato-geographic and administrative regions of the Ukraine was performed,non-insulin-dependent diabetes mellitus,insulin
502939318,7/14/2014 17:33:57,,1322983214,7/14/2014 17:33:44,instagc,1.0,18960682,GBR,"","",86.29.147.112,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,a 61 year - OLD MAN,34-36-39-43-44-48,81-99-103,dextroamPHETAMINE And amphetamine,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 17:37:42,,1322986842,7/14/2014 17:37:11,instagc,1.0,13763729,USA,"","",75.182.89.225,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,- narcolepsy,43-57,103,amphetamine,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 17:39:29,,1322988517,7/14/2014 17:36:23,clixsense,1.0,21875134,GBR,"","",91.125.61.83,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,a 61 - year - OLD MAN With narcolepsy,34-36-39-43-44-48-52-57-38,81-99-103,dextroamPHETAMINE And amphetamine,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 17:42:53,,1322991829,7/14/2014 17:42:03,clixsense,1,18408026,USA,WA,Tacoma,131.191.72.163,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,- narcolepsy,43-57,57,narcolepsy,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 17:46:07,,1322994911,7/14/2014 17:45:47,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,-,43,,,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 17:46:19,,1322995039,7/14/2014 17:45:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,- - narcolepsy,43-57-38,103,amphetamine,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 18:00:52,,1323001686,7/14/2014 18:00:37,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,61 year - OLD MAN,36-39-43-44-48,81,dextroamPHETAMINE,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 18:16:14,,1323010080,7/14/2014 18:15:25,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,- narcolepsy,43-57,57,narcolepsy,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 18:25:37,,1323013887,7/14/2014 18:24:50,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,- MAN With narcolepsy,43-48-52-57,81,dextroamPHETAMINE,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939318,7/14/2014 18:33:23,,1323017261,7/14/2014 18:33:06,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,43,89,,,53,100,NARCOLEPSY,AMPHETAMINE,61 year - OLD MAN,36-39-43-44-48,81,dextroamPHETAMINE,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure.",43,,43,89,53,100,1,RO-may_treat,907728,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� a case report, a 61-year-old man with narcolepsy taking daily dextroamphetamine and amphetamine for more than 40 years underwent a successful operation by avoidance of anesthetic agents that would cause wide swings in blood pressure",narcolepsy,amphetamine
502939319,7/14/2014 17:38:35,,1322987643,7/14/2014 17:38:21,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION in the lymphoid,114-125-132-135-139,57-65-76-82-87,mammary chain LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 17:39:59,,1322988971,7/14/2014 17:39:36,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,76-82-87,LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 17:42:42,,1322991686,7/14/2014 17:42:10,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,57-65-76-82-87,mammary chain LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 17:46:32,,1322995100,7/14/2014 17:46:20,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,76-82-87,LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 17:55:03,,1322999046,7/14/2014 17:54:28,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,76-82-87-98-101-104,LYMPH NODE METASTASES in 88 per,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 17:56:16,,1322999682,7/14/2014 17:56:08,elite,1.0,27888773,GBR,"","",128.199.166.81,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,"88 per cent, METASTATIC LESION in the lymphoid",101-104-108-114-125-132-135-139,57-65-71-76-82-87-98-101-104,mammary chain were LYMPH NODE METASTASES in 88 per,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 18:20:04,,1323011680,7/14/2014 18:19:59,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,"88 per cent, METASTATIC LESION in the lymphoid",101-104-108-114-125-132-135-139,57-65-71-76-82-87-98-101-104,mammary chain were LYMPH NODE METASTASES in 88 per,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 18:20:28,,1323011885,7/14/2014 18:20:05,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,76-82-87,LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 18:31:33,,1323016553,7/14/2014 18:31:13,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION,114-125,76-82-87,LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939319,7/14/2014 18:32:13,,1323016876,7/14/2014 18:31:52,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,114,76,,,131,97,METASTATIC LESION,LYMPH NODE METASTASES,METASTATIC LESION in the lymphoid tissue,114-125-132-135-139-148,76-82-87,LYMPH NODE METASTASES,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent.",114 125,76 82 87,114,76,131,97,-1,RO-disease_has_finding,901920,"The types of lymphatic invasion observed in the internal mammary chain were lymph node metastases in 88 per cent, metastatic lesion in the lymphoid tissue in 29 per cent and cancer cell emboli in the lymphatic channel in 71 per cent",metastatic lesion,lymph node metastases
502939320,7/14/2014 17:35:08,,1322984391,7/14/2014 17:34:55,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,222,193,,,233,195,TACHYCARDIA,VT,polymorphic ventricular TACHYCARDIA,198-210-222,168-180,ventricular tachycardia,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 17:36:26,,1322985705,7/14/2014 17:36:09,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,222,193,,,233,195,TACHYCARDIA,VT,"polymorphic ventricular TACHYCARDIA (PMVT),",198-210-222-234,180-192-168,"ventricular tachycardia (VT),","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 17:53:50,,1322998505,7/14/2014 17:53:37,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,222,193,,,233,195,TACHYCARDIA,VT,TACHYCARDIA,222,192,"(VT),","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 17:57:13,,1323000074,7/14/2014 17:56:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,222,193,,,233,195,TACHYCARDIA,VT,TACHYCARDIA,222,,,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:06:13,,1323005326,7/14/2014 18:06:11,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,222,193,,,233,195,TACHYCARDIA,VT,"(VT), polymorphic ventricular TACHYCARDIA and ventricular",192-198-210-222-242-246,168-180-192-198-210-222,"ventricular tachycardia (VT), polymorphic ventricular tachycardia","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:15:33,,1323009792,7/14/2014 18:14:10,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,222,193,,,233,195,TACHYCARDIA,VT,TACHYCARDIA,222,,,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:15:40,,1323009851,7/14/2014 18:15:25,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,222,193,,,233,195,TACHYCARDIA,VT,"(VT), polymorphic ventricular TACHYCARDIA and ventricular fibrillation",192-198-210-222-242-246-258,168-180-192-198-210-222,"ventricular tachycardia (VT), polymorphic ventricular tachycardia","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:29:06,,1323015467,7/14/2014 18:28:50,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,222,193,,,233,195,TACHYCARDIA,VT,polymorphic ventricular TACHYCARDIA,198-210-222,168-180,ventricular tachycardia,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:34:53,,1323017928,7/14/2014 18:34:07,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,222,193,,,233,195,TACHYCARDIA,VT,polymorphic ventricular TACHYCARDIA,198-210-222,168-180-192,"ventricular tachycardia (VT),","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939320,7/14/2014 18:38:02,,1323019304,7/14/2014 18:37:33,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,222,193,,,233,195,TACHYCARDIA,VT,polymorphic ventricular TACHYCARDIA,198-210-222,168-180-192,"ventricular tachycardia (VT),","The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF.",222,,222,193,233,195,-1,RO-has_definitional_manifestation,904997,"The spectrum of ventricular arrhythmias includes isolated premature ventricular contractions (PVCs), nonsustained ventricular tachycardia (NSVT), sustained monomorphic ventricular tachycardia (VT), polymorphic ventricular tachycardia (PMVT), and ventricular fibrillation (VF",tachycardia,VT
502939321,7/14/2014 17:29:17,,1322979017,7/14/2014 17:29:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,line treatment of HYPERCALCEMIA of malignancy include,32-37-47-50-64-67-78,67-78-86-98-110-118-127,"malignancy include plicamycin, CALCITONIN, gallium nitrate, and","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 17:35:59,,1322985251,7/14/2014 17:35:46,instagc,1.0,13763729,USA,"","",75.182.89.225,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA,50,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 17:36:01,,1322985256,7/14/2014 17:35:29,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA of malignancy,50-64-67,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 17:53:41,,1322998474,7/14/2014 17:53:17,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA of malignancy,50-64-67,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 17:56:06,,1322999627,7/14/2014 17:55:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA,50,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 17:58:40,,1323000687,7/14/2014 17:56:46,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,"second line treatment HYPERCALCEMIA malignancy plicamycin, calcitonin, gallium nitrate, glucocorticoids.",25-32-37-50-67-86-98-110-118-135,25-32-37-50-67-86-98-110-118-135,"second line treatment hypercalcemia malignancy plicamycin, CALCITONIN, gallium nitrate, glucocorticoids.","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 18:06:05,,1323004794,7/14/2014 18:05:51,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,line treatment of HYPERCALCEMIA of malignancy include,32-37-47-50-64-67-78,67-78-86-98-110-118-127,"malignancy include plicamycin, CALCITONIN, gallium nitrate, and","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 18:20:26,,1323011875,7/14/2014 18:19:57,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,"second line treatment of HYPERCALCEMIA of malignancy plicamycin, calcitonin, gallium nitrate,",25-32-37-47-50-64-67-86-98-110-118,25-32-37-47-50-64-67-86-98-110-118-127-135-131,"second line treatment of hypercalcemia of malignancy plicamycin, CALCITONIN, gallium nitrate, and the glucocorticoids.","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 18:24:29,,1323013432,7/14/2014 18:24:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA of malignancy,50-64-67,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939321,7/14/2014 18:33:38,,1323017385,7/14/2014 18:33:23,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,50,98,,,63,108,HYPERCALCEMIA,CALCITONIN,HYPERCALCEMIA,50,98,"CALCITONIN,","Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids.",50,98,50,98,63,108,1,RO-may_treat,907491,"Other agents used in the second-line treatment of hypercalcemia of malignancy include plicamycin, calcitonin, gallium nitrate, and the glucocorticoids",hypercalcemia,calcitonin
502939322,7/14/2014 17:27:23,,1322977584,7/14/2014 17:27:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,117,131,,,127,133,THROMBOSIS,PV,recurrent THROMBOSIS,107-117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:30:06,,1322979802,7/14/2014 17:29:03,clixsense,1.0,21875134,GBR,"","",91.125.61.83,117,131,,,127,133,THROMBOSIS,PV,recurrent THROMBOSIS in PV.,107-117-128-131,107-117-128-131,recurrent thrombosis in PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:44:57,,1322994333,7/14/2014 17:44:41,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,117,131,,,127,133,THROMBOSIS,PV,THROMBOSIS,117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:47:04,,1322995382,7/14/2014 17:46:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,117,131,,,127,133,THROMBOSIS,PV,THROMBOSIS,117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:50:31,,1322996907,7/14/2014 17:50:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,117,131,,,127,133,THROMBOSIS,PV,THROMBOSIS,117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:51:16,,1322997280,7/14/2014 17:50:40,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,117,131,,,127,133,THROMBOSIS,PV,THROMBOSIS,117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 17:58:53,,1323000762,7/14/2014 17:58:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,117,131,,,127,133,THROMBOSIS,PV,THROMBOSIS,117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 18:05:51,,1323004046,7/14/2014 18:05:48,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,117,131,,,127,133,THROMBOSIS,PV,risk of recurrent THROMBOSIS in PV.,99-104-107-117-128-131,107-117-128-131,recurrent thrombosis in PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 18:18:25,,1323011076,7/14/2014 18:18:19,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,117,131,,,127,133,THROMBOSIS,PV,risk of recurrent THROMBOSIS in PV.,99-104-107-117-128-131,107-117-128-131,recurrent thrombosis in PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939322,7/14/2014 18:25:01,,1323013632,7/14/2014 18:24:36,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,117,131,,,127,133,THROMBOSIS,PV,recurrent THROMBOSIS,107-117,131,PV.,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV.,117,131,117,131,127,133,1,RO-has_manifestation,906362,Rationale: ? History of thrombosis and advanced age have been significantly associated with a high risk of recurrent thrombosis in PV,thrombosis,PV
502939323,7/14/2014 17:29:57,,1322979664,7/14/2014 17:29:52,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,60,75,,,65,88,LIVER,LIVER FAILURE,"levels in the LIVER, causing liver failure;",46-53-56-60-67-75-81,56-60-67-75-81-90-93-98,"the liver, causing LIVER FAILURE; if this occurs,","Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 17:44:00,,1322992857,7/14/2014 17:43:48,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 17:47:45,,1322995707,7/14/2014 17:47:28,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,60,75,,,65,88,LIVER,LIVER FAILURE,"toxic levels in the LIVER,",40-46-53-56-60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:00:31,,1323001441,7/14/2014 18:00:03,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:24:02,,1323013324,7/14/2014 18:23:44,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER, liver failure;",60-75-81,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:29:54,,1323015794,7/14/2014 18:29:43,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:35:15,,1323018123,7/14/2014 18:34:30,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:37:12,,1323018927,7/14/2014 18:36:49,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,60,75,,,65,88,LIVER,LIVER FAILURE,"toxic levels in the LIVER,",40-46-53-56-60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:40:24,,1323020410,7/14/2014 18:39:58,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939323,7/14/2014 18:42:08,,1323021311,7/14/2014 18:41:26,prodege,1.0,22277051,USA,NY,Massena,24.58.192.131,60,75,,,65,88,LIVER,LIVER FAILURE,"LIVER,",60,75-81,LIVER FAILURE;,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary.",60,75 81,60,75,65,88,1,RO-disease_has_primary_anatomic_site,902160,"Protoporphyrins sometimes accumulate to toxic levels in the liver, causing liver failure; if this occurs, a liver transplant becomes necessary",liver,liver failure
502939324,7/14/2014 17:40:43,,1322989721,7/14/2014 17:40:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA,70,87,BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 17:41:38,,1322990595,7/14/2014 17:41:28,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA bumetanide.,70-87,76-79-81-87,24 h after BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 17:45:54,,1322994819,7/14/2014 17:45:33,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA,70,87,BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 17:50:17,,1322996753,7/14/2014 17:50:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA,70,87,BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 17:56:05,,1322999622,7/14/2014 17:55:58,elite,1.0,27888773,GBR,"","",128.199.166.81,70,87,,,75,97,EDEMA,BUMETANIDE,hr and no EDEMA 24 h after,60-63-67-70-76-79-81,76-79-81-87,24 h after BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 17:56:08,,1322999629,7/14/2014 17:55:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA,70,87,BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 18:05:29,,1323003922,7/14/2014 18:05:27,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,70,87,,,75,97,EDEMA,BUMETANIDE,hr and no EDEMA 24 h after,60-63-67-70-76-79-81,76-79-81-87,24 h after BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 18:14:34,,1323009302,7/14/2014 18:13:20,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,70,87,,,75,97,EDEMA,BUMETANIDE,Slight stria edema edema EDEMA bumetanide.,0-7-13-49-70-87,0-7-13-49-70-87,Slight stria edema edema edema BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 18:17:26,,1323010615,7/14/2014 18:17:18,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA 24 h after,70-76-79-81,76-79-81-87,24 h after BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939324,7/14/2014 18:17:30,,1323010653,7/14/2014 18:17:16,vivatic,1.0,25451531,GBR,"","",83.67.28.193,70,87,,,75,97,EDEMA,BUMETANIDE,EDEMA,70,87,BUMETANIDE.,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide.",70,87,70,87,75,97,1,RO-may_treat,908056,"Slight stria edema was present at 10 min, marked edema at 1 hr and no edema 24 h after bumetanide",edema,bumetanide
502939325,7/14/2014 17:28:57,,1322978800,7/14/2014 17:28:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,Down's syndrome and ALZHEIMER'S DISEASE are examined.,101-108-117-121-133-141-145,86-89-96-101-108-117-121-133,of people with DOWN'S SYNDROME and Alzheimer's disease,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 17:34:45,,1322983976,7/14/2014 17:34:29,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 17:34:54,,1322984150,7/14/2014 17:34:34,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 17:57:40,,1323000309,7/14/2014 17:57:25,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 17:59:13,,1323000910,7/14/2014 17:58:41,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,Down's syndrome ALZHEIMER'S DISEASE examined.,101-108-121-133-145,101-108-121-133-145,DOWN'S SYNDROME Alzheimer's disease examined.,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 18:00:42,,1323001611,7/14/2014 18:00:26,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,Down's syndrome and ALZHEIMER'S DISEASE,101-108-117-121-133,101-108-117-121-133,DOWN'S SYNDROME and Alzheimer's disease,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 18:18:37,,1323011190,7/14/2014 18:18:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 18:30:08,,1323015914,7/14/2014 18:29:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 18:30:29,,1323016108,7/14/2014 18:29:05,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939325,7/14/2014 18:33:28,,1323017301,7/14/2014 18:33:16,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,121,101,,,140,116,ALZHEIMER'S DISEASE,DOWN'S SYNDROME,ALZHEIMER'S DISEASE,121-133,101-108,DOWN'S SYNDROME,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined.",121 133,101 108,121,101,140,116,-1,RO-has_manifestation,906086,"In this article, the second of two parts, the needs of family and professional carers of people with Down's syndrome and Alzheimer's disease are examined",Alzheimer's disease,Down's syndrome
502939326,7/14/2014 17:50:31,,1322996906,7/14/2014 17:50:21,elite,1.0,27888773,GBR,"","",128.199.166.81,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"and prevention of IRON OVERLOAD, an effective orally",61-65-76-79-84-94-97-107,8-12-22-25-44-47,the successes of DEFEROXAMINE in the,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 17:53:16,,1322998276,7/14/2014 17:52:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25-38,DEFEROXAMINE (DFO),"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 17:56:50,,1322999929,7/14/2014 17:56:14,clixsense,1.0,21875134,GBR,"","",91.125.61.83,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"treatment and prevention of IRON OVERLOAD,",51-61-65-76-79-84,25,DEFEROXAMINE,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:04:34,,1323003229,7/14/2014 18:04:22,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD, effective orally",79-84-107-97,25-38,DEFEROXAMINE (DFO),"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:06:24,,1323005440,7/14/2014 18:06:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25-38,DEFEROXAMINE (DFO),"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:07:24,,1323005911,7/14/2014 18:07:21,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"and prevention of IRON OVERLOAD, an effective orally",61-65-76-79-84-94-97-107,8-12-22-25-44-47,the successes of DEFEROXAMINE in the,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:09:45,,1323007041,7/14/2014 18:07:18,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25,DEFEROXAMINE,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:24:34,,1323013462,7/14/2014 18:24:21,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25,DEFEROXAMINE,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:31:12,,1323016396,7/14/2014 18:30:51,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25-38,DEFEROXAMINE (DFO),"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939326,7/14/2014 18:38:28,,1323019475,7/14/2014 18:38:16,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,79,25,,,92,37,IRON OVERLOAD,DEFEROXAMINE,"IRON OVERLOAD,",79-84,25,DEFEROXAMINE,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients.",79 84,25,79,25,92,37,1,RO-may_prevent,907321,"Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients",iron overload,deferoxamine
502939327,7/14/2014 17:26:28,,1322976845,7/14/2014 17:26:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:29:21,,1322979114,7/14/2014 17:29:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23-34,BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP),"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:29:37,,1322979345,7/14/2014 17:29:32,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"zone of the SKIN and mucous membranes,",101-106-109-113-118-122-129,0-7-14-23-41-44,BENIGN MUCOUS MEMBRANE PEMPHIGOID is characterized,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:41:53,,1322990816,7/14/2014 17:41:39,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"SKIN mucous membranes,",113-122-129,0-7-14-23-34,BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP),"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:42:21,,1322991297,7/14/2014 17:42:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:45:08,,1322994438,7/14/2014 17:44:46,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 17:51:23,,1322997327,7/14/2014 17:50:52,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 18:01:59,,1323002129,7/14/2014 18:01:46,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"zone of the SKIN and mucous membranes,",101-106-109-113-122-129-118,0-7-14-23-34,BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP),"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 18:11:28,,1323007895,7/14/2014 18:11:08,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,SKIN,113,0-7-14-23,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939327,7/14/2014 18:16:33,,1323010205,7/14/2014 18:15:57,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,113,0,,,117,33,SKIN,BENIGN MUCOUS MEMBRANE PEMPHIGOID,"Benign mucous membrane pemphigoid (BMMP) immunoglobulin deposits basal zone of the SKIN and mucous membranes, blistering erosions",0-7-14-23-34-61-76-95-101-106-109-113-118-122-129-151-162,0-7-14-23-34-61-76-95-101-106-109-113-118-122-129-151-162,"BENIGN MUCOUS MEMBRANE PEMPHIGOID (BMMP) immunoglobulin deposits basal zone of the skin and mucous membranes, blistering erosions","Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions.",113,0 7 14 23,113,0,117,33,1,RO-disease_has_primary_anatomic_site,902325,"Benign mucous membrane pemphigoid (BMMP) is characterized by immunoglobulin deposits along the basal zone of the skin and mucous membranes, leading to blistering erosions of the involved regions",skin,Benign mucous membrane pemphigoid
502939328,7/14/2014 17:26:16,,1322976744,7/14/2014 17:26:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,reentrant ARRHYTHMIAS,54-64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:27:16,,1322977499,7/14/2014 17:26:32,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,heart rate dependence of reentrant ARRHYTHMIAS prognostic value antiarrhythmic drugs.,29-35-40-51-54-64-88-99-130-145,29-35-40-51-54-64-88-99-130-145,heart rate dependence of reentrant arrhythmias prognostic value ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:27:45,,1322977831,7/14/2014 17:27:21,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,ARRHYTHMIAS,64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:31:10,,1322980676,7/14/2014 17:30:57,instagc,1.0,18960682,GBR,"","",86.29.147.112,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,reentrant ARRHYTHMIAS,54-64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:47:56,,1322995741,7/14/2014 17:47:41,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,ARRHYTHMIAS,64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:51:28,,1322997361,7/14/2014 17:51:14,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,reentrant ARRHYTHMIAS,54-64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:52:54,,1322998111,7/14/2014 17:52:36,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,reentrant ARRHYTHMIAS,54-64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 17:57:01,,1322999992,7/14/2014 17:56:42,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,ARRHYTHMIAS,64,130-145,ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 18:05:47,,1323004025,7/14/2014 18:05:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,dependence of reentrant ARRHYTHMIAS,40-51-54-64,112-127-130-145,administration of ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939328,7/14/2014 18:06:46,,1323005639,7/14/2014 18:06:44,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,64,130,,,75,150,ARRHYTHMIAS,ANTIARRHYTHMIC DRUGS,dependence of reentrant ARRHYTHMIAS might be of,40-51-54-64-76-82-85,108-112-127-130-145,the administration of ANTIARRHYTHMIC DRUGS.,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs.,64,130 145,64,130,75,150,1,RO-may_prevent,907439,Our results suggest that the heart rate dependence of reentrant arrhythmias might be of prognostic value in the administration of antiarrhythmic drugs,arrhythmias,antiarrhythmic drugs
502939329,7/14/2014 17:26:57,,1322977244,7/14/2014 17:26:40,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 17:38:06,,1322987275,7/14/2014 17:37:43,instagc,1.0,13763729,USA,"","",75.182.89.225,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,uncomplicated COMPLICATED PREGNANCIES,24-42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 17:44:53,,1322994245,7/14/2014 17:44:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 17:50:02,,1322996668,7/14/2014 17:49:48,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 17:53:56,,1322998559,7/14/2014 17:53:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 18:00:04,,1323001224,7/14/2014 17:59:42,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,117-129-142-146,gestational hypertension and PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 18:00:36,,1323001493,7/14/2014 18:00:21,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 18:28:52,,1323015400,7/14/2014 18:28:30,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,uncomplicated and COMPLICATED PREGNANCIES gestational hypertension and preeclampsia.,24-38-42-54-117-129-142-146,24-38-42-117-129-142-146-54,uncomplicated and complicated pregnancies gestational hypertension and PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 18:35:51,,1323018367,7/14/2014 18:35:31,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939329,7/14/2014 18:36:28,,1323018622,7/14/2014 18:34:38,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,42,146,,,65,158,COMPLICATED PREGNANCIES,PREECLAMPSIA,COMPLICATED PREGNANCIES,42-54,146,PREECLAMPSIA.,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia.,42 54,146,42,146,65,158,-1,RO-disease_has_finding,901933,The differences between uncomplicated and complicated pregnancies offer new endpoints for an early identification of gestational hypertension and preeclampsia,complicated pregnancies,preeclampsia
502939330,7/14/2014 17:38:36,,1322987704,7/14/2014 17:38:10,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,VOMITING,98,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:01:49,,1323002048,7/14/2014 18:01:30,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,effect on the VOMITING center of the brain.,84-91-94-98-107-114-117-121,26-31-38-41-48-52,"side effect is NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:03:05,,1323002590,7/14/2014 18:02:38,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,the VOMITING center of the brain.,94-98-107-114-117-121,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:06:10,,1323005094,7/14/2014 18:06:07,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,effect on the VOMITING center of the,84-91-94-98-107-114-117,26-31-38-41-48-52-62-66-69,"side effect is NAUSEA AND VOMITING, due to direct","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:12:13,,1323008225,7/14/2014 18:11:43,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,"nausea and vomiting, VOMITING center of the brain.",41-52-98-107-114-117-121-48,41-48-52-98-107-114-117-121,"NAUSEA AND VOMITING, vomiting center of the brain.","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:12:20,,1323008281,7/14/2014 18:11:08,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,VOMITING,98,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:12:32,,1323008352,7/14/2014 18:12:11,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,VOMITING,98,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:16:41,,1323010244,7/14/2014 18:16:25,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,VOMITING center of the brain.,98-107-114-117-121,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:22:48,,1323012861,7/14/2014 18:22:17,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,VOMITING,98,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939330,7/14/2014 18:26:03,,1323014042,7/14/2014 18:25:39,instagc,1,28301350,GBR,K4,Plymouth,78.145.138.150,98,41,,,106,60,VOMITING,NAUSEA AND VOMITING,"nausea vomiting, VOMITING",41-52-98,41-48-52,"NAUSEA AND VOMITING,","The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain.",98,41 48 52,98,41,106,60,-1,RO-has_definitional_manifestation,904633,"The most common immediate side effect is nausea and vomiting, due to direct central effect on the vomiting center of the brain",vomiting,nausea and vomiting
502939331,7/14/2014 17:40:55,,1322989902,7/14/2014 17:40:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 17:46:04,,1322994882,7/14/2014 17:45:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:04:23,,1323003170,7/14/2014 18:04:01,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:26:16,,1323014144,7/14/2014 18:25:54,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:38:18,,1323019398,7/14/2014 18:38:05,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:39:10,,1323019813,7/14/2014 18:38:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:41:29,,1323020997,7/14/2014 18:41:19,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:42:04,,1323021259,7/14/2014 18:40:54,instagc,1,26801585,USA,WA,Everett,76.28.248.228,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:42:12,,1323021344,7/14/2014 18:41:53,clixsense,1,25595227,CAN,SK,North Battleford,24.72.96.119,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939331,7/14/2014 18:44:13,,1323022276,7/14/2014 18:43:58,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,109,69,,,134,83,CYTOMEGALOVIRUS RETINITIS,VALGANCICLOVIR,CYTOMEGALOVIRUS RETINITIS.,109-125,69,VALGANCICLOVIR,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.",109 125,69,109,69,134,83,1,RO-may_treat,907821,"Martin DF, Sierra-Madero J, Walmsley S, et al: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis",cytomegalovirus retinitis,valganciclovir
502939332,7/14/2014 17:53:29,,1322998385,7/14/2014 17:53:11,elite,1.0,27888773,GBR,"","",128.199.166.81,106,135,,,111,148,LIVER,LIVER ATROPHY,which preserve functional LIVER blood flow and,80-86-95-106-112-118-123,118-123-127-135-141-149-153-155,flow and prevent LIVER ATROPHY and a deterioration,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:01:28,,1323001916,7/14/2014 18:00:43,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,106,135,,,111,148,LIVER,LIVER ATROPHY,LIVER blood flow,106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:18:50,,1323011268,7/14/2014 18:18:46,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,106,135,,,111,148,LIVER,LIVER ATROPHY,which preserve functional LIVER blood flow and,80-86-95-106-112-118-123,118-123-127-135-141-149-153-155,flow and prevent LIVER ATROPHY and a deterioration,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:26:59,,1323014438,7/14/2014 18:26:37,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,106,135,,,111,148,LIVER,LIVER ATROPHY,LIVER liver atrophy,106-135-141,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:28:25,,1323015225,7/14/2014 18:28:12,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,106,135,,,111,148,LIVER,LIVER ATROPHY,LIVER blood flow,106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:31:26,,1323016504,7/14/2014 18:31:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,106,135,,,111,148,LIVER,LIVER ATROPHY,functional LIVER blood flow,95-106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:32:50,,1323017094,7/14/2014 18:32:32,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,106,135,,,111,148,LIVER,LIVER ATROPHY,functional LIVER blood flow,95-106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:33:27,,1323017288,7/14/2014 18:33:04,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,106,135,,,111,148,LIVER,LIVER ATROPHY,functional LIVER blood flow,95-106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:39:32,,1323020007,7/14/2014 18:39:11,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,106,135,,,111,148,LIVER,LIVER ATROPHY,LIVER blood flow,106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939332,7/14/2014 18:40:13,,1323020332,7/14/2014 18:39:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,106,135,,,111,148,LIVER,LIVER ATROPHY,functional LIVER blood flow,95-106-112-118,135-141,LIVER ATROPHY,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts.",106,135 141,106,135,111,148,1,RO-has_finding_site,905234,"These results suggest that in the cirrhotic rat, selective portasystemic shunts which preserve functional liver blood flow and prevent liver atrophy and a deterioration in liver function do not produce such a marked decrease in WHVP as total shunts",liver,liver atrophy
502939333,7/14/2014 17:37:06,,1322986340,7/14/2014 17:36:50,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA by radiophosphorus,17-31-36-39,58-69-71-82,BUSULPHAN: a randomized trial.,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 17:44:27,,1322993814,7/14/2014 17:44:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 17:54:10,,1322998622,7/14/2014 17:53:51,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 17:54:53,,1322998956,7/14/2014 17:54:33,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA by radiophosphorus,17-31-36-39,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:00:02,,1323001214,7/14/2014 17:59:34,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,1] POLYCYTHAEMIA VERA,0-17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:03:20,,1323002715,7/14/2014 18:03:06,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:15:28,,1323009748,7/14/2014 18:13:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:25:19,,1323013782,7/14/2014 18:25:06,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:36:12,,1323018538,7/14/2014 18:35:18,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939333,7/14/2014 18:37:32,,1323019042,7/14/2014 18:37:07,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,17,58,,,35,67,POLYCYTHAEMIA VERA,BUSULPHAN,POLYCYTHAEMIA VERA,17-31,58,BUSULPHAN:,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial.,17 31,58,17,58,35,67,1,RO-may_treat,907742,1]  Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial,polycythaemia vera,busulphan
502939334,7/14/2014 17:30:28,,1322980074,7/14/2014 17:30:22,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,"September 1989, 677 METASTATIC LESIONS were resected during",21-31-37-41-52-60-65-74,99-103-112-117-127-138-143-151,100 patients with PULMONARY METASTASES from various primary,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 17:38:20,,1322987489,7/14/2014 17:38:07,instagc,1.0,13763729,USA,"","",75.182.89.225,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 17:45:03,,1322994378,7/14/2014 17:44:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 17:54:23,,1322998730,7/14/2014 17:52:49,clixsense,1.0,21875134,GBR,"","",91.125.61.83,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 17:57:00,,1322999990,7/14/2014 17:56:54,elite,1.0,27888773,GBR,"","",128.199.166.81,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,"September 1989, 677 METASTATIC LESIONS were resected during",21-31-37-41-52-60-65-74,99-103-112-117-127-138-143-151,100 patients with PULMONARY METASTASES from various primary,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 18:04:46,,1323003411,7/14/2014 18:04:34,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 18:14:53,,1323009421,7/14/2014 18:14:20,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 18:27:11,,1323014552,7/14/2014 18:27:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 18:30:23,,1323016033,7/14/2014 18:30:12,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS,41-52,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939334,7/14/2014 18:34:51,,1323017916,7/14/2014 18:34:24,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,41,117,,,59,137,METASTATIC LESIONS,PULMONARY METASTASES,METASTATIC LESIONS pulmonary metastases,41-52-117-127,117-127,PULMONARY METASTASES,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan.",41 52,117 127,41,117,59,137,-1,RO-disease_has_finding,901700,"Between May 1969 and September 1989, 677 metastatic lesions were resected during 107 operations in 100 patients with pulmonary metastases from various primary sites at the Center for Adult Diseases, Osaka, Japan",metastatic lesions,pulmonary metastases
502939335,7/14/2014 17:31:54,,1322981383,7/14/2014 17:31:41,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 17:37:37,,1322986780,7/14/2014 17:37:27,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 17:39:00,,1322988002,7/14/2014 17:38:37,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 17:55:54,,1322999524,7/14/2014 17:55:28,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 17:57:31,,1323000194,7/14/2014 17:56:52,clixsense,1.0,21875134,GBR,"","",91.125.61.83,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 18:02:25,,1323002305,7/14/2014 18:02:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,"BACILLUS ANTHRACIS is the causative agent of anthrax,",0-9-19-22-26-36-42-45,0-9-19-26-36-42-45-22,"Bacillus anthracis is the causative agent of ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 18:17:39,,1323010708,7/14/2014 18:17:27,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,"BACILLUS ANTHRACIS is the causative agent of anthrax,",0-9-19-22-26-36-42-45,26-36-42-45-54-58-62,"causative agent of ANTHRAX, and the spore","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 18:26:36,,1323014284,7/14/2014 18:26:21,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,"BACILLUS ANTHRACIS anthrax,",0-9-45,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 18:28:04,,1323015031,7/14/2014 18:27:49,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,"BACILLUS ANTHRACIS is the causative agent of anthrax,",0-9-19-22-26-36-42-45,0-9-19-22-26-36-42-45,"Bacillus anthracis is the causative agent of ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939335,7/14/2014 18:32:09,,1323016823,7/14/2014 18:31:58,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,0,45,,,18,52,BACILLUS ANTHRACIS,ANTHRAX,BACILLUS ANTHRACIS,0-9,45,"ANTHRAX,","Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host.",0 9,45,0,45,18,52,1,RO-has_causative_agent,903605,"Bacillus anthracis is the causative agent of anthrax, and the spore form of the bacterium represents the infectious particle introduced into a host",Bacillus anthracis,anthrax
502939336,7/14/2014 17:27:42,,1322977805,7/14/2014 17:27:17,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,tuberculin TUBERCULOSIS.,84-137,84-137,TUBERCULIN tuberculosis.,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:28:37,,1322978499,7/14/2014 17:28:31,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,of these developed TUBERCULOSIS.,118-121-127-137,66-72-81-84-95-98-109,"more) reaction to TUBERCULIN on admission, 2%","Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:33:37,,1322982979,7/14/2014 17:33:25,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:44:26,,1322993820,7/14/2014 17:44:13,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:47:16,,1322995459,7/14/2014 17:46:53,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:50:14,,1322996740,7/14/2014 17:50:03,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,developed TUBERCULOSIS.,127-137,72-81-84-98-95,"reaction to TUBERCULIN on admission,","Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 17:51:36,,1322997461,7/14/2014 17:51:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 18:15:04,,1323009524,7/14/2014 18:14:42,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 18:26:19,,1323014170,7/14/2014 18:26:04,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84-137,TUBERCULIN tuberculosis.,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939336,7/14/2014 18:27:26,,1323014699,7/14/2014 18:27:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,137,84,,,149,94,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,137,84,TUBERCULIN,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis.",137,84,137,84,149,94,1,RO-may_diagnose,906630,"Whereas only 15% to 20% of persons showed a significant (10 mm or more) reaction to tuberculin on admission, 2% to 3% of these developed tuberculosis",tuberculosis,tuberculin
502939337,7/14/2014 17:43:47,,1322992666,7/14/2014 17:43:30,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,"salicylates, KNOWN HYpersensitivity",275-303-309,215-221,"renal impairment,","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 17:56:30,,1322999802,7/14/2014 17:55:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,HYpersensitivity,309,253-261-264-272-275,"allergy to aspirin or salicylates,","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:02:03,,1323002169,7/14/2014 18:01:20,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,"allergy to aspirin or salicylates,",253-261-264-275-272,204-212-215-221,"hepatic or renal impairment,","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:18:25,,1323011077,7/14/2014 18:18:04,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,HYpersensitivity,309,253,allergy,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:19:35,,1323011517,7/14/2014 18:19:28,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,"salicylates, and thoSE WITH KNOWN HYpersensitivity",275-288-292-298-303-309,215-221-233-242-247-253,"renal impairment, patienTS WITH known allergy","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:25:36,,1323013879,7/14/2014 18:24:49,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,KNOWN HYpersensitivity to any component of the kit.,303-309-326-329-333-343-346-350,253-261-264-272-275,"allergy to aspirin or salicylates,","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:25:54,,1323014009,7/14/2014 18:24:45,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,"Helidac (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and thoSE WITH KNOWN HYpersensitivity",23-56-61-72-86-101-109-124-140-143-152-155-163-170-180-190-199-204-212-215-221-233-242-247-253-261-264-275-288-292-298-303-309-272,56-61-72-86-101-109-124-140-143-152-155-163-170-180-190-199-204-215-221-233-242-247-253-261-264-272-275-288-292-298-303-309-212,"(kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patienTS WITH known allergy to aspirin or salicylates, and those with known hypersensitivity","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:31:10,,1323016371,7/14/2014 18:30:51,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,HYpersensitivity,309,215-221,"renal impairment,","152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:34:23,,1323017691,7/14/2014 18:32:10,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,HYpersensitivity,309,253,allergy,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939337,7/14/2014 18:36:01,,1323018429,7/14/2014 18:35:08,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,295,239,,,311,246,HYPERSENSITIVITY,ALLERGY,KNOWN HYpersensitivity,309-303,247-253,known allergy,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit.",,,295,239,311,246,-1,RO-cause_of,900091,"152 ,   197 ,   430 ?  Helidac ����渇�膩�����鐃緒申鐃順�herapy (kit containing tetracycline, metronidazole, bismuth subsalicylate) contraindicated in pregnant or nursing women, pediatric patients, patients with hepatic or renal impairment, patients with known allergy to aspirin or salicylates, and those with known hypersensitivity to any component of the kit",hypersensitivity,allergy
502939338,7/14/2014 17:26:31,,1322976885,7/14/2014 17:25:29,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,34,54,,,38,63,PAIN,NEURALGIA,symptoms local PAIN neuralgia syndrome rupture,14-28-34-54-64-83,28-34-54-64-83,local pain NEURALGIA syndrome rupture,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:30:15,,1322979919,7/14/2014 17:30:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:33:27,,1322982804,7/14/2014 17:33:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:40:14,,1322989239,7/14/2014 17:39:01,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,34,54,,,38,63,PAIN,NEURALGIA,PAIN,34,54,NEURALGIA,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:43:18,,1322992268,7/14/2014 17:43:06,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,34,54,,,38,63,PAIN,NEURALGIA,PAIN,34,54,NEURALGIA,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:45:49,,1322994781,7/14/2014 17:45:34,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:57:24,,1323000139,7/14/2014 17:57:02,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54,NEURALGIA,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 17:59:53,,1323001142,7/14/2014 17:59:36,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 18:24:27,,1323013430,7/14/2014 18:24:09,vivatic,1.0,25451531,GBR,"","",83.67.28.193,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939338,7/14/2014 18:33:14,,1323017218,7/14/2014 18:33:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,34,54,,,38,63,PAIN,NEURALGIA,local PAIN,28-34,54-64,NEURALGIA syndrome,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2.",34,54,34,54,38,63,-1,RO-has_definitional_manifestation,904590,"The principal symptoms were local pain in 8 patients, neuralgia syndrome in 3, and rupture in 2",pain,neuralgia
502939339,7/14/2014 17:28:03,,1322978020,7/14/2014 17:27:47,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 17:30:48,,1322980337,7/14/2014 17:30:41,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"mononucleosis, followed by FEVER, weight loss, and",73-88-97-100-107-114-120,49-51-59-62-73-88-97-100,"a history of INFECTIOUS MONONUCLEOSIS, followed by fever,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 17:39:13,,1322988261,7/14/2014 17:38:56,instagc,1.0,13763729,USA,"","",75.182.89.225,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 17:44:40,,1322994070,7/14/2014 17:44:27,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 17:48:15,,1322995869,7/14/2014 17:47:50,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 17:55:10,,1322999080,7/14/2014 17:54:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"infectious mononucleosis, followed by FEVER, weight loss, and splenomegaly.",62-73-88-97-100-107-114-120-124,62-73-88-97-100-107-114-120-124,"INFECTIOUS MONONUCLEOSIS, followed by fever, weight loss, and splenomegaly.","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 18:21:38,,1323012376,7/14/2014 18:21:29,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"mononucleosis, followed by FEVER, weight loss,",73-88-97-100-107-114,49-51-59-62-73-88-97-100,"a history of INFECTIOUS MONONUCLEOSIS, followed by fever,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 18:25:49,,1323013951,7/14/2014 18:25:29,vivatic,1.0,25451531,GBR,"","",83.67.28.193,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 18:28:49,,1323015385,7/14/2014 18:28:38,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",100,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939339,7/14/2014 18:36:06,,1323018489,7/14/2014 18:35:23,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,100,62,,,105,86,FEVER,INFECTIOUS MONONUCLEOSIS,"infectious mononucleosis, FEVER, splenomegaly.",62-73-100-124,62-73,"INFECTIOUS MONONUCLEOSIS,","We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly.",100,62 73,100,62,105,86,1,RO-disease_has_finding,901550,"We describe a case of a 29 year-old patient with a history of infectious mononucleosis, followed by fever, weight loss, and splenomegaly",fever,infectious mononucleosis
502939340,7/14/2014 17:32:45,,1322982089,7/14/2014 17:32:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION of the skull,45-56-63-66-70,15-24-29,"multiple BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 17:39:22,,1322988398,7/14/2014 17:39:02,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,"bone metastases, METASTATIC LESION",24-29-45-56,24-29-41-45-56,"BONE METASTASES, the metastatic lesion","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 17:39:50,,1322988866,7/14/2014 17:39:37,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,"bone metastases, METASTATIC LESION of the skull",24-29-45-56-63-66-70,15-24-29-41-45-56,"multiple BONE METASTASES, the metastatic lesion","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 17:42:52,,1322991843,7/14/2014 17:42:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION,45-56,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 17:54:34,,1322998824,7/14/2014 17:54:11,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION,45-56,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 18:16:54,,1323010406,7/14/2014 18:16:36,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION,45-56,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 18:28:27,,1323015235,7/14/2014 18:28:05,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION of the skull,45-56-63-66-70,15-24-29,"multiple BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 18:31:53,,1323016730,7/14/2014 18:31:34,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION of the skull,45-56-63-66-70,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 18:39:10,,1323019812,7/14/2014 18:38:44,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION of the skull,45-56-63-66-70,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939340,7/14/2014 18:39:48,,1323020109,7/14/2014 18:39:20,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,45,24,,,62,39,METASTATIC LESION,BONE METASTASES,METASTATIC LESION of the skull,45-56-63-66-70,24-29,"BONE METASTASES,","In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67.",45 56,24 29,45,24,62,39,1,RO-disease_has_finding,901939,"In the case of multiple bone metastases, the metastatic lesion of the skull was clearly demonstrated by Tl-201 but not by Ga-67",metastatic lesion,bone metastases
502939341,7/14/2014 17:35:16,,1322984524,7/14/2014 17:34:54,instagc,1.0,13763729,USA,"","",75.182.89.225,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 17:39:01,,1322988032,7/14/2014 17:38:12,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 17:44:46,,1322994148,7/14/2014 17:44:16,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,,,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 17:45:32,,1322994644,7/14/2014 17:45:09,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,,,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 17:50:52,,1322997051,7/14/2014 17:50:32,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 18:20:14,,1323011748,7/14/2014 18:19:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 18:21:28,,1323012284,7/14/2014 18:20:36,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,"heparin bolus of 60 U kg (maximum, 4000 U)",11-19-25-28-31-33-36-46-51,11-19-25-28-31-33-36-46-51,"heparin bolus of 60 U kg (maximum, 4000 U)","An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 18:28:43,,1323015370,7/14/2014 18:27:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 18:35:07,,1323018068,7/14/2014 18:34:45,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939341,7/14/2014 18:35:30,,1323018210,7/14/2014 18:34:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,153,126,,,174,135,MYOCARDIAL INFARCTION,ALTEPLASE,12-U,-1,-1,12-U,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction.",,,153,126,174,135,1,RO-may_treat,908164,"An initial heparin bolus of 60 U/kg (maximum, 4000 U) followed by a 12-U/kg/h infusion (maximum 1000 U/h) is recommended with alteplase for ST-elevation myocardial infarction",myocardial infarction,alteplase
502939342,7/14/2014 17:25:28,,1322976192,7/14/2014 17:24:18,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,"Atopic conditions allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS asthma.",0-7-35-45-52-60-69-88-26,0-7-26-35-45-52-60-69-88,"ATOPIC conditions allergic rhinitis, atopic eczema, allergic conjunctivitis asthma.","Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 17:32:58,,1322982298,7/14/2014 17:32:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0-7,ATOPIC conditions,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 17:49:30,,1322996459,7/14/2014 17:49:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0,ATOPIC,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 17:52:54,,1322998107,7/14/2014 17:52:35,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0-7,ATOPIC conditions,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:00:32,,1323001465,7/14/2014 18:00:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,"allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",35-45-52-60-69-84-88-26,0-7,ATOPIC conditions,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:06:52,,1323005684,7/14/2014 18:06:50,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,"rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",35-45-52-60-69-84-88,0-7-18-26,ATOPIC conditions include allergic,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:25:59,,1323014033,7/14/2014 18:25:47,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0,ATOPIC,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:32:19,,1323016893,7/14/2014 18:32:10,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0-7,ATOPIC conditions,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:36:24,,1323018597,7/14/2014 18:35:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,ALLERGIC CONJUNCTIVITIS,60-69,0-7,ATOPIC conditions,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939342,7/14/2014 18:36:47,,1323018762,7/14/2014 18:36:10,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,60,0,,,83,6,ALLERGIC CONJUNCTIVITIS,ATOPIC,"allergic rhinitis, atopic eczema, ALLERGIC CONJUNCTIVITIS and asthma.",35-45-52-60-69-84-88-26,0-7-18-26-35-45-52-60-69-88,"ATOPIC conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis asthma.","Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma.",60 69,0,60,0,83,6,-1,RO-cause_of,900211,"Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma",allergic conjunctivitis,Atopic
502939343,7/14/2014 17:30:40,,1322980264,7/14/2014 17:30:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 17:47:22,,1322995521,7/14/2014 17:47:06,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 17:49:33,,1322996465,7/14/2014 17:49:18,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 17:51:20,,1322997301,7/14/2014 17:51:03,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:00:45,,1323001655,7/14/2014 18:00:32,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:11:26,,1323007884,7/14/2014 18:11:04,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:22:10,,1323012593,7/14/2014 18:21:03,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,C] 4.1 endocrinologist specialist in HYPERTENSION diagnosis of pheochromocytoma.,0-4-31-50-61-64-118-128-131,0-4-31-50-61-64-118-128-131,C] 4.1 endocrinologist specialist in hypertension diagnosis of PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:29:42,,1323015688,7/14/2014 18:29:31,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:31:21,,1323016452,7/14/2014 18:31:11,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939343,7/14/2014 18:40:23,,1323020409,7/14/2014 18:40:08,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,64,131,,,76,147,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,64,131,PHEOCHROMOCYTOMA.,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma.,64,131,64,131,76,147,-1,RO-disease_may_have_finding,902674,C]  4.1 Consider consulting an endocrinologist or specialist in hypertension to assist in confirming or excluding the diagnosis of pheochromocytoma,hypertension,pheochromocytoma
502939344,7/14/2014 17:44:14,,1322993224,7/14/2014 17:43:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 17:45:48,,1322994760,7/14/2014 17:45:37,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 17:48:27,,1322995995,7/14/2014 17:48:14,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 17:52:48,,1322998055,7/14/2014 17:51:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 17:55:44,,1322999472,7/14/2014 17:55:37,elite,1.0,27888773,GBR,"","",128.199.166.81,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"nerve fibers, normal ISLET CELLS, and islet cell",41-47-55-62-68-75-79-85,62-68-75-79-85-90-98-102-116,"islet cells, and ISLET CELL TUMORS; its concentration was","Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 17:58:13,,1323000517,7/14/2014 17:57:37,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"normal ISLET CELLS,",55-62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 18:15:56,,1323009987,7/14/2014 18:15:14,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"Neuron specific enolase nerve fibers, normal ISLET CELLS, and islet cell tumors; tissue of islet cell tumors serum insulinoma.",0-7-16-41-47-55-62-68-75-79-85-90-141-148-151-157-162-176-201,0-7-16-41-47-55-62-68-75-79-85-90-141-148-151-157-176-201-162,"Neuron specific enolase nerve fibers, normal islet cells, and ISLET CELL TUMORS; tissue of islet cell tumors serum insulinoma.","Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 18:23:36,,1323013141,7/14/2014 18:23:18,vivatic,1.0,25451531,GBR,"","",83.67.28.193,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"normal ISLET CELLS,",55-62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 18:32:31,,1323016988,7/14/2014 18:32:20,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939344,7/14/2014 18:33:38,,1323017386,7/14/2014 18:31:30,clixsense,1.0,6336109,CAN,ON,Lindsay,204.237.88.59,62,79,,,73,96,ISLET CELLS,ISLET CELL TUMORS,"ISLET CELLS,",62-68,79-85-90,ISLET CELL TUMORS;,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma.",62 68,79 85 90,62,79,73,96,1,RO-disease_has_primary_anatomic_site,902422,"Neuron-specific enolase was localized in nerve fibers, normal islet cells, and islet cell tumors; its concentration was elevated only in the tissue of islet cell tumors and in serum from patients with insulinoma",islet cells,islet cell tumors
502939345,7/14/2014 17:38:55,,1322987959,7/14/2014 17:38:37,instagc,1.0,13763729,USA,"","",75.182.89.225,102,65,,,106,72,IDDM,INSULIN,(IDDM),101,65-73-83-92,INSULIN dependent diabetes mellitus,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 17:46:30,,1322995098,7/14/2014 17:44:24,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,102,65,,,106,72,IDDM,INSULIN,insulin dependent diabetes mellitus (IDDM),65-73-83-92-101,65-73-83-92-101,INSULIN dependent diabetes mellitus (IDDM),The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 17:53:17,,1322998277,7/14/2014 17:53:00,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,102,65,,,106,72,IDDM,INSULIN,(IDDM),101,65,INSULIN,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 17:54:32,,1322998818,7/14/2014 17:54:21,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,102,65,,,106,72,IDDM,INSULIN,diabetes mellitus (IDDM),83-92-101,65-73-83-92-101,INSULIN dependent diabetes mellitus (IDDM),The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:10:44,,1323007550,7/14/2014 18:10:19,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,102,65,,,106,72,IDDM,INSULIN,diabetes mellitus (IDDM),83-92-101,44-49-61-65-73-83-92,cell destruction and INSULIN dependent diabetes mellitus,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:30:57,,1323016233,7/14/2014 18:30:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,102,65,,,106,72,IDDM,INSULIN,diabetes mellitus (IDDM),83-92-101,65-73-83-92,INSULIN dependent diabetes mellitus,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:39:42,,1323020087,7/14/2014 18:39:26,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,102,65,,,106,72,IDDM,INSULIN,insulin dependent diabetes mellitus,73-83-92-65,65-73-83-92,INSULIN dependent diabetes mellitus,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:40:53,,1323020598,7/14/2014 18:40:40,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,102,65,,,106,72,IDDM,INSULIN,(IDDM),101,65,INSULIN,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:41:23,,1323020922,7/14/2014 18:41:09,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,102,65,,,106,72,IDDM,INSULIN,diabetes mellitus (IDDM),83-92-101,65-73-83-92,INSULIN dependent diabetes mellitus,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939345,7/14/2014 18:42:37,,1323021547,7/14/2014 18:41:34,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,102,65,,,106,72,IDDM,INSULIN,(IDDM),101,65,INSULIN,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific.,,65,102,65,106,72,1,RO-may_treat,908242,The pathogenetic mechanisms leading to beta-cell destruction and insulin-dependent diabetes mellitus (IDDM) are major histocompatibility complex (MHC) nonrestricted and are MHC associated and beta-cell specific,IDDM,insulin
502939346,7/14/2014 17:35:40,,1322984930,7/14/2014 17:34:06,clixsense,1.0,21875134,GBR,"","",91.125.61.83,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION of pheochromocytoma Patients,29-42-45-63,45-63,PHEOCHROMOCYTOMA Patients,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 17:38:59,,1322987997,7/14/2014 17:38:36,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,29,29-42-45-77-81,Hypertension of PHEOCHROMOCYTOMA MEN 2A,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:07:20,,1323005868,7/14/2014 18:06:59,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,29,45,PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:11:48,,1323008045,7/14/2014 18:11:28,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION of pheochromocytoma,29-42-45,29-42-45,Hypertension of PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:33:22,,1323017262,7/14/2014 18:33:03,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION pheochromocytoma,29-45,29-45-77-81-88,Hypertension PHEOCHROMOCYTOMA MEN 2A 2B,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:37:32,,1323019041,7/14/2014 18:36:43,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION of pheochromocytoma,29-42-45,29-42-45,Hypertension of PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:38:15,,1323019382,7/14/2014 18:37:56,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,29,45,PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:40:44,,1323020532,7/14/2014 18:40:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,29,45,PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:40:53,,1323020597,7/14/2014 18:40:32,instagc,1.0,26801585,USA,WA,Everett,76.28.248.228,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION of pheochromocytoma,29-42-45,29-42-45,Hypertension of PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939346,7/14/2014 18:41:31,,1323021008,7/14/2014 18:41:08,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,29,45,,,41,61,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,29,45,PHEOCHROMOCYTOMA,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma.,29,45,29,45,41,61,1,RO-disease_may_have_finding,902865,No statistics Physical exam  Hypertension of pheochromocytoma  Patients with MEN 2A and 2B may have little or no change in blood pressure at the earliest stages of pheochromocytoma,Hypertension,pheochromocytoma
502939347,7/14/2014 17:50:43,,1322997005,7/14/2014 17:50:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,of POLIOMYELITIS,167-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:18:04,,1323010891,7/14/2014 18:17:26,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,vaccines transmission of live vaccine viruses paralytic POLIOMYELITIS live poliovirus vaccine.,40-57-70-73-78-86-170-180-217-222-233,40-57-70-73-78-86-170-180-217-222-233,vaccines transmission of live vaccine viruses paralytic poliomyelitis LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:28:49,,1323015384,7/14/2014 18:28:28,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,occasional cases of paralytic POLIOMYELITIS,150-161-167-170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:38:54,,1323019701,7/14/2014 18:38:46,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:39:40,,1323020057,7/14/2014 18:39:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:41:36,,1323021064,7/14/2014 18:41:24,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:41:42,,1323021098,7/14/2014 18:41:30,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,POLIOMYELITIS,180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:41:52,,1323021191,7/14/2014 18:41:31,clixsense,1.0,25595227,CAN,SK,North Battleford,24.72.96.119,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:42:12,,1323021362,7/14/2014 18:41:48,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,180-170,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939347,7/14/2014 18:42:18,,1323021410,7/14/2014 18:42:06,instagc,1.0,26801585,USA,WA,Everett,76.28.248.228,180,217,,,193,240,POLIOMYELITIS,LIVE POLIOVIRUS VACCINE,paralytic POLIOMYELITIS,170-180,217-222-233,LIVE POLIOVIRUS VACCINE.,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine.,180,217 222 233,180,217,193,240,1,RO-may_prevent,907152,The principal differences between these vaccines are the transmission of live vaccine viruses from recipieits to their contacts and the occurrence of occasional cases of paralytic poliomyelitis associated with use of live poliovirus vaccine,poliomyelitis,live poliovirus vaccine
502939348,7/14/2014 17:41:18,,1322990276,7/14/2014 17:39:55,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42-60-64-51,THIAMINE (vitamin B1) deficiency,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 17:50:10,,1322996724,7/14/2014 17:49:54,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42,THIAMINE,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:07:45,,1323006084,7/14/2014 18:06:23,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42,THIAMINE,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:22:01,,1323012535,7/14/2014 18:21:33,vivatic,1.0,25451531,GBR,"","",83.67.28.193,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42-51-60-64-75,"THIAMINE (vitamin B1) deficiency (TD),","Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:22:04,,1323012557,7/14/2014 18:21:56,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"a model of WERNICKE'S ENCEPHALOPATHY, leads to elevation",81-83-89-92-103-119-125-128,25-27-39-42-60-64,a consequence of THIAMINE B1) deficiency,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:31:26,,1323016502,7/14/2014 18:31:08,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42-64,THIAMINE deficiency,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:31:56,,1323016751,7/14/2014 18:31:43,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42,THIAMINE,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:35:57,,1323018409,7/14/2014 18:35:33,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42-51-60-64-75,"THIAMINE (vitamin B1) deficiency (TD),","Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:38:35,,1323019527,7/14/2014 18:37:59,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42-64,THIAMINE deficiency,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939348,7/14/2014 18:39:09,,1323019827,7/14/2014 18:38:53,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,92,42,,,117,50,WERNICKE'S ENCEPHALOPATHY,THIAMINE,"WERNICKE'S ENCEPHALOPATHY,",92-103,42,THIAMINE,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity.",92 103,42,92,42,117,50,1,RO-may_treat,908170,"Metabolic dysfunction as a consequence of thiamine (vitamin B1) deficiency (TD), a model of Wernicke's encephalopathy, leads to elevation of extracellular glutamate concentration in vulnerable brain regions consistent with the development of excitotoxicity",Wernicke's encephalopathy,thiamine
502939349,7/14/2014 17:27:48,,1322977881,7/14/2014 17:27:35,instagc,1.0,18960682,GBR,"","",86.29.147.112,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,grade 3 (LEUKOPENIA,50-56-58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:30:41,,1322980275,7/14/2014 17:30:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:36:48,,1322986044,7/14/2014 17:36:20,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,58-80,(leukopenia GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:42:43,,1322991676,7/14/2014 17:42:11,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:49:52,,1322996596,7/14/2014 17:49:16,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,"grade 3 (LEUKOPENIA in three,",50-56-58-70-73,80-97-100,"GRANULOCYTOPENIA in three,","Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:51:39,,1322997468,7/14/2014 17:51:08,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 17:52:04,,1322997676,7/14/2014 17:51:18,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 18:04:39,,1323003285,7/14/2014 18:03:28,clixsense,1.0,21875134,GBR,"","",91.125.61.83,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 18:09:07,,1323006736,7/14/2014 18:08:36,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,(LEUKOPENIA,58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939349,7/14/2014 18:13:22,,1323008761,7/14/2014 18:13:07,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,59,80,,,69,96,LEUKOPENIA,GRANULOCYTOPENIA,grade 3 (LEUKOPENIA,50-56-58,80,GRANULOCYTOPENIA,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression.",,80,59,80,69,96,-1,RO-has_definitional_manifestation,904978,"Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression",leukopenia,granulocytopenia
502939350,7/14/2014 17:25:35,,1322976269,7/14/2014 17:25:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS infection.,196-209,142-146,PPD intradermal,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:28:01,,1322977999,7/14/2014 17:27:47,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,196,142,,,208,145,TUBERCULOSIS,PPD,to screen for TUBERCULOSIS infection.,182-185-192-196-209,134-136-139-142-146-158-161,5 TU of PPD intradermal is the,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:36:43,,1322985975,7/14/2014 17:36:28,instagc,1.0,13763729,USA,"","",75.182.89.225,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS,196,142,PPD,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:38:10,,1322987386,7/14/2014 17:37:54,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS,196,142-146,PPD intradermal,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:41:04,,1322990078,7/14/2014 17:40:41,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS,196,142,PPD,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:52:19,,1322997840,7/14/2014 17:52:05,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS,196,142,PPD,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:55:06,,1322999054,7/14/2014 17:54:54,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS infection.,196-209,142-146,PPD intradermal,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 17:57:08,,1323000054,7/14/2014 17:57:02,elite,1.0,27888773,GBR,"","",128.199.166.81,196,142,,,208,145,TUBERCULOSIS,PPD,to screen for TUBERCULOSIS infection.,182-185-192-196-209,134-136-139-142-146-158-161,5 TU of PPD intradermal is the,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 18:01:12,,1323001786,7/14/2014 18:00:53,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,196,142,,,208,145,TUBERCULOSIS,PPD,TUBERCULOSIS infection.,196-209,134-136-139-142-146,5 TU of PPD intradermal,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939350,7/14/2014 18:07:49,,1323006101,7/14/2014 18:07:46,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,196,142,,,208,145,TUBERCULOSIS,PPD,to screen for TUBERCULOSIS infection.,182-185-192-196-209,134-136-139-142-146-158-161,5 TU of PPD intradermal is the,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection.",196,142,196,142,208,145,1,RO-may_diagnose,906599,"Health Canada/Canadian Lung Association/Canadian Thoracic Society, 2007  Canadian tuberculosis standards  The Mantoux using 0.1 mL of 5 TU of PPD intradermal is the recommended test to screen for tuberculosis infection",tuberculosis,PPD
502939351,7/14/2014 17:40:01,,1322989013,7/14/2014 17:39:49,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 17:51:19,,1322997297,7/14/2014 17:51:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 17:58:27,,1323000575,7/14/2014 17:58:03,clixsense,1.0,21875134,GBR,"","",91.125.61.83,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,moderate and SEVERE DYSPLASIA.,227-236-240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 17:59:01,,1323000809,7/14/2014 17:58:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:00:25,,1323001388,7/14/2014 18:00:05,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:13:42,,1323008882,7/14/2014 18:13:23,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,moderate and SEVERE DYSPLASIA.,227-236-240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:16:01,,1323010014,7/14/2014 18:15:47,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:25:38,,1323013889,7/14/2014 18:25:16,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.150,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,dysplasia carcinoma SEVERE DYSPLASIA.,183-205-240-247,183-205-215-218-247,dysplasia CARCINOMA IN SITU dysplasia.,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:27:00,,1323014456,7/14/2014 18:26:49,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA.,240-247,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939351,7/14/2014 18:30:11,,1323015957,7/14/2014 18:29:15,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,240,205,,,256,222,SEVERE DYSPLASIA,CARCINOMA IN SITU,moderate and SEVERE DYSPLASIA.,236-240-247-227,205-215-218,CARCINOMA IN SITU,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia.,240 247,205 215 218,240,205,256,222,-1,RO-disease_has_finding,901746,There were significant differences in the number of nucleolar organizer regions between normal and abnormal tissues and between the different lesions except between moderate and mild dysplasia and between carcinoma in situ and moderate and severe dysplasia,severe dysplasia,carcinoma in situ
502939352,7/14/2014 17:42:08,,1322991079,7/14/2014 17:41:55,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29,FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 17:53:46,,1322998492,7/14/2014 17:53:29,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,0-4-14-24-29,The parasitic FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 17:56:27,,1322999765,7/14/2014 17:55:55,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29,FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:12:54,,1323008489,7/14/2014 18:12:29,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29-4,parasitic FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:20:20,,1323011798,7/14/2014 18:20:16,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,have predisposed the FALLOPIAN TUBES to a microbial,43-48-60-64-74-80-83-85,0-4-14-24-29-39-43-48,The parasitic FALLOPIAN TUBE INFECTION may have predisposed,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:24:49,,1323013554,7/14/2014 18:24:35,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29-4,parasitic FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:32:10,,1323016837,7/14/2014 18:31:58,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29,FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:37:55,,1323019215,7/14/2014 18:37:41,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29,FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:40:30,,1323020445,7/14/2014 18:39:58,instagc,1.0,26801585,USA,WA,Everett,76.28.248.228,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,4-14-24-29,parasitic FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939352,7/14/2014 18:40:38,,1323020515,7/14/2014 18:40:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,64,14,,,79,38,FALLOPIAN TUBES,FALLOPIAN TUBE INFECTION,FALLOPIAN TUBES,64-74,14-24-29,FALLOPIAN TUBE INFECTION,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess.,64 74,14 24 29,64,14,79,38,1,RO-has_finding_site,905312,The parasitic fallopian tube infection may have predisposed the fallopian tubes to a microbial tuboovarian abscess,fallopian tubes,fallopian tube infection
502939353,7/14/2014 17:28:16,,1322978247,7/14/2014 17:28:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,19,61,,,23,66,SKIN,HIVES,Involvement of the SKIN or mucosal tissue,0-12-15-19-24-27-35,35-42-49-61-68-76-79,"tissue (e.g., generalized HIVES; itching or flushing;","Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:41:27,,1322990402,7/14/2014 17:41:13,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,19,61,,,23,66,SKIN,HIVES,the SKIN or mucosal tissue,15-19-24-27-35,49-61-68,generalized HIVES; itching,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:42:09,,1322991096,7/14/2014 17:41:48,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,19,61,,,23,66,SKIN,HIVES,SKIN,19,61,HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:43:04,,1322992002,7/14/2014 17:42:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,19,61,,,23,66,SKIN,HIVES,SKIN,19,61,HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:48:16,,1322995877,7/14/2014 17:48:04,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,19,61,,,23,66,SKIN,HIVES,SKIN,19,61,HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:48:52,,1322996197,7/14/2014 17:48:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,19,61,,,23,66,SKIN,HIVES,SKIN,19,61,HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:50:55,,1322997070,7/14/2014 17:50:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,19,61,,,23,66,SKIN,HIVES,SKIN,19,61,HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:52:07,,1322997696,7/14/2014 17:51:39,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,19,61,,,23,66,SKIN,HIVES,"SKIN mucosal tissue generalized hives; itching flushing; swollen lips, tongue, uvula)",19-27-35-49-61-68-79-89-97-103-114,19-27-35-49-61-68-76-79-89-97-103-114,"skin mucosal tissue generalized HIVES; itching or flushing; swollen lips, tongue, uvula)","Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 17:53:13,,1322998228,7/14/2014 17:52:55,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,19,61,,,23,66,SKIN,HIVES,SKIN,19,49-61,generalized HIVES;,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939353,7/14/2014 18:04:34,,1323003237,7/14/2014 18:04:31,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,19,61,,,23,66,SKIN,HIVES,Involvement of the SKIN or mucosal tissue,0-12-15-19-24-27-35,35-42-49-61-68-76-79,"tissue (e.g., generalized HIVES; itching or flushing;","Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b.",19,61,19,61,23,66,1,RO-has_finding_site,905314,"Involvement of the skin or mucosal tissue (e.g., generalized hives; itching or flushing; swollen lips, tongue, or uvula)  b",skin,hives
502939354,7/14/2014 17:28:38,,1322978552,7/14/2014 17:28:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,DIC,198,146-152-166,"ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 17:35:13,,1322984450,7/14/2014 17:34:51,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,resolution of DIC and fewer bleeding complications,184-195-198-202-206-212-221,129-133-143-146-152-166,"DIC secondary to ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 17:39:10,,1322988254,7/14/2014 17:38:46,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,DIC,198,146-152-166,"ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 17:47:36,,1322995645,7/14/2014 17:47:24,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,DIC,198,146-152-166,"ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 17:47:52,,1322995724,7/14/2014 17:47:08,clixsense,1.0,21875134,GBR,"","",91.125.61.83,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,resolution of DIC,184-195-198,129-133-143-146-152-166,"DIC secondary to ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 17:53:52,,1322998536,7/14/2014 17:53:43,elite,1.0,27888773,GBR,"","",128.199.166.81,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,showing resolution of DIC and fewer bleeding,176-184-195-198-202-206-212,129-133-143-146-152-166-176-184-195,"DIC secondary to ACUTE PROMYELOCYTIC LEUKEMIA, showing resolution of","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 18:13:12,,1323008656,7/14/2014 18:12:55,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,DIC,198,146-152-166,"ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 18:14:00,,1323009073,7/14/2014 18:13:09,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,tranexamic acid hyperfibrinolysis DIC,18-51-198-29,129-146-152-166-51,"hyperfibrinolysis DIC ACUTE PROMYELOCYTIC LEUKEMIA,","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 18:19:11,,1323011349,7/14/2014 18:19:02,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,showing resolution of DIC and fewer bleeding,176-184-195-198-202-206-212,129-133-143-146-152-166-176-184,"DIC secondary to ACUTE PROMYELOCYTIC LEUKEMIA, showing resolution","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939354,7/14/2014 18:19:23,,1323011404,7/14/2014 18:18:35,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,198,146,,,201,174,DIC,ACUTE PROMYELOCYTIC LEUKEMIA,"tranexamic acid in patients hyperfibrinolysis DIC secondary acute promyelocytic leukemia, DIC bleeding complications placebo",18-29-34-37-51-129-133-146-152-166-198-212-221-254,18-29-34-37-51-129-133-146-152-166-198-212-221-254,"tranexamic acid in patients hyperfibrinolysis DIC secondary ACUTE PROMYELOCYTIC LEUKEMIA, DIC bleeding complications placebo","? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60.",198,146 152 166,198,146,201,174,-1,RO-disease_may_have_finding,902964,"? The efficacy of tranexamic acid in patients with hyperfibrinolysis was shown in a randomized controlled trial in patients with DIC secondary to acute promyelocytic leukemia, showing resolution of DIC and fewer bleeding complications in comparison with placebo ( 60",DIC,acute promyelocytic leukemia
502939355,7/14/2014 17:31:00,,1322980505,7/14/2014 17:30:56,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,diagnosis of complete DIABETES INSIPIDUS.,108-118-121-130-139,46-58-68-71-91-97,intravenous injection of VASOPRESSIN test) favoured,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:32:03,,1322981508,7/14/2014 17:31:51,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,complete DIABETES INSIPIDUS.,121-130-139,71,VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:32:28,,1322981909,7/14/2014 17:32:15,instagc,1,18960682,GBR,"","",86.29.147.112,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,complete DIABETES INSIPIDUS.,121-130-139,71-91-83,VASOPRESSIN (Miller test),Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:36:11,,1322985490,7/14/2014 17:36:01,instagc,1,13763729,USA,"","",75.182.89.225,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,DIABETES INSIPIDUS.,130-139,71,VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:41:38,,1322990591,7/14/2014 17:41:25,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,DIABETES INSIPIDUS.,130-139,71-83-91,VASOPRESSIN (Miller test),Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:47:07,,1322995380,7/14/2014 17:46:36,clixsense,1,21875134,GBR,"","",91.125.61.83,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,complete DIABETES INSIPIDUS.,121-130-139,46-58-68-71,intravenous injection of VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:50:39,,1322996964,7/14/2014 17:50:26,prodege,1,6579519,USA,OH,Fredericktown,71.55.40.105,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,DIABETES INSIPIDUS.,130-139,71,VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:51:07,,1322997169,7/14/2014 17:50:48,prodege,1,2767509,CAN,BC,Victoria,96.54.172.117,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,DIABETES INSIPIDUS.,130-139,71,VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 17:51:56,,1322997605,7/14/2014 17:51:23,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,DIABETES INSIPIDUS.,130-139,71,VASOPRESSIN,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939355,7/14/2014 18:05:32,,1323003949,7/14/2014 18:05:30,prodege,1,12944140,GBR,I4,Mitcham,92.21.55.247,130,71,,,148,82,DIABETES INSIPIDUS,VASOPRESSIN,diagnosis of complete DIABETES INSIPIDUS.,108-118-121-130-139,46-58-68-71-91-97,intravenous injection of VASOPRESSIN test) favoured,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus.,130 139,71,130,71,148,82,1,RO-may_diagnose,906588,Results of restriction of liquids followed by intravenous injection of vasopressin (Miller test) favoured a diagnosis of complete diabetes insipidus,diabetes insipidus,vasopressin
502939356,7/14/2014 17:30:05,,1322979794,7/14/2014 17:29:59,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,birth with congenital PSEUDARTHROSIS of the ulna,60-66-71-82-97-100-104,0-4-13-18-36-41-43-47-57,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 17:43:55,,1322992818,7/14/2014 17:43:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,PSEUDARTHROSIS,82,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 17:48:25,,1322995956,7/14/2014 17:48:10,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,PSEUDARTHROSIS,82,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:05:31,,1323003935,7/14/2014 18:05:16,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,congenital PSEUDARTHROSIS of the ulna and radius,71-82-97-100-104-109-113,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:06:33,,1323005489,7/14/2014 18:06:14,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,birth with congenital PSEUDARTHROSIS of the ulna,60-66-71-82-97-100-104,0-4-13-18-36-41-43-47-57,Two children with NEUROFIBROMATOSIS TYPE 1 who presented at,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:15:08,,1323009554,7/14/2014 18:14:54,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,congenital PSEUDARTHROSIS of the ulna,71-82-97-100-104,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:17:53,,1323010807,7/14/2014 18:17:32,vivatic,1,25451531,GBR,"","",83.67.28.193,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,congenital PSEUDARTHROSIS of the ulna and radius,71-82-97-100-104-109-113,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:22:40,,1323012822,7/14/2014 18:22:02,clixsense,1,23398628,USA,WA,Spanaway,50.149.99.43,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,neurofibromatosis type 1 congenital PSEUDARTHROSIS,18-36-41-71-82,18-36-41-71-82,NEUROFIBROMATOSIS TYPE 1 congenital pseudarthrosis,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:24:02,,1323013309,7/14/2014 18:22:04,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,congenital PSEUDARTHROSIS of the ulna and radius,71-82-97-100-104-109-113,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939356,7/14/2014 18:33:05,,1323017169,7/14/2014 18:32:51,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,82,18,,,96,42,PSEUDARTHROSIS,NEUROFIBROMATOSIS TYPE 1,congenital PSEUDARTHROSIS of the ulna,71-82-97-100-104,18-36-41,NEUROFIBROMATOSIS TYPE 1,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described.,82,18 36 41,82,18,96,42,1,RO-has_manifestation,906339,Two children with neurofibromatosis type 1 who presented at birth with congenital pseudarthrosis of the ulna and radius are described,pseudarthrosis,neurofibromatosis type 1
502939357,7/14/2014 17:30:28,,1322980098,7/14/2014 17:30:15,instagc,1.0,18960682,GBR,"","",86.29.147.112,19,88,,,26,97,STOMACH,GASTRITIS,STOMACH,19,79-88,"residual GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:30:35,,1322980168,7/14/2014 17:30:28,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,19,88,,,26,97,STOMACH,GASTRITIS,reflux to the STOMACH is believed as,5-12-15-19-27-30-39,63-76-79-88-99-107-111,"pathogenesis of residual GASTRITIS, however the prevention","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:33:41,,1322983012,7/14/2014 17:33:22,clixsense,1,27969116,NLD,04,Veendam,185.12.216.74,19,88,,,26,97,STOMACH,GASTRITIS,Bile reflux to the STOMACH,0-5-12-15-19,63-76-79-88,"pathogenesis of residual GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:34:03,,1322983339,7/14/2014 17:33:38,neodev,1,17111650,USA,PA,Millersburg,174.59.14.30,19,88,,,26,97,STOMACH,GASTRITIS,Bile reflux to the STOMACH,0-5-12-19-15,63-76-79-88,"pathogenesis of residual GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:43:11,,1322992116,7/14/2014 17:42:44,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,19,88,,,26,97,STOMACH,GASTRITIS,STOMACH,19,88,"GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:43:15,,1322992186,7/14/2014 17:42:56,neodev,1,28269997,GBR,H9,London,151.224.171.48,19,88,,,26,97,STOMACH,GASTRITIS,Bile reflux STOMACH,0-19-5,63-88,"pathogenesis GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:47:11,,1322995407,7/14/2014 17:46:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,19,88,,,26,97,STOMACH,GASTRITIS,STOMACH,19,88,"GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:49:50,,1322996578,7/14/2014 17:49:30,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,19,88,,,26,97,STOMACH,GASTRITIS,STOMACH,19,88,"GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:54:41,,1322998865,7/14/2014 17:54:28,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,19,88,,,26,97,STOMACH,GASTRITIS,reflux to the STOMACH,5-12-15-19,63-76-79-88,"pathogenesis of residual GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939357,7/14/2014 17:58:55,,1323000778,7/14/2014 17:58:41,prodege,1,7899370,USA,MI,Bay City,71.13.81.162,19,88,,,26,97,STOMACH,GASTRITIS,reflux to the STOMACH,5-12-15-19,79-88,"residual GASTRITIS,","Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis.",19,88,19,88,26,97,1,RO-disease_has_primary_anatomic_site,902170,"Bile reflux to the stomach is believed as one of the important pathogenesis of residual gastritis, however the prevention for bile reflux cannot always heal the gastritis",stomach,gastritis
502939358,7/14/2014 17:28:03,,1322978006,7/14/2014 17:27:49,instagc,1.0,18960682,GBR,"","",86.29.147.112,22,80,,,28,88,APNOEA,CAFFEINE,prolonged APNOEA,12-22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 17:37:30,,1322986639,7/14/2014 17:37:16,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,22,80,,,28,88,APNOEA,CAFFEINE,APNOEA,22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 17:51:33,,1322997455,7/14/2014 17:50:34,elite,1,27888773,GBR,"","",128.199.166.81,22,80,,,28,88,APNOEA,CAFFEINE,Episodes of prolonged APNOEA disappeared in all,0-9-12-22-29-41-44,56-62-77-80-89-93-96,after administration of CAFFEINE and in 11,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 17:59:12,,1323000918,7/14/2014 17:58:54,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,22,80,,,28,88,APNOEA,CAFFEINE,APNOEA,22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:02:13,,1323002215,7/14/2014 18:01:51,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,22,80,,,28,88,APNOEA,CAFFEINE,Episodes of prolonged APNOEA disappeared in all infants,0-9-12-22-29-41-44-48,56-62-77-80,after administration of CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:18:57,,1323011296,7/14/2014 18:18:28,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.131,22,80,,,28,88,APNOEA,CAFFEINE,APNOEA,22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:19:20,,1323011394,7/14/2014 18:19:12,neodev,1,12218487,CAN,ON,Oshawa,174.117.79.122,22,80,,,28,88,APNOEA,CAFFEINE,Episodes of prolonged APNOEA disappeared,0-9-12-22-29,56-62-77-80-89-93-96,after administration of CAFFEINE and in 11,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:26:24,,1323014196,7/14/2014 18:26:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,22,80,,,28,88,APNOEA,CAFFEINE,APNOEA,22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:28:29,,1323015255,7/14/2014 18:28:00,instagc,1,19686223,CAN,BC,Surrey,184.65.16.6,22,80,,,28,88,APNOEA,CAFFEINE,Episodes of prolonged APNOEA administration of caffeine pneumogram abnormalities,0-9-12-22-77-80-111-122-62,9-12-22-62-77-80-111-122-0,Episodes of prolonged apnoea administration of CAFFEINE pneumogram abnormalities,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939358,7/14/2014 18:31:05,,1323016324,7/14/2014 18:30:50,tremorgames,1,26860817,NLD,06,Boxmeer,84.29.157.221,22,80,,,28,88,APNOEA,CAFFEINE,APNOEA,22,80,CAFFEINE,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved.,22,80,22,80,28,88,1,RO-may_treat,908015,Episodes of prolonged apnoea disappeared in all infants after administration of caffeine and in 11 infants all pneumogram abnormalities resolved,apnoea,caffeine
502939359,7/14/2014 17:29:45,,1322979467,7/14/2014 17:29:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,documented biochemical abnormalities: HYPERCORTISOLISM and its resistance,26-37-49-64-81-85-89,85-89-100-103-117,its resistance to DEXAMETHASONE suppression.,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 17:36:40,,1322985964,7/14/2014 17:36:27,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 17:49:02,,1322996249,7/14/2014 17:48:47,zapbux,1,27754872,USA,SC,Graniteville,24.145.86.46,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 17:49:13,,1322996325,7/14/2014 17:48:53,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 17:50:25,,1322996847,7/14/2014 17:50:12,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 17:55:46,,1322999476,7/14/2014 17:54:42,clixsense,1,6336109,CAN,ON,Lindsay,204.237.88.59,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM and its resistance,64-81-85-89,103-117,DEXAMETHASONE suppression.,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 18:02:02,,1323002163,7/14/2014 18:01:45,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 18:04:00,,1323003002,7/14/2014 18:03:25,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103,DEXAMETHASONE,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 18:24:00,,1323013300,7/14/2014 18:23:34,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,103-117,DEXAMETHASONE suppression.,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939359,7/14/2014 18:24:03,,1323013327,7/14/2014 18:23:21,prodege,1,22277051,USA,NY,Massena,24.58.192.131,64,103,,,80,116,HYPERCORTISOLISM,DEXAMETHASONE,HYPERCORTISOLISM,64,64-89-100-103-117,hypercortisolism resistance to DEXAMETHASONE suppression.,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression.,64,103,64,103,80,116,1,RO-may_diagnose,906872,In MDD there are two well-documented biochemical abnormalities: hypercortisolism and its resistance to dexamethasone suppression,hypercortisolism,dexamethasone
502939360,7/14/2014 17:30:01,,1322979700,7/14/2014 17:29:51,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:30:07,,1322979822,7/14/2014 17:29:33,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:36:04,,1322985340,7/14/2014 17:35:46,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:40:15,,1322989254,7/14/2014 17:40:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:43:49,,1322992701,7/14/2014 17:43:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:46:34,,1322995133,7/14/2014 17:46:13,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 17:55:12,,1322999095,7/14/2014 17:54:55,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 18:00:15,,1323001297,7/14/2014 17:59:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,revealed HAEMOPHAGOCYTOSIS,47-56,113-129-156-161-149,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); such haemophagocytosis,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 18:03:36,,1323002841,7/14/2014 18:03:21,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS,56,113-129-149,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH);,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939360,7/14/2014 18:12:47,,1323008459,7/14/2014 18:12:14,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,56,113,,,73,148,HAEMOPHAGOCYTOSIS,HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HAEMOPHAGOCYTOSIS haemophagocytic lymphohistiocytosis (HLH); haemophagocytosis H5N1 infection.,56-113-129-149-161-228-233,56-96-99-108-113-129-149-161-228-233,haemophagocytosis in patients with HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH); haemophagocytosis H5N1 infection.,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection.,56,113 129,56,113,73,148,1,RO-disease_has_finding,901841,Post-mortem analyses in affected patients have revealed haemophagocytosis similar to that found in patients with haemophagocytic lymphohistiocytosis (HLH); such haemophagocytosis could be a very prominent post-mortem feature in H5N1 infection,haemophagocytosis,haemophagocytic lymphohistiocytosis
502939361,7/14/2014 17:28:53,,1322978769,7/14/2014 17:28:39,instagc,1.0,18960682,GBR,"","",86.29.147.112,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173-186,BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 17:35:56,,1322985199,7/14/2014 17:35:35,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,virus (BVDV) MYCOBACTERIUM BOVIS,59-65-76-90,150-163-166-173-186,transmission of BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 17:36:28,,1322985743,7/14/2014 17:36:11,instagc,1.0,13763729,USA,"","",75.182.89.225,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173,BOVINE TUBERCULOSIS,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 17:39:02,,1322988051,7/14/2014 17:37:02,instagc,1,28524232,CAN,ON,Toronto,99.244.116.246,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,bovine viral diarrhoea virus (BVDV) MYCOBACTERIUM BOVIS bovine tuberculosis (BTB),36-43-49-59-65-76-90-166-173-186,36-43-49-59-65-76-90-166-173-186,bovine viral diarrhoea virus (BVDV) Mycobacterium bovis BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 17:45:36,,1322994653,7/14/2014 17:45:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,163-166-173,of BOVINE TUBERCULOSIS,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 17:46:21,,1322995053,7/14/2014 17:46:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173-186,BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 18:03:27,,1323002780,7/14/2014 18:01:20,clixsense,1.0,21875134,GBR,"","",91.125.61.83,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173,BOVINE TUBERCULOSIS,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 18:06:58,,1323005717,7/14/2014 18:06:42,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173-186,BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 18:14:41,,1323009350,7/14/2014 18:14:02,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,(BVDV) MYCOBACTERIUM BOVIS,65-76-90,65-166-173-186-76,(BVDV) Mycobacterium BOVINE TUBERCULOSIS (BTB),Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939361,7/14/2014 18:16:04,,1323010047,7/14/2014 18:15:34,clixsense,1,15189335,GBR,A7,Birmingham,94.197.121.81,76,166,,,95,185,MYCOBACTERIUM BOVIS,BOVINE TUBERCULOSIS,MYCOBACTERIUM BOVIS,76-90,166-173,BOVINE TUBERCULOSIS,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests.,76 90,166 173,76,166,95,185,-1,RO-has_causative_agent,903869,Concurrent infection of cattle with bovine viral diarrhoea virus (BVDV) and Mycobacterium bovis is considered to be a possible risk factor for onward transmission of bovine tuberculosis (BTB) in infected cattle and is known to compromise diagnostic tests,Mycobacterium bovis,bovine tuberculosis
502939362,7/14/2014 17:25:59,,1322976532,7/14/2014 17:25:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 17:33:27,,1322982802,7/14/2014 17:32:31,clixsense,1.0,21875134,GBR,"","",91.125.61.83,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 17:40:52,,1322989837,7/14/2014 17:40:32,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 17:47:22,,1322995520,7/14/2014 17:47:01,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 17:47:49,,1322995718,7/14/2014 17:47:17,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 17:53:28,,1322998384,7/14/2014 17:53:14,clixsense,1,27812714,NLD,06,Tilburg,84.31.160.155,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 18:17:17,,1323010536,7/14/2014 18:17:06,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,caused by the WART VIRUS were cured,76-83-86-90-95-101-106,3-7-13-16-24-34-40,"243 cases of VERRUCA VULGARIS, about 85%","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 18:18:21,,1323011056,7/14/2014 18:17:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.131,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 18:18:23,,1323011060,7/14/2014 18:16:11,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,epidermal efflorescences caused by the WART VIRUS,51-61-76-83-86-90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939362,7/14/2014 18:20:33,,1323011917,7/14/2014 18:20:04,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,90,16,,,100,32,WART VIRUS,VERRUCA VULGARIS,WART VIRUS,90-95,16-24,"VERRUCA VULGARIS,","In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy.",90 95,16 24,90,16,100,32,1,RO-has_causative_agent,903573,"In 243 cases of verruca vulgaris, about 85% of the epidermal efflorescences caused by the wart virus were cured by two or more applications of Solcoderm in ambulant therapy",wart virus,verruca vulgaris
502939363,7/14/2014 17:27:20,,1322977561,7/14/2014 17:26:53,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,125,83,,,131,92,JOINTS,ARTHROSIS,age or overused JOINTS.,109-113-116-125,70-83-80,arthritis or ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:28:10,,1322978164,7/14/2014 17:28:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,125,83,,,131,92,JOINTS,ARTHROSIS,age or overused JOINTS.,109-113-116-125,65-70-80-83-93-97-100,with arthritis or ARTHROSIS due to advanced,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:40:26,,1322989357,7/14/2014 17:40:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,125,83,,,131,92,JOINTS,ARTHROSIS,JOINTS.,125,83,ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:41:08,,1322990168,7/14/2014 17:40:57,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,125,83,,,131,92,JOINTS,ARTHROSIS,JOINTS.,125,83,ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:43:06,,1322992027,7/14/2014 17:42:54,instagc,1.0,13763729,USA,"","",75.182.89.225,125,83,,,131,92,JOINTS,ARTHROSIS,JOINTS.,125,83,ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:45:53,,1322994804,7/14/2014 17:45:08,clixsense,1.0,21875134,GBR,"","",91.125.61.83,125,83,,,131,92,JOINTS,ARTHROSIS,overused JOINTS.,116-125,70-80-83,arthritis or ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 17:53:00,,1322998160,7/14/2014 17:52:46,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,125,83,,,131,92,JOINTS,ARTHROSIS,JOINTS.,125,83,ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 18:05:48,,1323004039,7/14/2014 18:05:32,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,125,83,,,131,92,JOINTS,ARTHROSIS,overused JOINTS.,116-125,83,ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 18:08:38,,1323006499,7/14/2014 18:08:15,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,125,83,,,131,92,JOINTS,ARTHROSIS,overused JOINTS.,116-125,70-80-83,arthritis or ARTHROSIS,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939363,7/14/2014 18:24:44,,1323013527,7/14/2014 18:24:08,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,125,83,,,131,92,JOINTS,ARTHROSIS,abnormal biomechanics arthritis arthrosis overused JOINTS.,14-23-70-83-125-116,14-23-70-83-116-125,abnormal biomechanics arthritis ARTHROSIS overused joints.,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints.",125,83,125,83,131,92,1,RO-disease_has_primary_anatomic_site,902442,"In each case, abnormal biomechanics were caused by or associated with arthritis or arthrosis due to advanced age or overused joints",joints,arthrosis
502939364,7/14/2014 17:35:42,,1322984964,7/14/2014 17:35:31,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 17:40:13,,1322989213,7/14/2014 17:39:52,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY, etiology.",41-55-58-104,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 17:55:40,,1322999441,7/14/2014 17:55:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY, is",41-55-58-85,0-41-55-58,"PREECLAMPSIA complications of pregnancy,","Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:13:38,,1323008857,7/14/2014 18:13:14,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"Preeclampsia COMPLICATIONS OF PREGNANCY, etiology.",0-41-55-58-104,0-41-55-58-104,"PREECLAMPSIA complications of pregnancy, etiology.","Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:26:06,,1323014079,7/14/2014 18:25:50,vivatic,1.0,25451531,GBR,"","",83.67.28.193,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:33:19,,1323017239,7/14/2014 18:32:40,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:36:47,,1323018771,7/14/2014 18:36:34,instagc,1,19636746,USA,NY,Andover,192.182.216.225,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:39:09,,1323019823,7/14/2014 18:38:53,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.213,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:39:25,,1323019959,7/14/2014 18:39:10,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939364,7/14/2014 18:39:44,,1323020090,7/14/2014 18:38:59,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.34,41,0,,,67,12,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY,",41-55-58,0,PREECLAMPSIA,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology.",41 55 58,0,41,0,67,12,-1,RO-disease_has_finding,901807,"Preeclampsia is one of the most frequent complications of pregnancy, however, little is known about its etiology",complications of pregnancy,Preeclampsia
502939365,7/14/2014 17:28:24,,1322978323,7/14/2014 17:28:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:29:51,,1322979564,7/14/2014 17:29:46,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,65,88,,,70,97,SPINE,SCOLIOSIS,the growing adolescent SPINE instance in,42-46-54-65-76-85,71-76-85-88-98-109-113,"(for instance in SCOLIOSIS research), the inclusion","Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:34:19,,1322983541,7/14/2014 17:34:04,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:43:48,,1322992685,7/14/2014 17:43:34,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:50:29,,1322996891,7/14/2014 17:50:15,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,65,88,,,70,97,SPINE,SCOLIOSIS,adolescent SPINE,54-65,71-76-85-88-98,"(for instance in SCOLIOSIS research),","Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:54:53,,1322998972,7/14/2014 17:54:29,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:55:13,,1322999115,7/14/2014 17:55:04,elite,1.0,27888773,GBR,"","",128.199.166.81,65,88,,,70,97,SPINE,SCOLIOSIS,the growing adolescent SPINE instance in,42-46-54-65-76-85,71-76-85-88-98-109-113,"(for instance in SCOLIOSIS research), the inclusion","Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 17:58:01,,1323000408,7/14/2014 17:57:32,clixsense,1.0,21875134,GBR,"","",91.125.61.83,65,88,,,70,97,SPINE,SCOLIOSIS,growing adolescent SPINE,46-54-65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 18:10:17,,1323007281,7/14/2014 18:09:47,listia,1,26989211,USA,VA,Suffolk,24.241.13.101,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939365,7/14/2014 18:14:05,,1323009147,7/14/2014 18:13:17,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,65,88,,,70,97,SPINE,SCOLIOSIS,SPINE,65,88,SCOLIOSIS,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential.",65,88,65,88,70,97,1,RO-has_finding_site,905141,"Hence, when analysing the biomechanics of the growing adolescent spine (for instance in scoliosis research), the inclusion of depth and width changes, in addition to the usually implemented height change, is essential",spine,scoliosis
502939366,7/14/2014 17:41:33,,1322990531,7/14/2014 17:41:19,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:48:29,,1322995988,7/14/2014 17:48:17,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:48:32,,1322996033,7/14/2014 17:48:22,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:49:02,,1322996243,7/14/2014 17:48:45,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:54:07,,1322998618,7/14/2014 17:53:10,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,Pimecrolimus topical non steroidal drug ATOPIC DERMATITIS.,0-44-52-56-66-96-103,0-44-52-56-66-96-103,PIMECROLIMUS topical non steroidal drug atopic dermatitis.,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:56:52,,1322999933,7/14/2014 17:56:46,elite,1.0,27888773,GBR,"","",128.199.166.81,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,for treatment of ATOPIC DERMATITIS.,79-83-93-96-103,0-13-17-27,PIMECROLIMUS has generated recognition,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 17:59:35,,1323001021,7/14/2014 17:59:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,for treatment of ATOPIC DERMATITIS.,79-83-93-96-103,0-17-27,PIMECROLIMUS generated recognition,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 18:09:20,,1323006868,7/14/2014 18:08:59,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 18:14:18,,1323009212,7/14/2014 18:14:06,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,ATOPIC DERMATITIS.,96-103,0,PIMECROLIMUS,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939366,7/14/2014 18:19:56,,1323011662,7/14/2014 18:19:28,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,96,0,,,113,12,ATOPIC DERMATITIS,PIMECROLIMUS,Pimecrolimus non steroidal drug treatment of ATOPIC DERMATITIS.,0-52-56-66-83-93-96-103,0-52-56-66-83-93-96-103,PIMECROLIMUS non steroidal drug treatment of atopic dermatitis.,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis.,96 103,0,96,0,113,12,1,RO-may_treat,908166,Pimecrolimus has generated recognition as a topical non-steroidal drug labeled for treatment of atopic dermatitis,atopic dermatitis,Pimecrolimus
502939367,7/14/2014 17:31:40,,1322981103,7/14/2014 17:31:07,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:31:52,,1322981338,7/14/2014 17:30:57,clixsense,1.0,21875134,GBR,"","",91.125.61.83,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,primary and METASTATIC LESIONS,65-73-77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:33:06,,1322982420,7/14/2014 17:32:43,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS liver metastasis,77-88-113-119,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:39:24,,1322988422,7/14/2014 17:39:10,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:41:48,,1322990732,7/14/2014 17:41:33,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:49:07,,1322996312,7/14/2014 17:48:52,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:49:17,,1322996366,7/14/2014 17:49:03,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 17:53:19,,1322998285,7/14/2014 17:52:55,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,METASTATIC LESIONS,77-88,113-119,LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 18:06:49,,1323005657,7/14/2014 18:06:48,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,26 primary and METASTATIC LESIONS in patients with,62-65-73-77-88-96-99-108,96-99-108-113-119-130-135,in patients with LIVER METASTASIS were studied.,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939367,7/14/2014 18:11:38,,1323007964,7/14/2014 18:10:54,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,77,113,,,95,129,METASTATIC LESIONS,LIVER METASTASIS,lesions metastasis primary METASTATIC LESIONS liver metastasis,19-47-65-77-88-113-119,19-47-65-77-88-113-119,lesions metastasis primary metastatic lesions LIVER METASTASIS,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied.,77 88,113 119,77,113,95,129,-1,RO-disease_has_finding,901605,Twenty-one primary lesions in patients without metastasis and 26 primary and metastatic lesions in patients with liver metastasis were studied,metastatic lesions,liver metastasis
502939368,7/14/2014 17:28:49,,1322978690,7/14/2014 17:28:45,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,correlations between serum DIGOXIN concentration and changes,52-65-73-79-87-101-105,7-16-21-30-38-48-52-65,patients with suicidal DIGOXIN POISONING the correlations between,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 17:34:27,,1322983654,7/14/2014 17:34:08,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,21-30-38-48-52,suicidal DIGOXIN POISONING the correlations,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 17:47:50,,1322995719,7/14/2014 17:47:33,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,DIGOXIN,79,30-38,DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 17:55:21,,1322999230,7/14/2014 17:55:07,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,21-30-38,suicidal DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:05:21,,1323003905,7/14/2014 18:05:05,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,correlations between serum DIGOXIN concentration and changes,52-65-73-79-87-101-105,7-16-21-30-38-48-52-65,patients with suicidal DIGOXIN POISONING the correlations between,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:06:40,,1323005568,7/14/2014 18:06:28,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,21-30-38,suicidal DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:09:52,,1323007071,7/14/2014 18:09:20,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,21-30-38,suicidal DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:26:31,,1323014251,7/14/2014 18:26:12,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,21-30-38,suicidal DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:37:59,,1323019275,7/14/2014 18:37:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,30-38,DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939368,7/14/2014 18:38:04,,1323019324,7/14/2014 18:37:39,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,79,30,,,86,47,DIGOXIN,DIGOXIN POISONING,serum DIGOXIN concentration,73-79-87,30-38,DIGOXIN POISONING,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied.,79,30 38,79,30,86,47,1,RO-has_causative_agent,903566,In two patients with suicidal digoxin poisoning the correlations between serum digoxin concentration and changes in the duration of QTc and the flattening of the T-waves were studied,digoxin,digoxin poisoning
502939369,7/14/2014 17:31:08,,1322980668,7/14/2014 17:31:03,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,unknown cause (SUDDEN INFANT DEATH SYNDROME; SIDS) was observed,87-95-101-109-116-122-132-138-142,41-48-61-64-71-78-84-87-95,solely attributable to SUDDEN INFANT DEATH of unknown cause,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 17:45:18,,1322994509,7/14/2014 17:45:00,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS),101-109-116-122-132,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 17:52:16,,1322997823,7/14/2014 17:51:56,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS),101-109-116-122-132,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 17:58:46,,1323000706,7/14/2014 17:58:12,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS),101-109-116-122-132,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 17:59:42,,1323001065,7/14/2014 17:59:03,elite,1,28276268,USA,MI,Taylor,67.149.247.166,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,INFANT DEATH SYNDROME;,109-116-122,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 18:08:27,,1323006417,7/14/2014 18:06:52,clixsense,1.0,23398628,USA,WA,Spanaway,50.149.99.43,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS) was observed,101-109-116-122-132-138-142,64-71-78-84-87-95-122-132,SUDDEN INFANT DEATH of unknown cause syndrome; SIDS),Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 18:11:07,,1323007751,7/14/2014 18:09:47,clixsense,1.0,15189335,GBR,A7,Birmingham,94.197.121.81,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,INFANT DEATH SYNDROME;,109-116-122,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 18:19:47,,1323011581,7/14/2014 18:19:36,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,unknown cause (SUDDEN INFANT DEATH SYNDROME; SIDS) was observed,87-95-101-109-116-122-132-138-142,41-48-61-64-71-78,solely attributable to SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 18:36:32,,1323018643,7/14/2014 18:35:57,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS),101-109-116-122-132,64-71-78-132,SUDDEN INFANT DEATH SIDS),Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939369,7/14/2014 18:38:18,,1323019401,7/14/2014 18:38:00,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,102,64,,,130,83,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,(SUDDEN INFANT DEATH SYNDROME; SIDS),101-109-116-122-132,64-71-78,SUDDEN INFANT DEATH,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns.,109 116 122,64 71 78,102,64,130,83,-1,RO-cause_of,900048,Higher and rising postneonatal mortality solely attributable to sudden infant death of unknown cause (sudden infant death syndrome; SIDS) was observed in the Nordic countries with a lower proportion of heavy newborns,sudden infant death syndrome,sudden infant death
502939370,7/14/2014 17:29:39,,1322979391,7/14/2014 17:29:00,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS Highlands J (HJ) virus,73-80-93-99-108-118-120-125,65-73-80-93-99-108-118-120,EASTERN EQUINE ENCEPHALITIS (EEE) virus Highlands J (HJ),Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 17:34:50,,1322984093,7/14/2014 17:34:28,clixsense,1.0,27969116,NLD,04,Veendam,185.12.216.74,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS or Highlands J (HJ) virus,73-80-93-99-105-108-118-120-125,54-62-65-73-80-93-99,strains of EASTERN EQUINE ENCEPHALITIS (EEE) virus,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 17:40:31,,1322989504,7/14/2014 17:40:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,(EEE) VIRUS,93-99,65-73-80-93-99,EASTERN EQUINE ENCEPHALITIS (EEE) virus,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 17:49:22,,1322996398,7/14/2014 17:49:01,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS or Highlands J (HJ),73-80-93-99-105-108-118-120,54-62-65-73-80,strains of EASTERN EQUINE ENCEPHALITIS,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 17:50:51,,1322997041,7/14/2014 17:50:11,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,(EEE) VIRUS,93-99,65-73-80,EASTERN EQUINE ENCEPHALITIS,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 18:18:06,,1323010896,7/14/2014 18:17:56,neodev,1.0,12218487,CAN,ON,Oshawa,174.117.79.122,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS or Highlands J,73-80-93-99-105-108-118,65-73-80-99-105,EASTERN EQUINE ENCEPHALITIS virus or,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 18:21:32,,1323012310,7/14/2014 18:21:03,vivatic,1.0,25451531,GBR,"","",83.67.28.193,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,73-80-93-99-65,65-73-80-93,EASTERN EQUINE ENCEPHALITIS (EEE),Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 18:32:59,,1323017142,7/14/2014 18:32:39,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS,73-80-93-99,65-73-80-93-99,EASTERN EQUINE ENCEPHALITIS (EEE) virus,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 18:33:03,,1323017190,7/14/2014 18:32:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS,73-80-93-99,65-73-80-93,EASTERN EQUINE ENCEPHALITIS (EEE),Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939370,7/14/2014 18:34:52,,1323017902,7/14/2014 18:34:35,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,94,65,,,104,92,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS,73-80-93-99,65-73-80-93-99,EASTERN EQUINE ENCEPHALITIS (EEE) virus,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production.,99,65 73 80,94,65,104,92,-1,RO-has_causative_agent,903980,Turkey breeder hens were experimentally infected with strains of eastern equine encephalitis (EEE) virus or Highlands J (HJ) virus previously isolated from turkey hens experiencing decreased egg production,EEE) virus,eastern equine encephalitis
502939371,7/14/2014 17:28:13,,1322978200,7/14/2014 17:27:43,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,"Preeclampsia PREGNANCY COMPLICATION hypertension proteinuria, endothelial dysfunction, hypoxic uteroplacental tissues.",0-18-28-54-71-101-113-166-174-189,0-18-28-41-54-71-101-113-166-174-189,"PREECLAMPSIA pregnancy complication diagnosed hypertension proteinuria, endothelial dysfunction, hypoxic uteroplacental tissues.","Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 17:29:06,,1322978855,7/14/2014 17:28:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 17:29:31,,1322979256,7/14/2014 17:29:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 17:49:48,,1322996575,7/14/2014 17:49:35,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 17:59:41,,1323001047,7/14/2014 17:59:24,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,"Preeclampsia is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria,",0-13-16-18-28-41-51-54-67-71,0-13-16-18-28,PREECLAMPSIA is a pregnancy complication,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 18:13:59,,1323009047,7/14/2014 18:13:45,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 18:21:01,,1323012100,7/14/2014 18:20:27,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,"Preeclampsia is a PREGNANCY COMPLICATION diagnosed by hypertension and proteinuria, endothelial dysfunction, hypoxic uteroplacental tissues.",0-13-16-18-28-41-51-54-67-71-101-113-166-174-189,0-18-28-41-51-54-67-71-101-113-151-166-174-189-161,"PREECLAMPSIA pregnancy complication diagnosed by hypertension and proteinuria, endothelial dysfunction, compounds from hypoxic uteroplacental tissues.","Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 18:30:33,,1323016117,7/14/2014 18:30:24,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 18:33:40,,1323017390,7/14/2014 18:33:24,prodege,1.0,17932518,GBR,Y2,Pwllheli,95.151.166.213,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,Preeclampsia PREGNANCY COMPLICATION,0-18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939371,7/14/2014 18:38:27,,1323019489,7/14/2014 18:38:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,18,0,,,40,12,PREGNANCY COMPLICATION,PREECLAMPSIA,PREGNANCY COMPLICATION,18-28,0,PREECLAMPSIA,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues.",18 28,0,18,0,40,12,-1,RO-disease_has_finding,901534,"Preeclampsia is a pregnancy complication diagnosed by hypertension and proteinuria, characterized by endothelial dysfunction, and supposedly caused by compounds from hypoxic uteroplacental tissues",pregnancy complication,Preeclampsia
502939372,7/14/2014 17:31:36,,1322981052,7/14/2014 17:31:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 17:37:39,,1322986806,7/14/2014 17:37:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 17:37:41,,1322986813,7/14/2014 17:37:15,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 17:46:52,,1322995285,7/14/2014 17:46:36,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 17:56:39,,1322999830,7/14/2014 17:56:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER and sepsis,0-58-62,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 17:57:32,,1323000212,7/14/2014 17:57:27,elite,1.0,27888773,GBR,"","",128.199.166.81,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER was secondary to,0-6-10-20,10-20-23-25-43-46-50,secondary to a PHAEOCHROMOCYTOMA in one patient,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 18:06:43,,1323005600,7/14/2014 18:06:41,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER was secondary to,0-6-10-20,10-20-23-25-43-46-50,secondary to a PHAEOCHROMOCYTOMA in one patient,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 18:08:55,,1323006642,7/14/2014 18:08:39,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 18:23:51,,1323013226,7/14/2014 18:23:37,vivatic,1.0,25451531,GBR,"","",83.67.28.193,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939372,7/14/2014 18:26:11,,1323014115,7/14/2014 18:26:00,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,0,25,,,5,42,FEVER,PHAEOCHROMOCYTOMA,FEVER,0,25,PHAEOCHROMOCYTOMA,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other.,0,25,0,25,5,42,1,RO-disease_may_have_finding,902821,Fever was secondary to a phaeochromocytoma in one patient and sepsis in the other,Fever,phaeochromocytoma
502939373,7/14/2014 17:26:52,,1322977180,7/14/2014 17:26:18,neodev,1.0,17111650,USA,PA,Millersburg,174.59.14.30,3,41,,,9,49,CARIES,FLUORIDE,CARIES,3,41,"FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:27:34,,1322977734,7/14/2014 17:27:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,3,41,,,9,49,CARIES,FLUORIDE,CARIES of,3-28,35-41,"fetal FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:29:00,,1322978790,7/14/2014 17:28:14,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,3,41,,,9,49,CARIES,FLUORIDE,"CARIES fetal fluoride, pertinent research.",3-35-41-86-96,35-41-86-96,"fetal FLUORIDE, pertinent research.","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:30:14,,1322979892,7/14/2014 17:30:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,3,41,,,9,49,CARIES,FLUORIDE,No CARIES protective effect of,0-3-10-21-28,28-31-35-41-51-60-64,"of the fetal FLUORIDE, however, has been","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:32:30,,1322981911,7/14/2014 17:31:53,clixsense,1.0,21875134,GBR,"","",91.125.61.83,3,41,,,9,49,CARIES,FLUORIDE,CARIES protective effect,3-10-21,35-41,"fetal FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:35:28,,1322984780,7/14/2014 17:35:09,neodev,1.0,28269997,GBR,H9,London,151.224.171.48,3,41,,,9,49,CARIES,FLUORIDE,"CARIES fetal fluoride,",3-35-41,35-41,"fetal FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:45:46,,1322994748,7/14/2014 17:45:32,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,3,41,,,9,49,CARIES,FLUORIDE,CARIES,3,41,"FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:51:12,,1322997260,7/14/2014 17:50:45,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,3,41,,,9,49,CARIES,FLUORIDE,"No CARIES protective effect of the fetal fluoride,",0-3-10-21-28-31-41-35,35-41,"fetal FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 17:52:09,,1322997741,7/14/2014 17:51:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,3,41,,,9,49,CARIES,FLUORIDE,CARIES,3,41,"FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939373,7/14/2014 18:13:45,,1323008898,7/14/2014 18:13:13,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,3,41,,,9,49,CARIES,FLUORIDE,CARIES protective,3-10,35-41,"fetal FLUORIDE,","No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research.",3,41,3,41,9,49,1,RO-may_prevent,907148,"No caries-protective effect of the fetal fluoride, however, has been substantiated by pertinent research",caries,fluoride
502939374,7/14/2014 17:30:14,,1322979890,7/14/2014 17:30:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,61-64-73-84,"GH receptOR ANTAGONIst pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 17:41:28,,1322990441,7/14/2014 17:40:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,84,"pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 17:45:09,,1322994440,7/14/2014 17:44:58,zapbux,1.0,27754872,USA,SC,Graniteville,24.145.86.46,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,,,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 17:49:37,,1322996521,7/14/2014 17:49:08,prodege,1.0,6579519,USA,OH,Fredericktown,71.55.40.105,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS acromegaly,19-33,84,"pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 17:49:58,,1322996637,7/14/2014 17:49:33,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS acromegaly,19-33,84,"pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 17:57:57,,1323000386,7/14/2014 17:57:38,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,,,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 18:04:59,,1323003738,7/14/2014 18:04:56,prodege,1.0,12944140,GBR,I4,Mitcham,92.21.55.247,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,鐃緒申鐃緒申羝�申��申鐃緒申鐃順� PATIENTS With acromegaly treated,0-19-28-33-44,57-61-64-73-84-97,"the GH receptOR ANTAGONIst pegvisomant, hormonal","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 18:13:44,,1323008899,7/14/2014 18:13:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,鐃緒申鐃緒申羝�申��申鐃緒申鐃順� PATIENTS With acromegaly,0-19-33-28,61-64-73-84,"GH receptOR ANTAGONIst pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 18:14:22,,1323009239,7/14/2014 18:13:45,listia,1.0,26989211,USA,VA,Suffolk,24.241.13.101,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,84,"pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
502939374,7/14/2014 18:22:57,,1323012911,7/14/2014 18:22:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,19,70,,,29,81,ACROMEGALY,PEGVISOMANT,PATIENTS,19,57-61-64-73-84,"the GH receptOR ANTAGONIst pegvisomant,","鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193.",19,,19,70,29,81,1,RO-may_treat,907741,"鐃緒申鐃緒申羝�申��申鐃緒申鐃順� patients with acromegaly treated with the GH receptor antagonist pegvisomant, hormonal follow-up can only be accomplished by obtaining IGF-I levels ( 193",acromegaly,pegvisomant
